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Cancer is a multifactorial disease. Environmental, genetic and behavioural factors all contribute 
to its development. Cancer cells are characterised by their aberrant functioning. In 2000, 
HANAHAN and WEINBERG described a number of features cancer cells are likely to present 
with and that contribute to their malignancy: the hallmarks of cancer (see Figure 1)1. A major 
characteristic of cancer cells is their uncontrollable and infinite cell division. In order to 
establish this, cancer cells have become self-sufficient in growth signals and are insensitive to 
growth-inhibitory signals. In addition, cancer cells continuously attempt to evade death 
(apoptosis) and in order to sustain growth, cancer cells need continuous angiogenesis for the 
supply of oxygen and nutrients. To be able to spread through their host, tumour cells can 
invade surrounding tissue and metastasise.  
As cancer research proceeds, new hallmarks are being recognised2. Evidence is emerging that 
cancer cells reprogram their energy metabolism and attempt to evade destruction by the 
immune system. In addition, tumour-promoting inflammation is also of interest for 
tumourigenesis as it can contribute in acquiring other cancer hallmarks. Another important 
feature is that cancer cells often have an unstable genome (genomic instability), characterised 
by increased mutation rates, chromosomal rearrangements and aberrant chromosome 
numbers. As the human body consists of billions of cells that are susceptible to become 
malignant, the chance of developing cancer seems enormous. However, most of these insults 
are averted by specialised cellular mechanisms: the DNA damage repair pathways. 
FIGURE 1 Hallmarks of cancer. The concept of cancer hallmarks describes a set of capabilities or enabling 
characteristics that are involved in the pathogenesis of cancer. Growth and progression of most - if not all - tumours is 
stimulated by these characteristics. So far, ten hallmarks have been formulated. Adapted from 2, © 2011 Elsevier, reprinted 
with permission. 
 
DNA damage repair 
The DNA damage repair pathways play a vital role in maintaining genome integrity and 
represent essential biological mechanisms to identify and repair DNA damage or DNA 
aberrations3. DNA integrity is continuously threatened by both exogenous and endogenous 
factors, such as UV irradiation, chemicals, ionising radiation, but also by reactive oxygen 
species that are part of normal cell metabolism4. There are different types of DNA damage 
that can occur and therefore, different kinds of repair mechanisms exist. All these pathways 
have in common that they are composed of four core components: sensors, mediators, 
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transducers and effectors5,6. After damage is inflicted, the sensors detect and mark the 
damaged region. Mediators and transducers are recruited to pass the signal on to effectors. 
These factors will in turn execute repair. Of the repair pathways described to date, base-
excision repair (BER), nucleotide-excision repair (NER) and mismatch repair (MMR) are 
responsible for the repair of damage associated with single bases and nucleotides7. Whereas in 
these instances only one strand of the DNA double helix is affected, so-called double-strand 
breaks (DSBs) represent a more lethal form of DNA damage. If left unrepaired, DSBs can 
cause cell death, but can also lead to chromosomal rearrangements and genomic instability, and 
eventually cancer8,9. Cells have two mechanisms to repair DSBs: non-homologous end-joining 
(NHEJ) and homologous recombination (HR). In HR, the sister chromatid is used as a 
template for repair7. Consequently, HR can only occur during S phase or G2. NHEJ can be 
used throughout the cell cycle, but is more error-prone. Another vital part of the DNA damage 
response is the activation of cell cycle checkpoints. This leads to cell cycle arrest, giving cells 
time to repair damage before it becomes lethal or can be passed on to daughter cells. If the 
damage is too severe, cell death pathways will be activated. 
The DNA damage response is an important tool to prevent genomic instability and therefore it 
can act as a barrier against tumourigenesis10,11. Deficiencies or mutations in the DNA damage 
repair pathways can predispose to cancer and other malignancies. Cells and organisms with 
defective DNA repair are also more radiosensitive12,13. This is exemplified by the presence of 
syndromes in individuals defective for genome maintenance components. Mutations in 
BRCA1 or BRCA2 (breast cancer susceptibility protein type 1/2) predispose humans to breast 
and ovarian cancer. Defects of the ATM (ataxia telangiectasia mutated) protein kinase lead to 
the cancer-prone, X-ray-sensitive syndrome ataxia telangiectasia. NBS1 deficiency gives rise to 
Nijmegen breakage syndrome, which leads to higher levels of cancer3. In contrast, evidence is 
emerging that cancers can also aberrantly express certain components of the DNA damage 
repair signalling10,14-17. This ‘pathological’ activation of the DNA damage response could 
already be observed in pre-malignant lesions10,11 and has been the incentive to regard the DNA 
damage repair pathways as anti-tumour barriers18. 
Besides having potential detrimental effects, DNA damage can also be used as a cancer 
therapy. Radiotherapy and a variety of chemotherapeutic drugs can target DNA integrity to 
cause cytotoxicity. Both treatment strategies cause either direct or indirect DNA damage. The 
aim is to generate such a large amount of damage that it is irreparable for the tumour cells with 
cell death as the end result. Both radio- and chemotherapy can induce DSBs, the type of 
damage most complex to repair and therefore most lethal to the cell. The efficacy of these 
treatments has been acknowledged for years. Nevertheless, the effectiveness of cancer 
therapies is highly influenced by the exact (sub)cellular organisation of the tumour: the tumour 
microenvironment. 
 
The tumour microenvironment and hypoxia 
Tumours are more than a collection of proliferating cancer cells. Instead, tumours are complex 
structures, in which multiple cell types are present. Together, these cells constitute what is 
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called the tumour microenvironment, consisting of blood vessels, stromal cells (fibroblasts) 
and immune cells (lymphocytes, natural killer cells and antigen presenting cells)19.  
Hypoxia is an important feature of the microenvironment of most solid tumours. In a rapidly 
proliferating tumour, vascularisation is often compromised. This may result in regions with an 
insufficient supply of blood and therefore an inadequate supply of oxygen and nutrients. Two 
manners in which hypoxia arises have been defined. Diffusion-limited or chronic hypoxia 
occurs when cells are located at a distance from the blood vessels beyond which oxygen 
cannot diffuse20. Perfusion-limited or acute hypoxia is caused by structural abnormalities in the 
vasculature, leading to a temporarily reduced, fluctuating and dynamic oxygen availability21. 
The occurrence of tumour hypoxia has multiple consequences. Oxygen plays a crucial part in 
the efficient production of energy. Therefore, hypoxia can lead to alterations in cellular and 
metabolic processes. As a result, hypoxia can induce the expression of genes involved in 
adaptation of tumour cells to hypoxic conditions22. Low oxygen levels can also promote 
genomic instability. The frequency of mutations is found to be higher in cells exposed to 
hypoxia than in normoxic cells23,24. This could be caused by reduced DNA repair during 
hypoxic conditions25,26 or elevated DNA damage by reactive oxygen species once 
reoxygenation takes place27. Hypoxia can also select for cells with low sensitivity to 
apoptosis28,29 and low oxygen can promote invasive phenotypes30-32. Furthermore, hypoxia is 
known to reduce the efficacy of cancer therapies, like radio- and chemotherapy33 and can 
affect the response to anti-cancer drugs by inducing the expression of multidrug 
transporters34,35. Alterations in gene expression during hypoxia are coordinated by several 
independent pathways36: the hypoxia-inducible factor (HIF) pathway, the unfolded protein 
response (UPR) and by the mammalian target of rapamycin (mTOR) (see Figure 2). The HIF 
pathway mediates a transcriptional response, whereas the UPR and mTOR pathways focus 
more on altering translation of mRNA.  
 
HIF pathway 
The HIF pathway is considered the master regulator of the hypoxic response. Several HIFs 
have been described, of which HIF1 is most frequently associated with tumour hypoxia. HIF1 
is a heterodimer, consisting of a constitutively expressed β-subunit and an O2 regulated α-
subunit. The α-subunit is rapidly degraded under normoxic conditions. However, during 
hypoxia ubiquitination of HIF1α is decreased, stabilising the α-subunit37,38. HIF1 can regulate 
transcription of hundreds of genes during hypoxia by binding to hypoxia-responsive element 
sequences39,40. 
 
UPR 
The UPR is induced by a broader range of stressors besides hypoxia. Various physiological and 
pathological conditions can cause accumulation of misfolded proteins in the endoplasmic 
reticulum (ER), resulting in ER-stress. The main function of the UPR is to alleviate this stress 
and to restore homeostasis36. Recently, ionising radiation has been shown to induce ER-stress 
as well41. The UPR consists of multiple pathways operating in parallel. To date, three arms 
have been described: the PERK (PKR-like endoplasmic reticulum kinase), IRE1 (inositol 
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requiring enzyme 1) and ATF6 (activating transcription factor 6) arms36,42,43. Activation of all 
three arms of the UPR depends on a factor named glucose-related protein 78 (GRP78, also 
known as BiP)43. GRP78 binds to the luminal domain of both PERK, IRE1 and ATF6, 
thereby blocking their activation. GRP78 can sense unfolded proteins in the ER. During stress 
conditions, GRP78 will bind to these proteins, thereby leaving PERK, IRE1 and ATF6 free 
for activation.  
 
FIGURE 2 Hypoxia responsive pathways. Schematic representation of the three main hypoxia regulated pathways. On 
the right, the HIF pathway is depicted, which transcriptionally activates a large number of genes. In the middle, the 
UPR is shown. The three arms of the UPR coordinate a response that leads to general inhibition of protein translation, 
as well as transcription and translation of specific genes. On the left, the mTOR pathway is presented, which is also 
involved in inhibition of general translation. Together, activation of these pathways leads to adaptation to hypoxia and 
cell survival. 
 
Upon activation of PERK, serine 51 of eIF2α (eukaryotic initiation factor 2α) is 
phosphorylated44. This will lead to an overall halt of protein synthesis, aimed at relieving the 
protein load of the ER45. In contrast, specific mRNAs can be upregulated, including ATF4 
(activating transcription factor 4)46,47. In turn, ATF4 can activate several genes aimed at 
restoring normal ER function48. ATF4 also activates growth arrest and DNA damage-inducible 
protein 34 (GADD34), which dephosphorylates eIF2α, thereby serving as a negative feedback 
loop49.  
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IRE1 and ATF6 are responsible for the transcriptional response of the UPR. IRE1 can activate 
XBP1 (x-box-binding protein 1)50,51, which in turn activates genes involved in ER protein 
maturation and ER-associated degradation51,52. Other results have indicated that IRE1 can also 
signal through JNK (c-jun N-terminal kinase)53. Upon activation, ATF6 is translocated to the 
nucleus and functions as a transcription factor activating numerous genes of which those 
encoding ER chaperone proteins are an example54. 
 
mTOR 
mTOR is a central factor in the integration of metabolic signals36. An important function is the 
regulation of protein synthesis. mTOR receives input for several signalling pathways and can 
regulate cell survival and proliferation. mTOR is also hypoxia responsive55. mTOR can be 
hypophosphorylated by hypoxia, rendering it less active and consequently not able to sustain 
universal initiation of translation.    
 
Autophagy 
Protein degradation in cells can be accomplished by two complementary, reciprocally regulated 
mechanisms: the ubiquitin-proteasome-system and autophagy56,57. Typically, the proteasome is 
responsible for the selective degradation of short-lived proteins, whereas autophagy is 
responsible for the less-selective degradation of long-lived proteins, protein aggregates and 
even entire cellular organelles. Autophagy, also known as macroautophagy, therefore 
represents a metabolic pathway in which cells can recycle their own components and remove 
defective structures58. It is evolutionary conserved as yeast, plants and animals have 
homologous systems58,59. Autophagy guards homeostasis and perturbations in normal function 
of the cell (stress) can activate autophagy60. Examples of such stresses are nutrient starvation, 
hypoxia, oxidative stress61, radiation62-64, anti-cancer drugs or pathogen infection. Autophagy 
can be induced by hypoxia through multiple mechanisms. HIF1 can induce autophagy via the 
mitochondrial associated BNIPs (Bcl-2/adenovirus E1B 19-kDa interacting proteins) BNIP3 
and BNIP3L65. In addition, a HIF-independent autophagy response can be launched through 
mTOR66-68 or the UPR60,69-71, where autophagy can help to alleviate ER-stress.  
The autophagic cascade, represented in Figure 3, is initiated by the formation of so-called 
phagophores, pre-autophagosomal structures, which elongate and mature into 
autophagosomes72,73. Cytosolic proteins and organelles are sequestered in these double-
membrane vesicles. Multiple autophagy-related proteins (ATG proteins) are involved in the 
formation of the autophagosome. One of the key ATG proteins is microtubule-associated 
protein 1 light chain 3B (MAP1LC3B or LC3B, a mammalian homologue of yeast ATG8). 
LC3B is transformed from its free form (LC3BI) to its membrane-bound, lipidated form 
(LC3BII) and coats the autophagosome74. To degrade their content, autophagosomes fuse with 
lysosomes, which contain hydrolases, disintegrating components back to their constituents. 
Autophagy is tightly regulated by the action of various kinases, phosphatases and GTPases 
(guanosine triphosphatases)59 and deregulation can have dramatic consequences. Elevated 
autophagy activity has been associated with Parkinson’s and other neurodegenerative diseases, 
whereas decreased autophagy is linked with cardiomyopathy59,75. Autophagy is also of 
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increasing interest in cancer76-80, but its role in this disease is seemingly controversial. Although 
proposed as a cell survival mechanism, several oncogenes were found to inhibit autophagy, 
whereas tumour suppressors could induce it81. Also beclin 1 (BECN1), the mammalian 
homologue of ATG6, was found to be mono-allelically deleted in numerous cancers82. Mice 
with a heterozygous disruption of BECN1 show a high incidence of spontaneous 
tumourigenesis83-85. This suggests that autophagy can suppress initial cancer development, but 
increases survival of tumour cells once they are present. Therefore, the exact role of autophagy 
in cancer depends on tumour type, context and stage. 
 
FIGURE 3 The autophagic process. Schematic representation of the cellular degradation pathway autophagy. Proteins 
and cellular organelles can be recycled to generate energy if required during times of stress. Cargo is selected by 
proteins such as p62 and delivered to autophagosomes. These double-membrane vesicles are coated with LC3BII. 
Autophagosomes fuse with lysosomes, upon which the cargo, including p62 is degraded by lysosomal hydrolases. 
 
Metastasis 
The impact tumour cells have on their host can be detrimental. The World Health 
Organisation (WHO) reported that in 2008 7.6 million people died of cancer worldwide. This 
number is expected to rise to an annual 13.1 million cancer-related deaths by 2030. The spread 
of tumour cells through their host represents the most life-threatening aspects of cancer: it is 
predicted that 90% of cancer-related deaths can be attributed to metastasis86,87. In order to 
acquire a metastatic phenotype, cells undergo massive transformations in their gene 
expression88-91. The actual process of metastasis is complex92,93. Cancer cells first need to 
disrupt the contact with neighbouring cells. They have to cross the basement membrane and 
migrate through the extracellular matrix. Next, cells need to infiltrate the lymphatic and/or 
haematogenous system, endure the host defence system and implant themselves in unfamiliar 
tissue in order to proliferate and initiate neo-vascularisation. Knowledge of these processes 
might allow for the pharmacological targeting of crucial steps in metastasis in the treatment of 
cancer. Interestingly, the aggressive metastatic tumour phenotype has been linked to hypoxia94-
96. A number of genes implicated in metastasis are hypoxia responsive88,91,97,98. Recently, the 
metastasis-associated factor LAMP3 was found to be under the control of hypoxia via the 
UPR99.  
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LAMP3 
In this thesis, the role of lysosome-associated membrane protein 3 (LAMP3) in cancer biology 
is examined. LAMP3 is a highly glycosylated, type I integral membrane protein, first described 
in 1998 by two independent research groups. LAMP3 was named DC-LAMP by DE SAINT-VIS 
et al.100, who showed that it was a marker of mature dendritic cells with a possible role in 
migration of dendritic cells from the periphery into lymph vessels. In addition, LAMP3 was 
called TSC403 by OZAKI et al.101. This group found that LAMP3 was expressed specifically in 
lung tissue but that in several carcinomas it was overexpressed. A subsequent study showed 
that LAMP3 was prognostic in a small cohort of cervical cancer patients and that it was 
associated with metastasis102. LAMP3 is also induced by hypoxia as part of the PERK/ATF4-
arm of the UPR99. However, the precise role of LAMP3 in cancer biology remains unclear. 
This thesis aims to shed further light on the function of LAMP3 in cancer. 
 
Outline of this thesis 
In CHAPTER TWO the effect of hypoxia on LAMP3 is examined in breast cancer and the 
prognostic value of LAMP3 in breast tumours is evaluated. CHAPTER THREE describes the 
difficulties of culturing multicellular tumour spheroids from breast cancer cells. In CHAPTER 
FOUR breast cancer spheroids are used to explore migration of cancer cells. The role of PERK, 
ATF4 and LAMP3 in hypoxia-induced migration of breast cancer cells is studied. CHAPTER 
FIVE extends these data by examining LAMP3 mediated hypoxia-induced metastasis in an 
orthotopic xenograft model of cervical cancer. In CHAPTER SIX the prognostic value of 
LAMP3 is examined in head and neck squamous cell carcinoma. In addition this chapter deals 
with the hypoxic regulation of the UPR in these cancers. The involvement of LAMP3 and the 
UPR in resistance to therapy is studied in the following two chapters. CHAPTER SEVEN deals 
with the effect of LAMP3 on resistance to the anti-oestrogen tamoxifen in breast cancer 
patients. In CHAPTER EIGHT the association between the UPR and resistance to radiotherapy 
in breast cancer cells is explored. In CHAPTER NINE the interesting phenomenon of 
constitutively active DNA repair is studied in a cohort of breast cancer patients. The value of 
the findings of this is further elaborated upon in CHAPTER TEN. Here, the origin of 
constitutively active DNA repair and the consequences for drug-sensitivity are examined. 
Finally, CHAPTER ELEVEN discusses the data presented in this thesis in light of previous 
knowledge in the field of cancer research and will give recommendations for future studies. 
CHAPTER TWELVE gives a summary of the work described in this thesis. 
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ABSTRACT 
Background 
LAMP3 is a newly described hypoxia-regulated gene of potential interest in hypoxia-induced 
therapy resistance and metastasis. The prognostic value of LAMP3 in breast cancer was 
investigated.  
Methods 
Expression levels of LAMP3 in breast cancer cell lines and patient tissues were determined by 
real time quantitative polymerase chain reaction and in a tissue microarray by 
immunohistochemistry. Immunofluorescent staining was used to evaluate the distribution of 
LAMP3 in tumour xenografts relative to pimonidazole. Kaplan-Meier analysis as well as 
multivariate Cox regression survival analyses were performed.  
Results 
LAMP3 was variably expressed in breast cancer cell lines and induced in an oxygen 
concentration-dependent manner. LAMP3 protein expression colocalised with hypoxic areas in 
breast cancer xenografts. LAMP3 mRNA was higher in breast tumours from patients with 
node-positive (p = 0.019) and/or steroid hormone receptor-negative tumours (p < 0.001). 
Breast cancer patients with high LAMP3 mRNA levels had more locoregional recurrences (p = 
0.032 log-rank). This was limited to patients treated with lumpectomy and radiotherapy as 
primary treatment (n = 53, p = 0.009). No association with metastasis-free survival was found. 
In multivariate Cox regression analysis, LAMP3 remained as a statistically independent 
prognostic factor for locoregional recurrence (hazard ratio, 2.76; 95% confidence interval, 1.01 
- 7.5; p = 0.048) after correction for menopausal status, histologic grade, tumour size, nodal 
status, therapy and steroid hormone receptor status. LAMP3 protein in breast cancer tissue 
proved also to be of prognostic relevance.  
Conclusions 
Evidence is provided for an association of LAMP3 with tumour cell hypoxia in breast cancer 
xenografts. In the current breast cancer cohorts, LAMP3 has independent prognostic value. 
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INTRODUCTION 
Lysosome-associated membrane protein 3 (LAMP3) was first identified in 1998 independently 
by two research groups. DE SAINT-VIS et al. named it DC-LAMP, a marker of mature dendritic 
cells1 with a possible role in migration of dendritic cells from the periphery into lymph vessels2, 
whereas OZAKI et al. described it as TSC403 with specific expression in the lung and 
overexpression in carcinomas of the breast, amongst others3. Significant similarities of TSC403 
with LAMP1 and LAMP2 were found3. LAMPs are highly glycosylated type I integral 
membrane proteins, which reside in lysosomal membranes1-4. Their function is still largely 
unknown. In non-cancerous cells, LAMP1 and LAMP2 are rarely expressed on the cell 
surface5. However, in cancer cells their presence on the plasma membrane is frequently 
observed, with an increased incidence in more metastatic cell lines6,7. Experiments with 
overexpression of LAMP3 indicated similar characteristics for this protein: a strong association 
between LAMP3 and the promotion of metastatic potential was described both in vitro and in 
vivo2. This suggests that LAMP3 expression might be related to metastasis. Indeed, high 
LAMP3 mRNA levels correlated significantly with poor prognosis in a small cohort of cervical 
cancers2. 
For several decades, hypoxia (oxygen deprivation) has been recognised as a hallmark of solid 
tumours. A low blood and oxygen supply to cancers complicates their (local) treatment. 
Hypoxia can decrease the effectiveness of both radiotherapy and chemotherapy and induce 
treatment resistance8. Especially for radiotherapy, hypoxia poses problems, as oxygen is 
required for radiation to cause DNA damage9. In addition, several studies have reported that 
less well-oxygenated tumours show a worse prognosis and a higher incidence of metastases 
compared with better oxygenated tumours10-12. Hypoxia has therefore been linked to a more 
aggressive and metastatic tumour phenotype. Several hypoxia-regulated genes have been 
described that influence metastasis of tumours, including factors that enhance dissociation and 
migration of tumour cells13. Recently, LAMP3 was shown to be upregulated by hypoxia in a 
panel of tumour cells, via the unfolded protein response (UPR)14. The UPR is a mechanisms of 
adaptation to endoplasmic reticulum stress and has been demonstrated to contribute to 
hypoxic adaptation in tumours through multiple mechanisms15. This adaptation may facilitate 
the survival of treatment-resistant hypoxic cells, leading to a poor prognosis of patients16. 
Whether LAMP3 is associated with treatment resistance or metastasis in solid tumours is 
unknown. In this study, we investigated the correlation between hypoxia and LAMP3 
expression in breast cancer xenografts and we assessed the prognostic value of LAMP3 
mRNA and protein expression in breast cancer patients. 
 
MATERIALS AND METHODS 
Cell culture 
MDA-MB-231 and SKBR-3 breast tumour cells were obtained from LGC Promochem 
(London, UK) and cultured at 37 ˚C with 5% CO2 in Dulbecco’s modified Eagles medium 
(Lonza, Biowhittaker, Walkersville, MD, USA) supplemented with 10% (v/v) heat-inactivated 
foetal bovine serum, 10 U/ml penicillin, 10 µg/ml streptomycin, 2 mM L-glutamine, 20 mM 
Hepes (all from Invitrogen, Carlsbad, CA, USA) and 1× non-essential amino acids (Promocell, 
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Heidelberg, Germany). Cells were harvested and reseeded at 100% confluence. cDNA from a 
panel of breast cancer cell lines (n = 16) was a gift from DR. M. SCHUTTE (Department of 
Medical Oncology, Josephine Nefkens Institute, Erasmus University Medical Centre, 
Rotterdam, the Netherlands)17,18. 
 
Cell culture in hypoxic conditions 
For culturing under hypoxic conditions, MDA-MB-231 cells were seeded at 300,000 cells per 
10-cm dish and were allowed to recover overnight. Hypoxia was induced using a H35 
Hypoxystation (Don Whitley Scientific Ltd., Shipley, UK), set at 0.5%, 0.2% or 0.1% oxygen. 
After incubation of up to 72 hours, cells were harvested. 
 
RNA isolation, cDNA synthesis and quantitative polymerase chain reactions (RT-
qPCR) 
RNA from hypoxic cultured cells was isolated using Norgen’s Total RNA purification kit 
(Norgen Biotek Corp., Thorold, Canada), according to the manufacturer’s instructions with 
addition of an on-column DNase treatment. Isolated RNA was stored at -80 ˚C until further 
processing. cDNA synthesis was performed by reverse transcribing 1 µg of RNA using the 
Reverse Transcription System (Promega, Madison, WI, USA) according to the manufacturer’s 
instructions. The primers used for LAMP3 RT-qPCR were FW 5’-
TGAAAACAACCGATGTCCAA-3’ and RV 5’-TCAGACGAGCACTCATCCAC-3’. mRNA expression 
was analysed on a CFX96 realtime PCR detection system (Bio-Rad Laboratories Inc., 
Richmond, CA, USA) using SYBR green (Applied Biosystems, Foster City, CA, USA). 
Hypoxanthine phosphoribosyl transferase 1 (HPRT1) was used as the reference gene, analysed 
with a pre-developed assay (Applied Biosystems). 
 
Western blot analysis 
Cells were harvested in RIPA buffer (1% NP-40, 0.5% sodium desoxycholate and 0.1% 
sodium dodecylsulfate) to which phosphatase and protease inhibitors (Roche, Indianapolis, IN, 
USA) were added. Protein concentrations were determined using the Pierce BCA assay 
(Thermo Fisher Scientific, Rockfold, IL, USA), after which 30 µg of protein was fractionated 
on 12% Criterion XT Bis-Tris gels (Bio-Rad). After running, samples were transferred to 
PVDF membranes (Millipore Immobilon, Millipore, Bedford, MA, USA) for 2 hours at 4 ˚C. 
After blocking with 4% non-fat dry milk (Bio-Rad), membranes were incubated overnight at 4 
˚C with rabbit anti-human-LAMP3 IgG (AP1827a, 0.25 mg/ml, Abgent, San Diego, CA, USA) 
in a dilution of 1:100 or rabbit anti-β-actin IgG (#4970, Cell Signaling Technology, Beverly, 
MA, USA) in a dilution of 1:1,000, both diluted in 5% (w/v) bovine serum albumin (Sigma 
Aldrich, St. Louis, MO, USA) in tris-buffered saline (TBS) with 0.1% Tween-20 (w/v) (Sigma). 
Next, membranes were incubated for 1 hour at room temperature with horseradish peroxidase 
(HRP)-labelled goat anti-rabbit immunoglobulin G (IgG; 1:2,000, #7074, Cell Signaling). 
Proteins were detected using chemiluminescent peroxidase substrate (Sigma) and imaged on a 
ChemiDoc XRS+ imaging system (Bio-Rad). 
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Growth of breast cancer cell xenografts 
Xenografts of breast cancer cells were grown on nu/nu BALB/c athymic mice, kept in a 
specific pathogen-free unit at the central animal facility of the Radboud University Nijmegen. 
All animal procedures were approved by the local ethics committee. In short, a cell suspension 
of MDA-MB-231 or SKBR-3 cells was diluted in Matrigel (BD Bioscience, Bedford, MA, 
USA) 2:1 and injected subcutaneously into the flank of the mice. At an average diameter of 8 
mm to 9 mm, mice were injected intraperitoneally with the hypoxic cell marker pimonidazole 
(1-[(2-hydroxy-3-piperidinyl)propyl]-2-nitroimidazole hydrochloride, Natural Pharmacia 
International Inc., Burlington, MA, USA). One hour post-injection, mice were sacrificed and 
tumours were harvested and immediately stored in liquid nitrogen until further processing. 
 
Immunohistochemistry 
Frozen 5 µm tumour sections were fixed in acetone for 10 minutes at 4 ˚C, after which they 
were rehydrated for 30 minutes in phosphate-buffered saline (PBS) pH 7.4 (Klinipath, Duiven, 
the Netherlands) and subjected to staining. All antibodies were dissolved in primary antibody 
diluent (PAD, AbD Serotec, Oxford, UK). Between all incubations, sections were rinsed three 
times in PBS. Sections were incubated overnight at 4 ˚C with goat anti-human-LAMP3 IgG 
(AF4087, 0.2 mg/ml, R&D Systems Inc., Minneapolis, MN, USA) used in a dilution of 1:100. 
Subsequently, sections were treated with Cy3-conjugated donkey anti-goat IgG (705-166-147, 
1.5 mg/ml, Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA) in a 1:600 
dilution for 30 minutes at 37 ˚C as the secondary antibody. Vessels were visualised by 
incubating sections with undiluted 9F1 supernatant, a rat monoclonal antibody to mouse 
endothelium (Department of Pathology, Radboud University Nijmegen Medical Centre) for 45 
minutes at 37 ˚C. Then sections were incubated with rabbit anti-pimonidazole (J.A. RALEIGH) 
diluted 1:1,000 for 30 minutes at 37 ˚C. Finally, sections were incubated with Alexa-Fluor-647-
conjugated chicken anti-rat IgG (A21472, 2 mg/ml, Invitrogen) diluted 1:100 and Alexa-Fluor-
488-conjugated donkey anti-rabbit IgG (A21206, 2 mg/ml, Invitrogen) diluted 1:600 for 60 
minutes at 37 ˚C. Nuclei were visualised using Hoechst 33342 (1 mg/ml) 1:3,000 for 5 
minutes. Slides were mounted in Fluorostab (ICN Pharmaceuticals Inc., Zoetermeer, the 
Netherlands). 
 
Tissue microarray (TMA) of breast cancer patients 
For the TMA construction, formalin fixed paraffin embedded (FFPE) tumour sections were 
marked on haematoxylin and eosin-stained slides of the primary tumours by a pathologist. 
TMAs were constructed with a tissue arrayer using a two mm diameter punch (Beecher 
Instruments, Silver Spring, MD, USA). Staining for LAMP3 was performed as described in the 
next section and scored blinded for outcome semiquantitatively as being either absent/low or 
present/high. 
 
Immunohistochemical assessment of LAMP3 in FFPE sections 
FFPE sections were dewaxed in Histosafe (Adamas Instruments BV., Leersum, the 
Netherlands) and rehydrated in graded alcohols. Antigen retrieval was performed by boiling 
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sections in 10 mM citrate buffer pH 6.0 (Dako, Glostrup, Denmark) for 30 minutes after 
which endogenous peroxidase was blocked for 10 minutes using 3% H2O2 in methanol. 
Sections were incubated for 30 minutes with 5% normal donkey serum (Jackson) in PAD and 
subsequently incubated overnight at 4 ˚C with goat anti-human-LAMP3 (R&D systems), 
diluted 1:100 in PAD. Next, sections were incubated for 60 minutes with biotin-conjugated 
donkey anti-goat IgG (705-066-147, 1.5 mg/ml, Jackson), diluted 1:200 in PBS, after which 
they were incubated for 30 minutes with avidin-biotin complex reagent (Vector Laboratories 
Inc., Burlingame, CA, USA). After rinsing with deionised water, sections were incubated with 
diaminobenzidine (Invitrogen) for 10 minutes. Next, sections were rinsed with tap water and 
counterstained with haematoxylin (Klinipath) for one minute, after which they were 
dehydrated and mounted in mounting medium (Klinipath). 
 
Microscopy 
All images were acquired using IP-lab imaging software (Scanalytics Inc., Fairfax, VA, USA) in 
combination with a Leica DM 6,000 (fluorescence) microscope. 
 
Patients 
Coded tumour tissues were used in accordance with the Code of Conduct of the Federation of 
Medical Scientific Societies in the Netherlands (Code for Proper Secondary Use of Human 
Tissue in the Netherlands, http://www.fmwv.nl). The study adhered to all relevant 
institutional and national guidelines and was reported according to REMARK guidelines19. A 
series of 183 patients with unilateral, resectable breast cancers who had undergone resection of 
their primary tumour between November 1987 and December 1997 were selected based on 
the availability of RNA in the tumour bank in the Department of Laboratory Medicine of the 
Radboud University Nijmegen Medical Centre20. This bank contains material from breast 
cancer patients of seven different hospitals of the Comprehensive Cancer Centre East in the 
Netherlands. The inclusion and exclusion criteria have been described earlier20. Post-operative 
radiotherapy was given to the breast after an incomplete resection or after breast-conserving 
treatment, or parasternal when the tumour was medially localised. Axillary irradiation was given 
in the case of positive lymph nodes. A TMA was constructed from FFPE tissues as described 
above from another cohort of 61 breast cancer patients who had undergone lumpectomy and 
radiotherapy as primary treatment of their tumours between 1991 and 1996 at the Rijnstate 
Hospital, Arnhem, the Netherlands. These patients had no involved axillary lymph nodes and 
received no systemic adjuvant therapy, as was the practice at the time. Other clinicopathologic 
characteristics (steroid hormone receptor status, tumour size and histologic grade) were 
essentially similar to those of the cohort from which RNA was extracted. 
 
Statistical analysis 
Statistical analyses were carried out using SPSS 16.0 software (SPSS Benelux BV., Gorinchem, 
the Netherlands). Normality of data distribution was tested by Kolmogorov-Smirnov testing. 
An analysis of variance (ANOVA) with post-hoc Tukey’s honestly significant difference 
(HSD) testing was used to assess the effect of hypoxia on LAMP3 mRNA levels. Non-
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parametric Mann-Whitney U tests or Kruskal-Wallis tests were used to assess differences in 
LAMP3 mRNA levels between categories of patients. Locoregional control (defined as the 
time from surgery until diagnosis of locoregional recurrent disease), disease-free survival (DFS) 
time (defined as the time from surgery until diagnosis of recurrent disease), metastasis-free 
survival (defined as the time between date of surgery and diagnosis of a distant metastasis) and 
overall survival (OS) time (defined as the time between date of surgery and death by any cause) 
were used as follow-up end points. Survival curves were generated using the Kaplan-Meier 
method. Equality of survival distributions was tested using log-rank testing and Cox univariate 
and multivariate regression analyses. Variables were selected for the multivariate survival 
analyses by backward stepwise selection with removal testing based on the probability of the 
likelihood-ratio statistic, at a p > 0.10. Two-sided p-values < 0.05 were considered to be 
statistically significant. 
 
RESULTS 
Expression of LAMP3  in breast cancer cell lines 
We first measured the expression of LAMP3 mRNA in a panel of 16 different breast cancer 
cell lines under standard (normoxic) culturing conditions (see Figure 1). Three cell lines 
(SUM44PE, MPE600 and ZR75-30) displayed no measurable LAMP3 mRNA expression. In 
the other breast cell lines, levels varied >100-fold between SKBR-3 and MDA-MB-361, with 
OCUB-F cells exhibiting even higher LAMP3 levels. No association between LAMP3 
expression and cancer subtype or oestrogen receptor (ESR), progesterone receptor (PGR) or 
human epidermal growth factor receptor 2 (ERBB2) expression was found (see Figure 1). 
FIGURE 1 LAMP3 mRNA expression in a panel of breast cancer cell lines. Gene expression levels are shown relative 
to phosphoribosyl transferase 1 (HPRT1). L indicates luminal; E, ERBB2; N, normal-like; B, basal-like; O, other 
subtype; −, not detectable; +, expressed; ++, overexpressed.18 
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Expression of LAMP3 in breast cancer cells under hypoxic conditions 
In MDA-MB-231 cells, which show moderate basal LAMP3 mRNA expression levels, 
LAMP3 was strongly induced under hypoxic conditions in an oxygen-dependent manner (see  
Figure 2A). The highest induction (i.e., four-fold) was observed after 48 hours of incubation 
under severe hypoxic conditions (0.1% O2, p = 0.003). An incubation of 72 hours at 0.1% O2 
led to a reduction in LAMP3 expression compared with 48 hours. At 0.2% O2 there was a 
two-fold increase overall as a maximum, whereas at 0.5% O2 no statistically significant change 
was seen. Thus, the level of LAMP3 mRNA induction is dependent on the level of hypoxia, 
with severe hypoxia leading to a stronger induction of LAMP3 mRNA than moderate hypoxia. 
This dependency is consistent with the known oxygen dependency of UPR activation21. 
Protein expression was found to be induced in a similar manner (see Figure 2B). 
 
FIGURE 2 Induction of LAMP3 in MDA-MB-231 cells under hypoxic conditions. mRNA expression (A) was found to 
be dependent on the level of hypoxia (0.1 [dark gray], 0.2 [gray], or 0.5 [white] % O2). Gene expression levels are 
shown relative to phosphoribosyl transferase 1 (HPRT1). Data (n = 6) are presented as box-and-whisker plots with 
median values, 25 and 75 percentiles and minimal and maximal values. A similar effect was observed for protein 
expression (B). The multiple bands are distinct forms of LAMP3 carrying different glycosylations. 
 
Colocalisation of LAMP3 with hypoxic areas in breast cancer xenografts 
Next, xenografts of SKBR-3 (low endogenous expression) and MDA-MB-231 breast cancer 
cells were established in immunodeficient mice. After subcutaneous injection of the hypoxic 
cell marker pimonidazole, mice were sacrificed and xenografted tumours were stained for 
LAMP3 and hypoxia. In agreement with our in vitro expression data, we found only limited 
staining of the SKBR-3 tumours for LAMP3 in normoxic areas (see Figures 3A-C). 
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Simultaneous staining for LAMP3 and pimonidazole revealed a regional colocalisation of 
intense LAMP3 staining with areas of severe hypoxia, distant from perfused blood vessels (see 
Figure 3D). A haematoxylin and eosin staining showed the epithelial cell origin of this breast 
cancer xenograft and LAMP3 expressing cells (see Figure 3E). The MDA-MB-231 xenografted 
tumours were well oxygenated and did not show hypoxic areas or LAMP3 expression (results 
not shown). 
 
FIGURE 3 Single-field pseudo-coloured immunofluorescent images of a SKBR-3 xenograft at 100× magnification. A. 
LAMP3 (red) B. pimonidazole binding (green) and C. vessels (white) and nuclei (blue). D. superimposed image of 
LAMP3, pimo and vessels and E. haematoxylin and eosin staining of an adjacent tumour section. Yellow arrows 
indicate vessels. Bar equals 200 µm. 
 
LAMP3  mRNA expression in breast cancer 
LAMP3/HPRT mRNA values were assessed in 183 human invasive breast cancer tissues and 
were found to be log-normally distributed with a >100-fold variation in values, similar to the 
range in the breast cancer cell lines. There was no association between LAMP3 and 
menopausal status, type of surgery, histologic grade, or tumour size (pT, see Table 1). 
However, LAMP3 was significantly higher in node-positive patients (p = 0.019, Kruskal-
Wallis, see Figure 4A), steroid hormone receptor-negative tumours (p < 0.001, Mann-Whitney 
U, see Figure 4B), patients receiving radiotherapy as part of their primary treatment (p = 0.022) 
and patients receiving adjuvant systemic chemotherapy (p = 0.050). Thus, LAMP3 is 
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associated with poor prognosis characteristics (node positive, steroid hormone receptor 
negative) and therefore with more aggressive treatment (radiotherapy, chemotherapy). 
 
TABLE 1 LAMP3  mRNA levels in different clinicopathological subgroups of breast cancer patients 
 n  LAMP3  mRNA  
Total 183 Median Interquartile range p 
Menopausal status    0.196a 
pre 48 10,825 21,005  
post 135 9,883 15,524  
Histological grade    0.082a 
I/II 70 9,403 14,898  
III 65 13,998 23,164  
Tumour size    0.533b 
pT1 45 9,409 15,340  
pT2 115 9,986 16,148  
pT3 16 16,973 25,150  
pT4 6 7,772 10,803  
Nodal  status    0.019b 
0 78 9,017 14,348  
1-3 57 13,998 18,262  
≥ 4 26 10,129 15,667  
Surgery    0.904a 
lumpectomy 55 9,884 16,389  
mastectomy 128 9,889 16,440  
Radiotherapy    0.022a 
no 49 7,292 11,895  
yes 134 10,688 17,814  
Adjuvant therapy    0.195b 
none 82 9,017 15,967  
endocrine 67 10,670 15,070  
chemo 24 14,104 25,642  
both 10 15,317 15,200  
ESR    <0.001a 
neg 55 21,499 42,924  
pos 126 8,336 10,630  
PGR    <0.001a 
neg 71 15,751 28,429  
pos 111 8,932 12,471  
aMann-Whitney U test 
bKruskall-Wallis test 
 
Prognostic value of LAMP3  mRNA expression 
Patients were dichotomised based on LAMP3 levels in their primary tumour and evaluated for 
response parameters. Patients with higher levels of LAMP3 (n = 99) had more locoregional 
recurrences than those with low LAMP3 mRNA levels (n = 84), p = 0.032 log-rank (see Figure 
5A). In Cox regression analysis, this amounted to a hazard ratio (HR) of 2.85 (95% CI, 1.05 - 
7.8). There was no association with distant metastasis-free or overall survival. In exploratory 
subgroup analyses, we found that the association of LAMP3 with locoregional control was 
limited to patients who had received radiotherapy as part of their primary treatment. In 
LAMP3 AND BREAST CANCER 
  35 
patients who had not received radiotherapy, LAMP3 showed no association with locoregional 
control (n = 49, p = 0.762, see Figure 5B), whereas in patients who had received radiotherapy, 
a significant association was found (n = 134, p = 0.034, see Figure 5C). Within the patient 
cohort that had received radiotherapy, no association was found if this was part of a modified 
radical mastectomy procedure (n = 81, p = 0.615, see Figure 5D). LAMP3 was significantly 
associated with locoregional control but only in those patients who received radiotherapy as 
part of breast-conserving lumpectomy (n = 53, p = 0.009, see Figure 5E). In multivariate Cox 
regression analysis, only LAMP3 remained as an independent prognostic factor for 
locoregional recurrences (HR = 2.76, 95% CI, 1.01 - 7.5, p = 0.048) after correction for 
menopausal status, histologic grade, tumour size, nodal status, therapy and steroid hormone 
receptor status (see Table 2). 
 
FIGURE 4 Differences in LAMP3/phosphoribosyl transferase 1 (HPRT1) values in (A) patients with 0, 1 to 3 or ≥ 4 
positive lymph nodes (p = 0.019) and (B) ESR-negative and ESR-positive (p < 0.001) tumours. Horizontal bars 
represent median values. Open symbols represent outliers above the range of the chosen y-axis. 
 
Immunohistochemical validation of prognostic value of LAMP3  mRNA 
We set out to validate the data on LAMP3 mRNA as being prognostic in breast cancer 
patients who were treated with lumpectomy and radiotherapy on the protein level. For this, 
LAMP3 protein was semiquantitatively scored in TMA of a series of FFPE sections of breast 
cancer patients that were only treated with lumpectomy and radiotherapy. These patients 
received no adjuvant systemic therapy, making it possible to distinguish a prognostic from a 
predictive value of LAMP3 in these patients. Of the 61 patients, 21 (34%) had low or absent 
levels of LAMP3 protein (see Figure 6A) and 40 (66%) had high levels (see Figure 6B) of 
LAMP3 protein in their tumour. Despite the clear difference in the number of events between 
these subgroups (1 vs. 8 in the LAMP3 low and high cohort, respectively), the power was too 
low to obtain a significant difference in locoregional control (p = 0.121). These two categories 
of patients did, however, differ significantly in both disease-free survival (DFS) (p = 0.024, see 
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Figure 6C) and overall survival (OS) time (p = 0.019, see Figure 6D), confirming the 
prognostic value of LAMP3 mRNA levels in this patient group on the protein level. 
FIGURE 5 Prognostic value of LAMP3 mRNA levels. A. Patients with high LAMP3 mRNA levels (dashed line) in 
their primary tumour experienced more locoregional recurrences (p = 0.032, log-rank). B. There is no association with 
locoregional control in patients who had no radiotherapy (n = 49, p = 0.762), but (C) only in patients who had 
received radiotherapy (n = 134, p = 0.034). D. LAMP3 was not prognostic if radiotherapy was part of a modified 
radical mastectomy procedure (n = 81, p = 0.615), but (E) only as part of a breast-conserving lumpectomy (n = 53, p = 
0.009). 
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TABLE 2 Uni- and Multivariate Cox Regression survival analyses for locoregional control 
 Univariate analysis Multivariate analysis 
 HR 95% CI p HR 95% CI p 
Menopausal status   0.827   0.942 
post vs. pre 0.827 0.320 - 2.134  0.964 0.360 - 2.579  
Histological grade   0.459   0.598 
III vs. I/II 1.433 0.553 - 3.718  1.622 0.605 - 4.352  
Tumour size   0.571   0.368 
pT2 vs. pT1 1.905 0.630 - 5.768  1.989 0.640 - 6.185  
pT3 vs. pT1 0.974 0.108 - 8.746  1.125 0.118 - 10.74  
pT4 vs. pT1 2.783 0.309 - 25.07  6.663 0.646 - 68.72  
Nodal  status   0.596   0.669 
1-3 vs. 0 1.531 0.621 - 3.771  1.414 0.104 - 19.283  
≥ 4 vs. 0 0.906 0.194 - 4.227  0.523 0.027 - 10.197  
Surgery   0.766   0.545 
mastectomy vs. lumpectomy 0.873 0.360 - 2.117  0.761 0.314 - 1.845  
Radiotherapy   0.561   0.718 
yes vs. no 1.381 0.465 - 4.108  0.826 0.215 - 3.172  
Adjuvant therapy   0.462   0.952 
endocrine vs. none 1.173 0.465 - 2.956  1.384 0.546 - 3.506  
chemo vs. none 1.311 0.353 - 4.868  1.196 0.319 - 4.477  
both vs. none -a -     
ESR   0.497   0.641 
pos vs. neg 0.726 0.293 - 1.798  1.371 0.364 - 5.155  
PGR   0.488   0.699 
pos vs. neg 0.736 0.310 - 1.749  0.833 0.329 - 2.107  
LAMP3   0.028   0.048 
high vs. low 2.853 1.044 - 7.792  2.758 1.010 - 7.534  
a too few events  
DISCUSSION 
In this study, the occurrence and prognostic relevance of LAMP3 in breast cancer was 
evaluated. We present evidence indicating that LAMP3 mRNA levels are elevated in aggressive 
ESR-negative breast tumours and in tumours that have already spread to the axillary lymph 
nodes. Patients with high LAMP3 mRNA levels also have more locoregional recurrences than 
those with low levels, a phenomenon that remains after correction for menopausal status, 
tumour size, histologic grade, nodal status, steroid hormone receptor status, adjuvant therapy 
and radiotherapy. The prognostic value of LAMP3 for locoregional control is limited to 
patients treated with breast-conserving lumpectomy and radiotherapy. The prognostic value of 
LAMP3 mRNA is also seen for LAMP3 protein as assessed by immunohistochemistry. 
In 2004, TREILLEUX et al. examined the potential prognostic role of LAMP3 in breast cancer 
tissue using a semiquantitative immunohistochemical analysis22. They found that the presence 
of mature LAMP3 positive dendritic cells within clusters of lymphocytes at the margin of the 
tumour correlated with lymph node involvement and tumour grade, although no association 
with prognosis was found. Our immunohistochemical data indicate that tumour hypoxia is also 
an important regulator of LAMP3 in the epithelial cancer cells. LAMP3 expression in breast 
cancer xenografts colocalises with tumour cell hypoxia as revealed by pimonidazole labelling. 
Together with our immunohistochemical data on actual breast tumours, this indicates that 
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lymphocyte infiltration, which reportedly has different effects on prognosis in breast cancer 
depending on ESR-status23, is unlikely to be the sole cause of the association of LAMP3 
mRNA with prognosis we report here. Rather, the tumour epithelial cells themselves aberrantly 
express LAMP3, with consequences for locoregional control. 
 
FIGURE 6 Validation of the prognostic value of LAMP3 mRNA via immunohistochemical staining of LAMP3 protein 
on a tissue microarray of formalin fixed paraffin embedded breast cancer tissues (n = 61). A. Typical example of a 
tumour with low/absent levels of LAMP3 protein expression at 100× and 400× magnification. B. Typical example of 
a tumour with high levels of LAMP3 protein at 100× and 400× magnification. Patients with high levels of LAMP3 
protein (dashed line, n = 40, 66%) have a worse (C) disease-free survival (DFS, p = 0.024) and (D) overall survival 
(OS, p = 0.019) compared with patients with low LAMP3 protein levels (solid line, n = 21, 34%). 
 
LAMPs have previously been implicated in cancer24-26, especially in relation to metastatic 
potential of tumours they may serve important functions6,27,28. LAMPs are characterised by 
high and complex levels of glycosylation4,29. They are the main carriers of sialyl-Lex (sialylated 
Lewis X antigen), which is amplified in carcinoma cells30. Via these carbohydrates, tumour cells 
are able to connect with E-selectins, adhere to endothelial cells and form metastases, 
suggesting that LAMPs play a role in the metastasis of certain solid tumours31-33. Indeed, 
overexpression of LAMP3 in cervical cancer cells used for xenografts led to an enhancement 
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of formation of metastasis2. Our observation that mRNA levels are significantly higher in 
breast cancer patients with positive axillary lymph nodes would indicate that LAMP3 might 
also serve a role in metastasis of breast cancers. Other studies have demonstrated that tumour 
hypoxia is also associated with a more malignant phenotype and a higher prevalence of 
metastasis10-12. Although a direct link between hypoxia, LAMP3 and metastasis has not yet 
been explored, hypoxia was found to increase the expression of LAMP-associated sialyl-Lex at 
the surface of colon cancer cells34. This leads to increased adhesion to endothelial E-selectin 
and potentially could provide a mechanism for hypoxia-mediated metastasis. We did not find 
an association between LAMP3 mRNA expression in breast cancer and distant metastasis-free 
survival in our breast cancer cohort. However, it is possible that protein localisation and/or 
glycosylation patterns of the protein may be relevant for its association with metastasis. 
Interestingly, unlike most other hypoxia targets, LAMP3 induction occurs independently of the 
master hypoxia transcription factor hypoxia-inducible factor 1α (HIF1α)14. Consistent with 
previous reports, we found that LAMP3 induction was dependent on the level of hypoxia, 
with severe hypoxia being most effective. This is consistent with the reported dependency of 
UPR activation in response to hypoxia. The UPR is induced potently and rapidly under 
conditions of severe hypoxia but requires oxygen levels well below those required for most 
HIF1 target genes21. As such, LAMP3 may serve as a unique biomarker for the presence of 
UPR activation under conditions of severe hypoxia in human tumours. This is interesting in 
the context of our intriguing finding that LAMP3 is specifically related to locoregional control 
in patients treated with breast-conserving lumpectomy and radiotherapy. We speculate that 
high levels of LAMP3 and UPR activation may indicate the presence of substantial number of 
radiation resistant hypoxic cells in these tumours. As such, LAMP3 may be a particularly useful 
marker of the radiation resistant fraction of the tumour. There have been intense efforts made 
at identifying endogenous markers of tumour hypoxia35,36, although most of these studies have 
focused on HIF target genes such as carbonic anhydrase 9 (CA9), glucose transporters 
(GLUT-1,4) and vascular endothelial growth factor (VEGF). Although clearly important, these 
hypoxia targets are activated at moderate oxygen concentrations (1% to 2% oxygen), which 
may not be sufficient to cause radiation resistance. Tumour cells become maximally radiation 
resistant below 0.1% oxygen, levels that are well below those required to activate HIF. The 
UPR and LAMP3 may thus provide a more accurate surrogate of oxygenation levels associated 
with clinical resistance to radiotherapy. Our results suggest that the prognostic value of 
LAMP3 in breast cancer is due to its induction by severe hypoxia, the consequential 
association with radiotherapy resistance and lack of locoregional control. 
In conclusion, LAMP3 is expressed to highly variable levels within a large panel of breast 
cancer cell lines and breast cancer patient samples. In addition, LAMP3 is strongly induced by 
hypoxia both in vitro and in vivo. The correlation between LAMP3 mRNA expression and nodal 
spread strengthens the concept of a function of LAMP3 in (hypoxia-mediated) metastasis 
formation in (breast) cancer. Furthermore, the identification of LAMP3 as an independent 
prognostic factor for locoregional recurrence supports the notion that LAMP3 may be a 
biomarker for hypoxia-mediated treatment resistance. 
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ABSTRACT 
The multicellular tumour spheroid model is a widely used culture system to mimic the three-
dimensionality of tumours. Several methods and an even larger number of protocols are 
available to prepare spheroids from regular monolayers. This paper describes the assessment of 
several techniques frequently used to culture spheroids of breast cancer cells. We found that 
some methods produced suboptimal results. Ultimately, an adapted liquid overlay technique 
generated tight, compact and robust spheroids of the breast cancer cells tested.  
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An important characteristic of solid tumours is their rapid expansion. Due to the incapability 
of blood vessels to keep up with tumour growth, beyond a certain size poorly vascularised 
regions will occur. Consequently, areas with oxygen deficiency (hypoxia) and nutrient 
deprivation are present in most solid tumours. To study this characteristic tumour 
microenvironment, several methods are available, including the use of biopsy material from 
patients, animal models and two-dimensional in vitro cell cultures. These models have their own 
advantages and disadvantages. Patient material has its own microenvironment, but 
manipulating experimentally is difficult. Material is prone to inter- and intra-experiment 
variation and does usually not allow for multiple measurements during experiments. Animal 
models have microenvironmental complexity and can be manipulated but are relatively 
expensive and time-consuming and can require large numbers of animals. Two-dimensional 
cell cultures are easily used and manipulated but lack the complexity of a malignant tumour. 
Microenvironmental conditions, such as hypoxia or nutrient deficiency can be artificially 
induced in cultures, but the characteristic regional pattern of tumours will always be absent. 
This leaves a tremendous difference between in vitro cultures and in vivo tumours, that can be 
partially filled by the use of three-dimensional cell cultures: spheroids. Multicellular tumour 
spheroids have been employed since the pioneering work of SUTHERLAND and co-workers, 
who used spheroids to study the in vitro response to drugs and radiotherapy1,2. Ever since then, 
spheroids have been applied to study several aspects of cell biology: metabolism, apoptosis, 
necrosis, proliferation, differentiation, angiogenesis and metastasis3-7. In literature, the term 
spheroid is not well defined. Several terms are used to describe three-dimensional cell clusters: 
aggregates, spheres, spheroids, tumouroids and organoids3. Typically, spheroids are round or 
elliptic globe-like structures. In our view, spheroids should be tight and compact structures, 
similar to in vivo tumours and can be handled without causing mechanical dissociation of the 
cells. In proliferating spheroids, at a certain diameter cells in the centre will encounter 
limitations in their oxygen and nutrient supplies. Consequentially, a necrotic core will develop. 
This core is surrounded by a rim of quiescent, hypoxic cells, which itself is surrounded by a 
rim of proliferating cells. Numerous techniques are available to culture cancer cells as 
spheroids (reviewed in 3,8). However, in literature there is little technical information available 
that compares different methods to generate spheroids. We have tried several techniques to 
make spheroids of two commonly used breast cancer cell lines, MCF-7 and MDA-MB-231. 
Notably, we found that some regularly used methods do not yield the compact, uniformly 
shaped spheroids we are looking for. Here, we report our findings on which methods we could 
use to make our spheroids tight and compact.   
 
To culture spheroids, cells must prefer to adhere to each other instead of to the substratum on 
which they are plated. This can be achieved both mechanically, by continuous movement of 
the cells (spinner culture) or by defying gravity (hanging drop technique), and chemically, by 
using non-adhesive substrates to culture cells on (liquid overlay technique).  
Spinner cultures are widely used3,5. Permanent movement prevents cells from adhering to the 
flask. Consequently, cells will attach to each other and form spheroids. This method has the 
advantage that spheroids can be produced on a large scale. However, the mechanical forces 
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exerted on the cells may cause damage. Spinner cultures require specialised equipment and for 
each cell line conditions need to be optimised. In addition, the spheroids generated tend to be 
of different size and shape, making standardisation problematic. For example, the effect of a 
drug on spheroid size would be difficult to quantify if starting points already differ. Other 
methods are therefore worthwhile exploring. 
In the hanging drop technique gravitational force induces cell aggregation. We used this 
method on MDA-MB-231 and MCF-7 cells. Ten thousand cells were plated in 25 µl drops on 
the lids of standard 10-cm cell culture plates. Lids are more hydrophobic (i.e. better able to 
hold a drop together) than the bottom of the dish. Often viscous components, like 
methylcellulose, are added to the medium to increase its thickness. Addition of 0.24% (w/v) 
methylcellulose to the culture medium was indeed necessary for cell aggregation (see Figure 1A 
and B). To form clusters, we also tried adding 2.5% reconstituted basement membrane 
(Matrigel) to the medium. This, however, did not result in the formation of cell clusters at all. 
In contrast, with addition of methylcellulose, within 24 hours after plating cell clusters formed 
at the bottom of the drops. Still, tight and compact spheroids never formed. Instead, these 
aggregates were flat and disc-shaped (see Figure 1C and D) and cells adhered to each other 
very weakly. This made aggregates extremely delicate to handle and often they disintegrated by 
simply pipetting them. The disc-shape caused aggregates to lack the characteristic hypoxic 
core, evident by the absence of the exogenous hypoxia marker pimonidazole (see Figure 1E 
and F). Several studies on gliomas indicated that after aggregate formation in hanging drops, 
cell clusters should be placed on a non-adherent surface, such as agar, for several days to make 
them form true ball-shaped spheroids9,10. For our breast cancer cells this was not the solution. 
On agar, aggregates stuck to each other and did not compact to true spheroids. Instead, 
aggregates adopted a cup-shaped appearance, after which they disaggregated and cells died. 
Therefore, we continued our search for an optimal method to generate spheroids. 
FRIEDRICH and co-workers suggested a liquid overlay technique in 96-wells plates using 
agarose as the non-adherent substrate11. The advantage of using 96 separate wells in 
comparison with one big plate is the generation of similar-sized spheroids that cannot adhere 
to each other. The authors tested the ability of several cell lines of different origin, including 
six breast cancer cell lines, to generate spheroids. Spontaneous spheroid formation was 
assessed four days after seeding cells in coated plates. This study showed a vast difference in 
the ability of cell lines to compact into tight spheroids. Several cell lines did not compact at all 
and remained in a state of loose aggregation. MCF-7 cells did generate a compact spheroid, 
albeit of irregular shape11.  
We tested this method on our MDA-MB-231 and MCF-7 cells and confirmed the results 
found by FRIEDRICH and co-workers. Our MCF-7 cells formed firm aggregates but were 
uneven in appearance (see Figure 2A and Supplementary Movie 1). Our MDA-MB-231 cells 
did not compact into the tight spheroids we sought and formed loose aggregates (see Figure 
2B). Because this method could not provide us with the spheroid structure we were seeking, 
we attempted another protocol. 
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FIGURE 1 Hanging drop aggregates of MDA-MB-231 cells after 24 hours with (A) and without (B) methylcellulose 
addition. Per drop 10,000 cells were plated. C. Schematic illustration of the effect of rotating a cell culture plate with 
hanging drops when microscopically imaging aggregates. D. Microscopic image sequence of a rotating hanging drop 
with an aggregate of MCF-7 cells 24 hours after initiation. Per drop 10,000 cells were plated. Time frame of the image 
sequence is 5 seconds. Cross-sections of hanging drop aggregates with methylcellulose of MCF-7 (E) and MDA-MB-
231 (F) cells. Per drop 10,000 cells were plated. Twenty-four hours after seeding aggregates were incubated with 200 
µM pimonidazole (1-[(2-hydroxy-3-piperidinyl)propyl]-2-nitroimidazole hydrochloride, Natural Pharmacia 
International Inc., Burlington, MA, USA) for 1 hour, after which aggregates were fixed and sectioned. Sections were 
stained as previously described13 with mouse anti-pimonidazole (Natural Pharmacia) diluted 1:800 and biotin-
conjugated donkey anti-mouse (Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA) 1:200. Notice the 
absence of hypoxia. Bars equal 100 µm. 
 
FIGURE 2 Aggregate formation of MCF-7 (A) and MDA-MB-231 (B) cells after plating 5,000 cells on agarose for 24 
hours. Effect of Matrigel addition on spheroid formation with poly-HEMA coated plates in MDA-MB-231 cells. 
Without (C) and with (D) Matrigel addition. Per well 10,000 cells were plated, images were acquired after 24 hours. 
Staining of a 24 hour-old MDA-MB-231 spheroid for hypoxia (E) and integrin β1 (F). Integrin β1 staining was 
performed as previously described13 with rabbit anti-integrin β1 (Cell Signaling Technology, Danvers, MA, USA) 
diluted 1:500 and biotin-conjugated donkey anti-rabbit (Jackson) 1:400. Bars equal 100 µm. 
 
A different liquid overlay technique in 96-wells plates was described by IVASCU and KUBBIES12. 
The non-adherent substrate poly-hydroxyethylmethacrylate (poly-HEMA) was used to coat V-
shaped 96-wells plates. V-shaped wells have the advantage that cells can be collected in the 
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cone of the V by a gentle centrifugation step, generating rounder spheroids12. This study also 
examined the cause of the difference between breast cancer cells that only aggregate and those 
compacting to true spheroids. Spheroid compaction of MDA-MB-231 cells was tested with 
addition of exogenous extracellular matrix compounds such as fibronectin, laminin, or 
Matrigel. Matrigel addition gave compact, tight spheroids12. Our experiments confirmed that 
several breast cancer cell lines can use Matrigel to form compact spheroids (see Figure 2C and 
D and Supplementary Movie 2). Below, we specify the precise protocol used.  
At least three days before initiating spheroid culture, V-shaped 96-wells plates (Greiner Bio-
one, Alphen a/d Rijn, the Netherlands) are coated with a 0.5% (w/v) solution of poly-HEMA 
(Sigma Aldrich, St. Louis, MO, USA) in 95% ethanol. To dissolve poly-HEMA, we incubate 
the solution in a water bath of 65 ˚C and vortex it frequently. Each well is coated with 50 µl of 
this solution. Plates are incubated at 37 ˚C to evaporate the ethanol for 72 hours. Next, 10,000 
cells are added per well. Medium containing 2.5% Matrigel (BD biosciences, San Jose, CA, 
USA) is used if cells do not compact into a spheroid on their own. The plate is centrifuged for 
10 minutes at 1,000 × g, after which it is placed in a standard cell incubator at 37 ˚C with 5% 
CO2 and left alone until the required spheroid size is reached. 
Using this technique we generated spheroids of MCF-7 and MDA-MB-231 cells, but also of 
other breast cancer cell lines: MDA-MB-175, MDA-MB-436, MDA-MB-468, OCUB-F, 
SKBR-3 and HCC-1937. All cell lines compacted into firm spheroids within 24 hours (see 
Figure 2D and Supplementary Movie 2B), during which a striking tendency to attach to each 
other was observed (see Supplementary Movies 2B and 3). Spheroids harvested 24 hours after 
initiation already showed hypoxic cores (see Figure 2E). An overview of all techniques tested 
and their outcomes is given in Table 1. 
After spheroids were generated, we used them originally for immunohistochemistry. We 
produced both cryo- and formalin fixed paraffin embedded (FFPE) sections. For cryosections, 
spheroids were collected in a test-tube and accumulated at the bottom using gravitational 
force. The supernatant was discarded before washing the spheroids with HBSS containing 
calcium and magnesium (Gibco, Carlsbad, CA, USA). Spheroids were embedded in TissueTek 
OCT (Sakura Finetek Europe, Zoeterwoude, the Netherlands) diluted with HBSS (1:1) and 
snap frozen. The generated spheroid block was then ready for sectioning. We made FFPE 
spheroids by again collecting and washing the spheroids. They were fixed overnight at room 
temperature in 4% paraformaldehyde (Sigma), after which they were washed once more with 
HBSS. Next, spheroids were embedded in 2% (w/v) agarose (Sigma) in HBSS. This agarose 
disc was embedded in paraffin, after which it could be sectioned and stained. Examples of 
stainings are shown in Figure 2E and F. Here, FFPE sections were used to stain for 
pimonidazole (hypoxia) and integrin β1 (cell-cell adhesion). 
 
Taken together, we found that several methods to generate spheroids of breast cancer cells can 
provide the user with suboptimal results. Using the Matrigel addition method with poly-
HEMA coated V-shaped 96-wells plates, we were able to generate the firm spheroids with 
strong cell-cell contacts and a microenvironment that we were seeking instead of loosely 
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coherent aggregates. This method allows for experimental manipulation and 
immunohistochemical analysis of the spheroids. 
 
TABLE 1 Evaluation of different techniques to generate spheroids of breast cancer cells after 24 hours 
Technique Cell line Cell 
number* 
Evaluation after 24 hours 
   Standard cell 
culture medium 
Addition of 
Matrigel 
Addition of 
Methylcellulose 
Hanging 
drop 
MDA-MB-231 10,000 No aggregation No aggregation Loose without 
hypoxic core 
 MCF-7 10,000 No aggregation No aggregation Tight without 
hypoxic core 
MDA-MB-231 5,000 Irregular shaped 
loose fragile 
aggregate 
n.d. n.d. Liquid 
overlay 
(agarose) 
MCF-7 5,000 Irregular shaped 
tight aggregate 
n.d. n.d. 
MDA-MB-231 10,000 Loose Tight with 
hypoxic core 
n.d. 
MCF-7 10,000 Tight Tight with 
hypoxic core 
n.d. 
MDA-MB-175 10,000 Loose Tight with 
hypoxic core 
n.d. 
MDA-MB-436 10,000 Loose Tight with 
hypoxic core 
n.d. 
MDA-MB-468 10,000 Loose Tight with 
hypoxic core 
n.d. 
OCUB-F 10,000 Loose Tight with 
hypoxic core 
n.d. 
SKBR-3 10,000 Loose Tight with 
hypoxic core 
n.d. 
Liquid 
overlay 
(poly-
HEMA) 
HCC-1937 10,000 Loose Tight with 
hypoxic core 
n.d. 
n.d. not determined; * The cell number indicated reflects the optimal number to generate spheroids. Use of a larger 
number of cells resulted in not all cells participating in spheroid formation. With a smaller number of cells spheroids 
were generated, but naturally they were smaller in size and the hypoxic core took longer to establish. 
 
SUPPLEMENTARY MATERIAL 
Supplementary data associated with this article can be found, in the online version, at 
http://dx.doi.org/10.1016/j.ab.2013.02.004. 
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ABSTRACT 
Background 
The hypoxia-inducible factor (HIF) 1 pathway can stimulate tumour cell migration and 
metastasis. Furthermore, hypoxic tumours are associated with a poor prognosis. Besides the 
HIF1 pathway, the unfolded protein response (UPR) is also induced by hypoxic conditions. 
The PKR-like ER kinase (PERK)/activating transcription factor 4 (ATF4)-arm of the UPR 
induces expression of lysosome-associated membrane protein 3 (LAMP3), a factor that has 
been linked to metastasis and poor prognosis in solid tumours. In this study the role of UPR-
induced LAMP3 in hypoxia-mediated migration of breast cancer cells was examined.  
Methods  
A number of in vitro metastasis models was used to study the migration and invasion of MDA-
MB-231 breast cancer cells under hypoxic conditions. PERK, ATF4 and their downstream 
factor LAMP3 were knocked down to examine their role in cell migration. In addition, 
multicellular tumour spheroids were used to study the involvement of the tumour 
microenvironment in invasion.  
Results  
Using transwell assays, migration of different breast cancer cell lines was assessed. A direct 
correlation was found between cell migration and baseline LAMP3 expression. Furthermore, 
moderate hypoxia (1% O2) was found to be optimal in stimulating migration of MDA-MB-231 
cells. siRNA mediated knockdown of PERK, ATF4 and LAMP3 reduced migration of cells 
under these conditions. Using gap closure assays, similar results were found. In a three-
dimensional invasion assay into collagen, LAMP3 knockdown cells showed a diminished 
capacity to invade compared to control cells when collectively grown in multicellular spheroids.  
Conclusions  
Thus, the PERK/ATF4/LAMP3-arm of the UPR is an additional pathway mediating hypoxia-
induced breast cancer cell migration. 
 
KEYWORDS 
breast cancer, hypoxia, UPR, LAMP3, metastasis, spheroid
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INTRODUCTION 
Breast cancer mortality is caused foremost by the spread of cancer cells within the host in a 
process called metastasis1. Before tumour cells can metastasise, the tumour will need to invade, 
seek access to the lymphatic or vascular system and colonise the metastatic site2,3. Insights in 
this process will aid in the prevention of cancer metastasis and help improve prognosis. 
An important characteristic of most solid tumours is the presence of hypoxic regions4-6. 
Absent or inadequate vasculature within the tumour causes disruption of the supply of blood 
and consequentially an impaired delivery of oxygen and nutrients and an impaired removal of 
carbon dioxide and waste products. Several studies found low oxygen tension in tumours to be 
an adverse prognostic marker in different tumour types7-10. In addition, endogenous hypoxia-
related markers, such as carbonic anhydrase 9, were also shown to negatively influence patient 
outcome in breast cancer11,12. Furthermore, hypoxic tumours were found to correlate with 
metastatic occurrences: patients with hypoxic primary tumours developed more metastases 
than patients with less hypoxic tumours7,13-15. Mechanistically, numerous factors have been 
identified that are induced by hypoxia and that can promote metastasis (reviewed in 16-20). The 
common denominator of most, if not all, of these factors is that they are either directly or 
indirectly influenced by the action of the family of master transcription regulators during 
hypoxic conditions: the hypoxia-inducible factor (HIF)-family18.  
Recently, a separate pathway from the HIFs was described, which is able to regulate gene 
expression during hypoxia, namely the unfolded protein response or UPR21-24. Within this 
response three distinct arms have been classified: the PKR-like endoplasmic reticulum kinase 
(PERK)/activating transcription factor 4 (ATF4)-arm, the inositol-requiring enzyme 1 (IRE1)-
arm and the activating transcription factor 6 (ATF6)-arm. These pathways are activated during 
endoplasmic reticulum stress conditions and enable cell survival by regulating apoptosis, 
angiogenesis and autophagy22-25. Thus far, the UPR has not been directly implicated in 
hypoxia-induced metastasis. However, recently lysosome-associated membrane protein 3 
(LAMP3, also known as DC-LAMP, TSC403 or CD208) was identified as a factor induced by 
hypoxia as part of the PERK/ATF4-arm of the UPR26,27. In addition, we found that LAMP3 
has prognostic relevance in breast cancer28. Two homologues of LAMP3, LAMP1 and 
LAMP2, have been associated with cancer metastasis previously29,30. LAMP3 itself was also 
found to be involved in metastasis: overexpression of LAMP3 in a cervical xenograft model 
showed an increased metastatic potential31. In what way LAMP3 is involved in breast cancer 
metastasis and which role hypoxia may have in this process is unknown. Therefore, we set out 
to determine whether the UPR can influence migration and invasion of breast cancer cells via 
LAMP3 under hypoxic conditions. 
 
MATERIALS AND METHODS 
Cell culture and hypoxic incubations 
All cell lines used were obtained from LGC Promochem (Teddington, UK) and maintained in 
Dulbecco’s modified Eagles medium supplemented with 10% (v/v) foetal bovine serum, 20 
mM Hepes, 1× non-essential amino acids, 2 mM L-glutamine and 10 U/ml penicillin, 10 
µg/ml streptomycin (all from PAA Laboratories, Cölbe, Germany) at 37 ˚C with 5% CO2. 
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Hypoxic conditions were induced with a H35 Hypoxystation (Don Whitley Scientific Ltd., 
Shipley, UK). 
 
Cell migration using modified Boyden Chambers 
Membranes with 8 µm pores (Greiner Bio-one, Alphen a/d Rijn, the Netherlands) were used 
in a 24-wells format. A total of 40,000 cells, serum-starved overnight where indicated, were 
added to the upper compartment. The lower compartment was filled with standard cell culture 
medium. Cells were allowed to migrate for 24 hours, after which chambers were fixed for 10 
minutes in cold 70% ethanol. Membranes were stained with 0.5% (w/v) crystal violet (Sigma 
Aldrich, St. Louis, MO, USA) for 30 minutes and subsequently washed thoroughly with tap 
water. Cells that had not migrated to the lower compartment were removed with a cotton 
swab. Migrated cells were quantified by solubilising bound crystal violet in 1% (w/v) sodium 
dodecyl sulfate (SDS, Sigma) for 1 hour at 37 ˚C. Absorbance was measured at 595 nm. 
 
RNA isolation, cDNA synthesis and quantitative RT-PCR 
RNA was isolated with Norgen’s Total RNA purification kit (Norgen Biotek Corp., Thorold, 
Canada) and stored at -80 ˚C until further processing. cDNA was synthesised using the iScript 
cDNA synthesis kit (Bio-Rad Laboratories Inc., Richmond, CA, USA) with 1 µg RNA as 
input. The following primers were used for the RT-qPCR: PERK FW: 5’-
CTGATTTTGAGCCAATTC-3’ and RV: 5’-CCGGTACTCGCGTCGCTG-3’, ATF4 FW: 5’-
CCTTCACCTTCTTACAACCT-3’ and RV: 5’-GTAGTCTGGCTTCCTATCTC-3’, LAMP3 FW: 5’-
TGAAAACAACCGATGTCCAA-3’ and RV: 5’-TCAGACGAGCACTCATCCAC-3’. RT-qPCR was 
carried out on a CFX96 real-time PCR detection system (Bio-Rad) with SYBR green (Applied 
Biosystems, Foster City, CA, USA). As a reference gene, hypoxanthine phosphoribosyl 
transferase 1 (HPRT1) in a pre-developed assay (Applied Biosystems) was used.  
 
Transient transfection 
Cells were transfected transiently for PERK, ATF4 or LAMP3 using mission siRNAs (Sigma): 
PERK: SASI_HS01_00096845 and SASI_HS01_00096846, ATF4: SASI_HS02_00332313 and 
SASI_HS01_00175197, LAMP3: SASI_HS01_00214233 and SASI_HS02_00345584. 
Transfections were performed using Saint-Red (Synvolux Therapeutics, Groningen, the 
Netherlands) according to the manufacturer’s instructions. 
 
Generation of stable MDA-MB-231 shLAMP3 pools  
A U6 promoter-driven short hairpin RNA (shRNA) expression vector targeting LAMP3 and a 
non-targeting control vector (pLKO1_shLAMP3 (TRCN0000148784, number 842) and 
pLKO.1 control, respectively) were purchased from Sigma. Briefly, pseudo-typed lentiviral 
particles were produced in HEK293FT cells using the ViraPower lentiviral expression system 
according to the manufacturer’s instructions (Invitrogen, Carlsbad, CA, USA). MDA-MB-231 
cells were infected at a low passage number after which a pool of transfected cells was derived 
by puromycin (4 µg/ml) selection for approximately 10 days.  
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Colony forming assays 
For the colony forming assays 500 transiently transfected cells were plated in T25 cell culture 
flasks (Greiner Bio-one) and allowed to adhere overnight. Cells were incubated under hypoxic 
conditions (1% O2) for 24 hours after which they were transferred to the normoxic incubator 
and given time to form colonies. Once colonies in the normoxic controls comprised at least 50 
cells, flasks were fixated in 70% ethanol for 10 minutes at 4 ˚C and stained with 0.5% crystal 
violet for 30 minutes. Colonies of at least 50 cells were scored manually. 
 
Gap closure assays 
Monolayer gap closure assays (formerly known as scratch assays) were conducted using 
silicone cell culture inserts (Ibidi, Martinsried, Germany) attached to culture plates. In short, 
30,000 cells were seeded in the inserts and allowed to recover overnight to form a confluent 
monolayer. Inserts were removed with tweezers, after which cells were rinsed thrice with 
Hank’s buffered saline solution (HBSS, PAA) to remove detached cells. Culture medium was 
re-added and closure of the gap was followed for 24 hours using live imaging (see below). Gap 
closure was quantified using ImageJ (National Institutes of Health, Bethesda, MD, USA).  
 
Spheroid culture 
Multicellular tumour spheroids were prepared from conventional monolayer cultures using an 
adapted liquid overlay technique. In short, V-shaped 96-wells plates (Greiner Bio-one) were 
coated with 0.5% (w/v) poly-HEMA (Sigma). A total of 1,000 cells in 100 µl of standard 
culture medium with 2.5% (v/v) Matrigel (BD Biosciences, San Jose, CA, USA) were added to 
each well, after which cells were spun down for 10 minutes at 1,000 × g. Within 24 hours 
spheroids were formed. 
 
Pimonidazole staining 
After formation, MDA-MB-231 spheroids were incubated for 1 hour with 200 µ M of 
pimonidazole (1-[(2-hydroxy-3-piperidinyl)propyl]-2-nitroimidazole hydrochloride, Natural 
Pharmacia International Inc., Burlington, MA, USA). Next, spheroids were fixed in 4% 
paraformaldehyde (Merck Chemicals, Darmstadt, Germany) and embedded in paraffin. 
Staining was performed on 5-µm sections as previously described28, using the following 
antibodies: mouse anti-pimonidazole (Natural Pharmacia International Inc.) diluted 1:800 and 
biotin-conjugated donkey anti-mouse IgG (715-066-150, Jackson ImmunoResearch 
Laboratories Inc., West Grove, PA, USA) diluted 1:200. 
 
Cell labelling with cell tracker 
To label cells with CellTracker Green (Life Technologies, Carlsbad, CA, USA) or CellTracker 
Orange (Life Technologies), 0.15 x 106 cells/ml were seeded in a T75 cell culture flask (Greiner 
Bio-one). Cells were allowed to adhere, after which CellTracker was dissolved in DMSO and 
added at 10 µM to the cell culture medium. Flasks were incubated at 37 ˚C for 45 minutes. 
Next, cell culture medium was replenished and cells were allowed to recover for 30 minutes, 
after which they were ready for further experimentation. 
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Spheroid invasion assays in collagen 
Twenty-four hours after formation, spheroids were embedded into collagen. Spheroids were 
collected in a 15 ml tube and allowed to descend to the bottom. Cell culture medium was 
renewed once. Next, the spheroids were combined with 4 mg/ml of rat-tail collagen type I 
(BD Biosciences), according to the manufacturer’s instructions. The collagen was allowed to 
polymerise for 10 minutes at room temperature, after which the mixture was pipetted carefully 
into a 12-wells plate (Greiner Bio-one). The collagen disc was incubated at 37 ˚C until fully 
solidified, after which standard cell culture medium was added. Spheroids were allowed to 
invade the collagen for several days, as indicated in the legends to the figures.  
 
F-actin staining 
After invasion of spheroids into collagen, collagen discs were fixed in 4% paraformaldehyde 
for 30 minutes at room temperature. Next, discs were washed with PBS, after which they were 
incubated with Alexa-fluor-488-conjugated Phalloidin (1:100; Life Technologies) for three 
hours at room temperature. After washing once more with PBS, images were acquired.  
 
Live imaging and microscopy 
Live imaging of cells was performed using the JULI (Just Unbelievable Live Imaging) system 
from PAA. All other microscopic images were obtained using a Leica DM 6,000 fluorescence 
microscope in combination with IP-lab imaging software (Scanalytics Inc., Fairfax, VA, USA). 
 
Data analysis and statistics 
Unless stated otherwise, all data are presented as mean values ± standard deviation. Statistical 
analysis was carried out using Student’s t-tests or one-way analysis of variance (ANOVA) with 
Tukey’s post-hoc test where appropriate unless stated otherwise. Two-sided p values < 0.05 
were considered statistically significant. Asterisks indicate statistical significance: *** is p < 
0.001, ** is p < 0.01 and * is p < 0.05. 
 
RESULTS 
Breast cancer cell migration in transwell assays 
To study the role of the UPR in the process of breast cancer cell migration, a number of 
models for in vitro metastasis were used. First, cell migration was studied in a series of six breast 
cancer cell lines under normoxic conditions using a transwell assay. In this assay cells have to 
actively migrate through a porous membrane. Cells were serum-deprived overnight and added 
to the upper compartment of modified Boyden chambers. In the lower compartment serum 
was added as a chemoattractant. As shown in Figure 1A, vast differences were found in the 
capability of cells to migrate to the lower compartment. The largest percentage of migrated 
cells was found in MDA-MB-231 and MDA-MB-468 cells, both triple-negative cell lines (that 
is, lacking expression of the oestrogen receptor, progesterone receptor and human epidermal 
growth factor receptor 2). In contrast, MCF-7 and MDA-MB-175 cells demonstrated very little 
migration. A direct comparison between the potential to migrate and the expression of LAMP3 
on the mRNA level revealed a moderate correlation in this small group of cell lines (see Figure 
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1B). All subsequent experiments were performed with the MDA-MB-231 cells, a commonly 
used breast cancer cell line to study cell migration. 
 
FIGURE 1 Migration of breast cancer cells correlates with LAMP3 mRNA expression. A. Migration of six different 
breast cancer cell lines under normoxic conditions during 24 hours in a transwell assay. B. mRNA expression of 
LAMP3 in the same six cell lines. Results are from two representative experiments with three replicates each.  
 
Importance of serum deprivation for migration of MDA-MB-231 cells in a transwell 
assay 
The standard protocol for a transwell assay includes serum deprivation of the cells before the 
assay. This enables the addition of serum as a chemoattractant to the lower compartment. 
However, starvation induces the UPR profoundly and could therefore influence cell migration, 
especially under hypoxic conditions. In the present study, the chemoattractant function of 
serum was confirmed: overnight starvation of cells led to an increase in migration compared to 
cells that were not starved and thus allowed to migrate in complete medium (see Figure 2A). 
Next, this assay was used to establish the optimal percentage of oxygen to increase the 
migration of MDA-MB-231 breast cancer cells, in both serum-depleted and serum-
supplemented conditions. When cells were serum-deprived overnight, cells migrated optimally 
at 1% O2 (see Figure 2B). Cell migration decreased at lower or higher oxygen concentrations. 
Subsequently, the assay was performed without starvation. The availability of serum influenced 
the optimal oxygen percentage profoundly. Figure 2C shows that in the presence of serum cells 
favoured lower oxygen percentages for optimal cell migration (0.1% O2). 
 
Effect of knockdown of PERK , ATF4 and LAMP3  on cell migration in transwell 
assays during hypoxia 
Next, the effect of knockdown of PERK, ATF4 and LAMP3 on cell migration during hypoxia 
using the transwell assay was studied. First, we examined whether PERK, ATF4 and LAMP3 
expression was induced by 1% O2 (see Figure 3A). Expression of these UPR components 
showed a moderate induction. Next, to ensure that any effects of knockdown on the migratory 
capacity during hypoxia were not due to reduced survival of the cells, a series of colony 
forming assays was performed first. No significant effect of hypoxia (1% O2) on colony 
forming ability of knockdown cells was found in the time frame in which assays are performed 
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(see Figure 3B). Figure 3C shows that transfection with the siRNAs used successfully 
diminished expression of the mRNA of PERK, ATF4 and LAMP3. In addition, knockdown 
of PERK and ATF4 reduced the expression of their downstream targets (that is ATF4 and 
LAMP3) after serum starvation (see Figure 3D). Subsequently, transwell assays were 
performed. First, cell migration through the porous membrane was studied at 1% O2 under 
serum-starved conditions. The most profound effect of knockdown on cell migration was 
induced when cells were pre-incubated under hypoxic conditions prior to the assay, which 
itself was also performed under hypoxia (see Figure 3E). Hypoxia without pre-incubation 
showed a diminished migration of cells for all knockdowns tested, but the effect was less 
profound than with the pre-incubated cells. Performing the assay in normoxic conditions led 
to a non-significant decrease in cell migration and only for some of the knockdowns tested. In 
addition, the cell migration after knockdown in a transwell assay at 0.1% O2, without serum 
starvation was also studied (see Figure 3F). Here, effects similar to the assay at 1% O2 were 
found, albeit less prominent. 
 
FIGURE 2 Serum starvation and hypoxia increase cell migration in transwell assays. A. Effect of the addition of serum 
on the migration of MDA-MB-231 cells in a transwell assay during 24 hours. Effect of exposure to hypoxia on 
migration of MDA-MB-231 cells in a transwell assay under (B) serum-depleted or (C) serum-supplemented conditions, 
where cells were seeded in the transwell assays and then put in the hypoxic chamber for 24 hours (black bars) or cells 
received a 24 hour pre-incubation under the hypoxic conditions indicated on the x-axis and seeded in the transwell 
assays under hypoxia (white bars). Results are from two representative experiments with three replicates each. 
Asterisks indicate statistical significance compared to the corresponding control. 
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FIGURE 3 Knockdown of PERK, ATF4 and LAMP3 reduces cell migration under hypoxic conditions in transwell 
assays. A. mRNA expression of PERK, ATF4 and LAMP3 after exposure of MDA-MB-231 cells to 1% O2 for the 
time indicated on the x-axis. B. Clonogenic survival of MDA-MB-231 cells transiently transfected with siRNAs 
directed against PERK, ATF4 or LAMP3 after exposure to 1% O2 for a 24-hour period. C. mRNA expression of 
PERK, ATF4 and LAMP3 in MDA-MB-231 cells after transient transfection with siRNAs directed against the 
corresponding genes. D. mRNA expression of ATF4 and LAMP3 in MDA-MB-231 cells, transfected with siRNAs 
directed against PERK and ATF4, after serum starvation for 24 hours. E. Effect of hypoxia (1% O2) in combination 
with transient knockdown of PERK, ATF4 or LAMP3 in MDA-MB-231 cells on cell migration in a transwell assay 
under serum-starved conditions. F. Effect of hypoxia (0.1% O2) in combination with transient knockdown of PERK, 
ATF4 or LAMP3 in MDA-MB-231 cells on cell migration in a transwell assay under serum-supplemented conditions. 
Pre-incubated cells were exposed to hypoxic conditions 16 hours prior to the start of the assay. Assays were carried 
out under normoxic or hypoxic conditions during 24 hours. The pre-incubated assays were also performed under 
hypoxia. Results are from two representative experiments with three replicates each. Asterisks indicate statistical 
significance of knockdown compared to the corresponding negative control. 
 
Migration of MDA-MB-231 breast cancer cells in a gap closure assay under hypoxic 
conditions  
To confirm and extend the data from the transwell assay, similar experiments were performed 
using a gap closure assay, which does not require serum deprivation. First, the effect of 
exposure to hypoxia on the migration of MDA-MB-231 breast cancer cells was studied. Figure 
4 shows the percentage of the gap that the cells filled in a 16-hour period. Compared to 
normoxic conditions, 1% O2 showed the largest percentage of gap closure. 0.5% O2 revealed a 
moderate but still significant effect. Exposure to even lower oxygen concentrations, that is 
0.1% O2, did not reveal an increase in gap closure speed compared to normoxia. 
 
FIGURE 4 Hypoxia has a profound effect on cell migration in a gap closure assay. Shown is the percentage of the gap 
that is closed after 16 hours. Results are from two representative experiments with two replicates each. Asterisks 
indicate statistical significance compared to the normoxic control. 
 
Effect of knockdown of PERK , ATF4  and LAMP3 on cell migration during hypoxia 
in a gap closure assay  
As 1% O2 was found to be the optimal level of hypoxia for cells to migrate, subsequent gap 
closure experiments were performed at this oxygen level. Figure 5 shows the effect of 
knockdown of PERK, ATF4 and LAMP3 on migration of MDA-MB-231 cells. Under 
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normoxic conditions no significant difference between cells transfected with a negative control 
and cells transfected with siRNAs against PERK, ATF4 or LAMP3 could be demonstrated 
(see Figure 5A, 5C and 5E). In contrast, when the assay was performed under 1% O2 a 
considerable effect was observed (see Figure 5B, 5D and 5F). Knockdown of PERK, ATF4 or 
LAMP3 led to a substantial decrease in the speed at which cells close the created gap (see also 
Supplementary File 1).  
 
FIGURE 5 Knockdown of PERK, ATF4 and LAMP3 reduces cell migration under hypoxic conditions in gap closure 
assays. A-F. Effect of hypoxia (1% O2) in combination with transient knockdown of PERK, ATF4 or LAMP3 in 
MDA-MB-231 cells on cell migration in a gap closure assay. Results are from two representative experiments.  
 
Importance of the tumour microenvironment for migration of MDA-MB-231 cells 
All assays used so far required an artificial induction of hypoxic conditions. To study the effect 
of hypoxia on migration with endogenous hypoxia, multicellular tumour spheroids were 
employed. Beyond a certain diameter, tumour spheroids will develop a core consisting of 
hypoxic cells (see Figure 6A). Expression of PERK, ATF4 and LAMP3 was found to be 
higher in cells grown as a spheroid than cells grown in a monlayer (see Figure 6B). To directly 
compare the potential to migrate of a standard two-dimensional monolayer and three-
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dimensional spheroids both transwell and gap closure assays were performed. Directly before 
the start of the assays, spheroids were disintegrated by standard trypsinisation into a single-cell 
suspension, which was used as the input for the assays. In both assays the cells initially cultured 
as spheroids showed an increased capacity to migrate compared to the cells grown as a 
monolayer (see Figure 6C and D). Thus, once cells have experienced a simplified, transient 
tumour microenvironment, their migratory capacity increases. 
FIGURE 6 Cells derived from tumour spheroids are more migratory than monolayer cells. A. MDA-MB-231 spheroid 
stained against the hypoxia marker pimonidazole. Bar is 100 µm, original magnification is 200×. B. mRNA expression 
of PERK, ATF4 and LAMP3 in MDA-MB-231 monolayers compared to cells grown as spheroids. Migration of 
monolayer cells compared to cell initially grown as a spheroid in a transwell assay (C) during 24 hours and a gap 
closure assay (D) during 16 hours in standard cell culture medium. Spheroids were disintegrated into a single-cell 
suspension prior to the start of the assay. Results are from two representative experiments with three replicates each.  
 
Effect of LAMP3  knockdown on collagen invasion of MDA-MB-231 spheroids  
Next, the ability of spheroids generated from cells with a stable knockdown of LAMP3 to 
invade a collagen matrix was studied. Figure 7A shows that stable knockdown of LAMP3 
attenuated the mRNA expression of LAMP3. After 4 days of growth, both control and 
knockdown spheroids were of similar size, indicating that there is no difference in proliferation 
between these cells when grown as a spheroid (see Figure 7B). MDA-MB-231 negative control 
spheroids were found to invade the collagen with string-like protrusions (see Supplementary 
File 2). Stable knockdown of LAMP3 reduced these invasive filaments to some extent (see 
Figure 7C and Supplementary File 2). The effect of LAMP3 knockdown on invasion of the 
spheroids into collagen was quantified by measuring the surface of collagen invaded by the 
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spheroids. The surface of the invasive zone was found to be smaller in the knockdown 
spheroids (see Figure 7D).  
FIGURE 7 Knockdown of LAMP3 reduces invasion of spheroids into collagen. A. Expression of LAMP3 mRNA in 
control cells vs. LAMP3 knockdown cells. B. Spheroid size of MDA-MB-231 control and LAMP3 knockdown 
spheroids after 4 days of growth. Results are from two independent experiments with 32 replicates each. C. F-actin 
staining of MDA-MB-231 spheroids of control and LAMP3 knockdown cells, after 6 days of invasion in collagen. Bar 
is 100 µm, original magnification is 50×. D. Surface of collagen invaded by MDA-MB-231 control and LAMP3 
knockdown spheroids during 72 hours. E. Collagen invasion of a mixed MDA-MB-231 spheroid after 6 days. Control 
cells were labelled with CellTracker Green and LAMP3 knockdown cells were labelled with CellTracker Orange. 
Control and LAMP3 knockdown cells were mixed in a 1:1 ratio. Bar is 100 µm, original magnification is 100×. F. 
Quantification of E. The total amount of green and red signal was analysed in five different zones: the spheroid body 
and four consecutive invasive zones, n = 5.  
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The diminished invasion of LAMP3 knockdown spheroids was validated further by generating 
spheroids of a mixed origin. Control cells were labelled with CellTracker Green and LAMP3 
knockdown cells were labelled with CellTracker Orange. Subsequently, mixed spheroids in a 
1:1 ratio were generated. Invasion of these spheroids in collagen demonstrated the enhanced 
ability of the control cells to deeply invade the collagen compared to the LAMP3 knockdown 
cells (see Figure 7E). This effect was quantified by analysing the green and red signal present 
within the spheroid body and the invasive zone (see Figure 7F). The invasive zone was divided 
into four circular zones with increasing distance from the spheroid body. Analysis of the signal 
present within each zone revealed that the green signal was more prevalent in the invasive 
zones than the red signal, indicating that the control cells invaded the collagen deeper than the 
LAMP3 knockdown cells.  
 
DISCUSSION 
In this study, evidence is provided that UPR-induced LAMP3 can influence hypoxia-mediated 
cell migration of breast cancer cells. We provide evidence that apart from the established 
involvement of the HIF-pathway in the induction of cancer cell spread, the UPR is a second 
manner in which hypoxia is implicated in breast cancer cell migration. 
A characteristic of the UPR is its maximum induction under conditions of severe hypoxia 
(<0.2% O2) or anoxia32. Indeed, LAMP3 as a UPR-induced factor was found to have its peak 
of induction under these conditions26,28. However, cell migration and invasion is often studied 
under conditions of more moderate hypoxia, around 1% oxygen33-38, conditions which 
maximally induce HIF1α expression23. The current study shows that knockdown of PERK, 
ATF4 or LAMP3 in combination with hypoxic exposure to 1% O2 led to a reduction in cell 
migration. If the UPR and its associated factors are maximally induced by anoxia, why are the 
largest effects observed at moderate levels of hypoxia? Several studies have shown that the 
UPR can indeed be induced by moderate hypoxia as well, but with different kinetics21,39,40. In 
this study assays were performed at 1% O2 as stronger hypoxic conditions did not lead to a 
stimulation of cell migration. Possibly, at severe hypoxic conditions, cells apply the UPR more 
for cell survival25 than migration.  
In the transwell assays an intriguing effect of the addition of serum on the induction of cell 
migration by hypoxia was observed. Serum-starved cells migrated most profoundly at 1% O2, 
whereas serum-supplemented cells migrated best at 0.1% O2. Serum dependency of cancer cell 
invasion has been observed before41,42. When MDA-MB-231 cells were serum depleted, no 
increase in invasion was found for a hypoxic incubation (1.5% O2)42. As addition of serum led 
to an increased invasion under hypoxia, it was suggested that serum might contain factors that 
increase invasion under hypoxic conditions42. In a different study, the effect of hepatocyte 
growth factor (HGF) on tumour invasion was examined in U2-OS and SiHa cells43. Mild 
hypoxia (3% O2) was found to increase invasion by amplifying HGF-signalling, thereby 
sensitising cells to HGF stimulation43. These and the current data indicate that the role of 
serum in cancer cell migration and invasion is more than just a chemoattractant and that 
growth factor signalling has a vast influence on the effects of hypoxia in migration and 
invasion assays. Trying to survive during hypoxia is of critical importance for cells. Depriving 
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cells of serum may make survival even more difficult. Possibly, without serum and under 
severe hypoxic conditions (0.1% O2) cells are not migrating as fast as under moderate hypoxia 
(1% O2) because cell survival is more essential. When serum is present, the need for survival 
may become less critical even at 0.1% O2, causing the increase in cell migration.   
The importance of the tumour microenvironment during cell migration was emphasised when 
migration assays were performed with cells grown as monolayer and cells initially grown as 
spheroids. The latter were found to be more migratory than the former. In other words, cells 
that experienced a simplified microenvironment prior to the assay were more migratory, 
despite the fact that spheroids had to be disintegrated back to a single-cell suspension. This 
behaviour was also observed previously with murine breast cancer cell lines in transwell 
invasion assays44. As the spheroids used contain a central hypoxic core, the enhanced ability of 
spheroid cells to migrate or invade could be a consequence of hypoxia. This, however, remains 
to be established. 
With the evidence that LAMP3 is involved in hypoxia-induced cell migration, it needs to be 
elucidated which mechanism LAMP3 uses to cause the actual spread of cancer cells. LAMP3 
protein under physiological conditions is localised within the lysosomal membrane45. For 
LAMP1 and LAMP2 it has been previously established that their expression can relocalise to 
the plasma membrane in cancer cells29. Cell lines with a stronger metastatic capacity showed an 
enhanced expression of LAMP1 and LAMP2 on the cell membrane29. It is believed that LAMP 
surface expression provides a cancer cell with means to attach to selectins on endothelial cells 
and enhance their capacity to form metastases30. A similar mechanism could be responsible for 
the role of LAMP3 in hypoxia-induced cell migration. LAMP3 was found to have the ability to 
relocalise to the plasma membrane upon influenza A virus infections in HeLa cells46. 
Nevertheless, we have not been able to show LAMP3 expression on the cell surface in the 
MDA-MB-231 cells used, under either normoxic or hypoxic conditions. 
Immunohistochemically, in MDA-MB-231 cells we have only observed LAMP3 expression in 
the cytoplasm. An alternative explanation for the function of LAMP3 in cell migration is the 
link LAMP proteins have with autophagy47. Autophagy has been previously suggested as a 
possible mechanism responsible for increased survival and increased metastasis of cancer 
cells48,49. Analysis of the autophagy marker LC3B expression in a large subset of breast 
tumours revealed that it is associated with metastasis and a worse outcome50. However, 
INDELICATO et al. found that chemically induced autophagy results in reduced invasion of 
MDA-MB-231 cells under both normoxic and hypoxic (1% O2) conditions, whereas LC3B 
silenced cells showed a decreased invasion during hypoxic conditions37. Thus, there is evidence 
that autophagy may function as a mechanism behind hypoxia-induced metastasis, but its 
precise role is far from clarified.  
In conclusion, this study provides evidence that the UPR with LAMP3 is involved in the 
process of hypoxia-induced cell migration. In addition, growth factor signalling via the serum 
component of cell culture medium is a factor of vital importance in the migration of cells 
under conditions of both moderate and severe hypoxia. Furthermore, the tumour 
microenvironment, experienced by cells when grown as multicellular spheroids is of 
significance in the process of cell migration and invasion. The PERK/ATF4/LAMP3-arm of 
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the UPR might function as a new target for therapy combating hypoxia-induced metastasis in 
breast cancer. 
 
SUPPLEMENTARY MATERIAL 
Supplementary data associated with this article can be found, in the online version, at 
http://breast-cancer-research.com/content/15/1/R2/additional. 
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ABSTRACT 
Background 
Conditions of poor oxygenation (hypoxia) are present in many human tumours including 
cervix cancer and are associated with increased risk of metastasis and poor patient prognosis. 
Hypoxia is a potent activator of the PERK/eIF2α-signalling pathway, a component of the 
unfolded protein response (UPR) and an important mediator of hypoxia tolerance and tumour 
growth. Here, the importance of this pathway in the metastasis of human cervix carcinoma was 
investigated. 
Methods 
Amplification and expression of LAMP3, a UPR metastasis-associated gene, was examined 
using FISH and immunofluorescence in a cohort of human cervix tumours from patients who 
had received oxygen needle electrode tumour oxygenation measurements. To evaluate the 
importance of this pathway in metastasis in vivo, we constructed a series of isogenic and 
inducible cell lines to interfere with PERK-signalling during hypoxia and used these in an 
orthotopic cervix cancer model of hypoxia-driven metastasis. 
Results 
We demonstrate that LAMP3 is regulated by both amplification and hypoxia in human cervix 
tumours. Induced disruption of PERK-signalling in established orthotopic xenografts resulted 
in complete inhibition of hypoxia-induced metastasis to the lymph nodes. This is due in part to 
a direct influence of the UPR pathway on hypoxia tolerance. However, we also find that 
LAMP3 is a key mediator of hypoxia-driven lymph node metastasis, through its ability to 
promote metastatic properties including cell migration. 
Conclusions 
These data suggest that the association between hypoxia, metastasis and poor prognosis is due 
in part to hypoxic activation of the UPR and expression of LAMP3. 
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INTRODUCTION 
The microenvironment of solid tumours is profoundly different from that of the normal 
tissues from which they derive. Tumour proliferation coupled with insufficient vasculature 
result in poorly oxygenated (hypoxic) regions where oxygen and nutrient demand exceeds 
supply. Clinical studies have established an association between tumour hypoxia and poor 
patient prognosis in several tumour types. For example, large clinical studies have shown that 
the hypoxic fraction measured by oxygen electrodes is prognostic in uterine cervix and head 
and neck carcinoma1-3. Tumour hypoxia negatively impacts prognosis by conferring resistance 
to both radio- and chemotherapy, and also induces biological changes that promote increased 
malignancy, including metastasis4-6. Studies in both cervix carcinoma and soft tissue sarcoma 
have shown directly that patients with hypoxic tumours are more likely to fail therapy due to 
distant metastases4,5,7. Likewise, a recent study in prostate cancer has identified tumour hypoxia 
as an independent predictor of biochemical relapse, but only within the first 48 months of 
completing treatment, suggesting the presence of subclinical metastatic disease at time of 
treatment in patients with hypoxic tumours8. Laboratory and animal models support a direct 
role for hypoxia in promoting metastasis. In vitro hypoxia exposure has been shown to 
potentiate experimental metastasis of several cancer cell lines when injected into mice9-12. 
Moreover, increasing tumour hypoxia by subjecting tumour-bearing animals to periodically 
breathe low oxygen gas increases metastasis in a number of models, including an orthotopic 
model of human cervical carcinoma13-15. 
Tumour cells respond to hypoxia through several adaptive oxygen-sensitive signalling 
pathways. This includes activation of the hypoxia-inducible factor family of transcription 
factors (HIFs), which regulate the expression of many genes involved in metabolism and 
angiogenesis16. Hypoxia also acts as a potent activator of the unfolded protein response (UPR), 
an evolutionally conserved program that responds to endoplasmic reticulum (ER) stress17-19. 
The UPR consists of three signalling pathways initiated by PKR-like ER kinase (PERK, also 
known as EIF2AK3), inositol-requiring enzyme 1 (IRE1), and activating transcription factor 6 
(ATF6). Several studies have demonstrated that both the PERK- and IRE1-arm of the UPR 
are strongly activated by hypoxia and important for the tolerance of tumour cells to hypoxic 
stress19-22. PERK activation leads to a rapid inhibition of protein synthesis during hypoxia 
through phosphorylation of the α subunit of eukaryotic translation initiation factor 2 (eIF2α) 
on serine 51 (ref. 18). Paradoxically, eIF2α phosphorylation also results in selective translation 
of activating transcription factor 4 (ATF4) due to the presence of an unusual 5’ UTR that 
contains multiple upstream open reading frames17,23,24. ATF4 initiates a widespread 
transcriptional response that mediates adaptation to ER-stress25. ATF4 promotes hypoxia 
tolerance directly by inducing LC3B (MAP1LC3B) that enables high rates of autophagy 
required to protect hypoxic cells from cell death26. Finally, ATF4 also initiates a negative 
feedback loop by inducing growth arrest and DNA damage-inducible protein 34 (GADD34, 
also known as PPP1R15A), which promotes dephosphorylation of eIF2α and restoration of 
protein synthesis27.  
Several studies have demonstrated that HIF1 activation can regulate pathways involved in 
metastasis28,29. Direct or indirect targets of HIF1 include genes that regulate the epithelial and 
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mesenchymal transition (EMT), matrix metalloproteinases (MMPs) and lysyl oxidase (LOX), 
which are involved in the establishment of the pre-metastatic niche30-32. The relevance of UPR-
signalling in hypoxia-induced metastasis has not been examined. However, we recently showed 
that expression of a putative metastasis promoting gene, lysosome-associated membrane 
protein 3 (LAMP3) is strongly induced by hypoxia in a PERK/ATF4-dependent and HIF-
independent manner33. LAMP3 has been hypothesised as a potential mediator of metastasis 
and is overexpressed in several cancer types34. Here, we examined the expression and hypoxic 
regulation of LAMP3 in human cervix tumours with known oxygenation status. We have also 
created a series of isogenic and inducible models and used these in an orthotopic model of 
cervical cancer to test the contribution of PERK and LAMP3 in hypoxia-induced metastasis in 
vivo. 
 
MATERIALS AND METHODS 
Cell models and hypoxia exposure 
The ME180 (human cervix carcinoma) cell line with doxycycline inducible expression of the 
hamster GADD34 C-terminus (GADD34-C)35 was created using the Flp-In T-Rex system 
according to the manufacturer’s instructions (Invitrogen). ME180 cells were transfected with a 
pRetroSuper vector containing a short hairpin against LAMP3 to generate stable LAMP3 
knockdown cells (shLAMP3) or with an empty vector (EV control). For anoxic exposure cells 
were transferred into a H85 Hypoxystation (Hypoxgyen, USA). The composition of the 
atmosphere in the incubator consisted of 5% H2, 5% CO2, 0.0% O2 and residual N2. 
 
RNA isolation and quantitative RT-PCR analysis 
Total RNA isolation and quantitative RT-PCR was performed as previously described33. 
Relative transcript abundance was determined using the standard curve method and 
normalised to 18S rRNA expression. 
 
Western blot analysis 
Cell lysis and immunoblot analysis was performed as described previously33. For the detection 
of phosphorylated eIF2α cells were lysed in 20 mM Hepes, 100 mM KCl, 5 mM EDTA, 10% 
glycerol, 0.5% Triton-X, 0.005% SDS and 1 mM DTT supplemented with Halt Phosphatase 
Inhibitor Cocktail (Thermo Scientific). See supplementary materials and methods for 
antibodies used. 
 
Spontaneous metastasis assay and cyclic hypoxia treatment 
Orthotopic implantations were performed as described previously13. Expression of the 
GADD34-C transgene was induced 8 days after implantation by administration of doxycycline 
(2 g/L in 5% sucrose) in the drinking water of the animals. The cyclic hypoxia treatment was 
started the following day (day 9) and repeated daily until 24 hours prior to sacrifice, as 
described previously13. Pair one and pair two were given an equal weight because they are 
located at a similar distance from the primary tumour and colonisation of pair one has been 
shown to be independent of hypoxia exposure13. To identify viable hypoxic cells, animals were 
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injected with the hypoxia marker drug EF5 [2-(2-nitro-1H-imidazole-1-yl)-N-(2,2,3,3,3-
pentafluoropropyl) acetamide], obtained from DR. CAMERON KOCH (University of 
Pennsylvania), 4 hours before tumour excision (100 µmol/kg i.p.). All animal experiments were 
performed according to the regulations of the Canadian Council on Animal Care. 
 
Immunohistochemical staining and image analysis 
See supplementary materials and methods for the staining protocols. Images were analysed 
using Definiens Tissue Studio software, which allows for semi-automatic histology image 
analysis. Briefly, the software was trained to identify viable tumour areas, necrotic areas, 
tumour stroma and empty areas within the scanned section. For human cervix carcinoma 
biopsies the average LAMP3 staining intensity within the tumour areas was measured as well as 
the LAMP3 positive area above a background threshold obtained from the average intensity of 
all patient sections. The product of average staining intensity and fractional labelled tumour 
area was calculated for each case to represent relative protein abundance. Two sections per 
case were stained and analysed at different times. 
 
FISH analysis 
The LAMP3 containing clone RP11-1012H23 was selected from the Human UCSC Genome 
Browser assembly (Feb.2009 CRch37/hg19) and obtained from TCAG Genome Resource 
Facility (Toronto, Canada). Prior to experiments, the RP11-1012H23 probe was verified on 
normal blood metaphases to confirm its correct location on chromosome 3q27. The BAC 
probe was used along with centromeric probes CEP3 (labelled with SpG) and CEP7 (labelled 
with aqua) purchased from Abbott Molecular and utilised as internal controls. FISH was 
performed on paraffin embedded tissues - TMA’s. See supplementary materials and methods 
for protocol. Haematoxylin and eosin-stained adjacent TMA sections were compared with 
FISH stained slides in order to properly identify tumour cells. One hundred non-overlapping, 
intact cells were scored for each case. Total LAMP3, CEP3 and CEP7 signal was determined 
for each case and subsequently the LAMP3 to CEP3 and LAMP3 to CEP7 ratio was 
calculated. A ratio of 1.5 or higher was considered an abnormal signal. 
 
Patients and oxygen measurements 
Biopsies were obtained from a previously described group of uterine cervix cancer patients 
enrolled in a single institutional prospective study36. Written informed consent was obtained 
from each participant prior to study entry and the Research Ethics Board at the Princess 
Margaret Hospital approved the trial. The clinical characteristics of the group of patients with 
LAMP3 protein expression (IHC) are found in Supplementary Table 1. The first date of 
treatment in this group was 25 January 2000 and the last 25 April 2007. The median follow-up 
is 5.866 years (range 0.764 - 10.610). 
 
Statistical analysis 
Unless stated otherwise, Student’s t-test or one-way ANOVA with Bonferroni's post test was 
used to test significance of differences in numerical data. Two-sided p-values of less than 0.05 
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were considered statistically significant. 
 
RESULTS 
LAMP3 expression correlates with hypoxia in human cervix tumours 
We recently demonstrated that LAMP3, a protein implicated in cervical cancer metastasis, is 
induced by hypoxia through activation of the PERK/eIF2α/ATF4-dependent arm of the 
UPR33. To evaluate the clinical relevance of these findings we investigated whether hypoxia 
also influences LAMP3 expression in patients with cervical cancer, a disease in which hypoxia 
is associated with increased metastasis and poor overall survival5,7. Since LAMP3 is reported to 
be amplified in cervix cancer37, we developed both immunohistochemical techniques to assess 
LAMP3 protein expression within the epithelial tumour compartment, and FISH techniques to 
assess copy number changes. LAMP3 was examined in a cohort of cervical carcinoma patient 
samples obtained from clinical trials at the Princess Margaret Hospital (Toronto) in which 
patient tumours had been assessed for hypoxia with oxygen needle electrodes prior to 
treatment. Consistent with previously reported results, elevated LAMP3 gene copy number 
was observed in 48% of all cases (see Figure 1A). A strong relationship was also observed 
between copy number alteration and both LAMP3 protein and mRNA expression levels (see 
Supplementary Figure 1A and 1B, respectively). No LAMP3 copy number aberrations were 
identified in normal cervix tissue (see Supplementary Figure 1C). Using quantitative 
immunofluorescence, LAMP3 protein expression was then measured within tumour areas 
(excluding stroma) of the biopsies (see Figure 1B). Infiltrating, LAMP3-positive, mature 
dendritic cells were also excluded from the analysis. As reported earlier33, LAMP3 staining 
intensity was highly heterogeneous and the protein was found primarily on the cell membrane. 
Importantly, in patients with normal LAMP3 copy numbers a positive and significant 
association between hypoxia (HP5) and LAMP3 expression was observed (see Figure 1C and 
Supplementary Table 2) whereas no such correlation was seen in the amplified subset. These 
data indicate that LAMP3 expression in cervical cancer is induced through both genetic means 
as well as by hypoxia. A subgroup analysis showed a positive relationship between LAMP3 
expression and clinical stage at diagnosis, but again only in patients with normal copy numbers 
(see Supplementary Table 3) indicating that, like hypoxia, LAMP3 is associated with more 
advanced disease. 
 
Generation of an isogenic inducible PERK-signalling defective cervical cancer 
xenograft model 
To address the functional importance of UPR and LAMP3 activation in hypoxia-induced 
metastasis, we focused first on the requirement for the PERK-signalling arm. We selected the 
ME180 cervical carcinoma cell line that when grown orthotopically in the mouse cervix, 
metastasises to the lymph nodes in a hypoxia regulated manner13,38. We introduced a flippase 
recombination target site together with a tetracycline repressor into this line and tested its 
functionality by inserting a doxycycline-regulated eGFP reporter into the target site. 
Doxycycline resulted in strong induction of eGFP expression both in vitro and in vivo (see 
Supplementary Figure 2 and Figure 2A, respectively). Importantly, the potential of the ME180 
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cell line to spread to the local pelvic lymph nodes when grown orthotopically was maintained 
(see Supplementary Figure 3A-C) and doxycycline treatment alone had no effect on lymph 
node metastasis (see Supplementary Figure 3D-F). Next, we generated an ME180 subline with 
doxycycline-regulated expression of the C-terminal region of the hamster GADD34 protein 
(referred to as ME180-GADD34-C). Overexpression of this protein promotes 
dephosphorylation of eIF2α and thus prevents signalling through the PERK-arm of the 
UPR25. Maximum induction of GADD34-C is reached after 8 hours of doxycycline treatment 
and persists for 48 hours (see Supplementary Figure 4A). To test the functionality of these 
cells, we exposed them to the potent ER-stress inducing agent dithiothreitol (DTT). DTT 
induced strong phosphorylation of eIF2α in the ME180-GADD34-C cells (see Figure 2B lanes 
2,3,5,7), which was prevented in cells exposed to doxycycline for 6, 16 or 24 hours (see Figure 
2B lanes 4,6,8). Functionality was then tested in cells exposed to severe hypoxia (<0.02%) by 
monitoring downstream activation of the UPR target gene CHOP. In doxycycline-free cells, 
hypoxia caused a rapid induction of both CHOP protein (see Figure 2C) and mRNA (see 
Supplementary Figure 4B), which again was strongly inhibited in cells exposed to doxycycline. 
Importantly, inducible expression of GADD34 was also detectable in tumour xenografts at 
levels comparable to those in vitro (see Figure 2D). 
 
Disruption of UPR-signalling inhibits hypoxia-induced lymph node metastasis 
The metastatic potential of ME180 cells with intact vs. defective PERK-signalling was tested by 
implanting ME180-GADD34-C xenografts orthotopically and allowing them to establish for 
eight days before expressing the GADD34 transgene with doxycycline. This approach 
eliminates confounding effects of the transgene on primary tumour establishment, which is 
influenced by PERK20. Starting on day 9, tumour-bearing mice were exposed daily to a cycling 
hypoxia regimen that promotes lymph node metastasis in this model13 (see Figure 3A). As 
observed previously, doxycycline-free tumours (with a functional PERK-pathway) from 
hypoxia-treated animals were noticeably smaller compared to sham-treated mice (see Figure 
3B; compare -dox sham and -dox hypoxia)13,39. Doxycycline induced disruption of PERK-
signalling also reduced primary tumour size (compare -dox and +dox sham), but only in the 
air-breathing group. As expected, the doxycycline free group also demonstrated a hypoxia-
induced increase in lymph node metastasis as assessed by the total number of involved nodes 
(see Figure 3C; compare -dox sham and -dox hypoxia). Strikingly, inhibition of PERK-
signalling in the doxycycline treated group prevented this increase (compare +dox sham and 
+dox hypoxia). In order to account for the location of the involved nodes, we assigned 
weights to the four lymph node pairs based on their distance from the primary tumour and 
calculated a metastatic score for each animal. Similar to the effect on the total number of 
metastatic nodes, disruption of PERK-signalling significantly decreased the metastatic score in 
hypoxia treated animals, indicating diminished colonisation of the more distant lymph node 
pairs (see Figure 3D). In fact, disruption of PERK-signalling also significantly reduced the 
metastatic score in air-breathing mice. Together these results indicate that the PERK/eIF2α-
arm of the UPR influences both primary tumour growth as well as hypoxia-induced nodal 
metastasis. 
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FIGURE 1 LAMP3 expression correlates with the degree of hypoxia in human cervix tumours. A. Left: waterfall plot of 
LAMP3/CEP7 ratios measured in human cervical cancer biopsies. Dashed line represents the cut-off between normal 
and aberrant LAMP3 gene copy numbers. Right: representative images of cases with normal (top) and amplified 
(bottom) LAMP3 copy numbers. LAMP3 = red signal, CEP7 = aqua, CEP3 = green. B. LAMP3 protein expression 
quantification exemplified in two human cervix tumours. Panels 1a and 2a: immunofluorescence staining of total 
biopsy sections for LAMP3 (green, unthresholded signal), overlaid with DAPI signal (blue); panels 1b and 2b: viable 
tumour areas within sections indicated in blue; panels 1c and 2c: LAMP3 (thresholded signal) within viable tumour 
areas. C. Scatter plots of HP5 values and LAMP3 expression in patients with normal (LAMP3/CEP7 <1.5 - left) and 
aberrant (LAMP3/CEP7 ≥1.5 - right) LAMP3 gene copy numbers. A straight line was fitted through the data 
(Spearman correlation test). 
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FIGURE 2 A doxycycline-regulated ME180 cervix carcinoma cell line with inducible expression of the GADD34 
protein. A. EGFP expression in orthotopic xenografts. Doxycycline was administered to tumour-bearing mice in water 
(2 g/L) for a total period of two weeks. EGFP expression was evaluated under a fluorescent stereomicroscope. B. 
Right: The PERK/eIF2α/ATF4-arm of the UPR. Left: DTT-induced phosphorylation of eIF2α was assessed by 
immunoblotting in ME180-GADD34-C cells pre-exposed to 0, 6, 16 or 24 hours of doxycycline. Total eIF2α protein 
levels were used as loading control. C. ME180-GADD34-C and EV control (EV) cells were pre-incubated with 
doxycycline for 72 hours (+dox) or left untreated (-dox), and subsequently exposed to 0, 6 or 16 hours of anoxia. 
CHOP protein expression was measured by immunoblotting. D. GADD34 transgene protein expression was assessed 
in four different intramuscularly grown ME180-GADD34-C derived xenografts (T1-T4) following a 7-day 
administration of doxycycline to the animals. 
 
LAMP3 promotes hypoxia-induced lymph node metastasis 
To directly assess the involvement of the PERK target gene LAMP3 in hypoxia-induced 
metastasis, we introduced stable expression of an shRNA targeting LAMP3 in ME180 cells 
and showed that it fully abrogated the hypoxia-induced increase in mRNA and protein (see 
Supplementary Figure 5A and 5B, respectively). Xenografts established from LAMP3 
knockdown cells also showed a marked reduction in LAMP3 protein expression in vivo 
compared with controls (see Figure 4A and Supplementary Figure 6). 
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FIGURE 3 Inhibition of UPR-signalling suppresses hypoxia-induced lymph node metastasis. A. Time line metastasis 
assay. Cervical tumours were initiated by orthotopic implantation of fragments derived from several different 
intramuscular ME180-GADD34-C tumours. B. Size orthotopic xenografts. The cervix tumours were excised and 
weighed at the end of the experiment (day 28). Each symbol represents a tumour from one animal. Horizontal lines 
represent the mean values for each group. Animals carrying tumours 2 standard deviations above or below group 
mean were excluded from analysis because of positive correlation between primary tumour size and lymph node 
metastasis13 (Unpaired Student’s t-test, one-tailed *p < 0.05, **p < 0.005). C. On the y-axis is shown the total number 
of colonised lymph nodes in each animal (out of a total of eight). The size of the circle represents the number of 
animals (labelled in the centre). D. On the y-axis is shown metastatic scores. The metastatic score for each animal was 
calculated using the formula: (p1*1)+(p2*1)+(p3*2)+(p4*3) where p1 is the number of involved nodes for lymph 
node pair 1, p2 is the number of involved nodes for lymph node pair 2 etc. The size of the circle represents the 
number of animals (labelled in the centre, Mann-Whitney U test, one-tailed *p < 0.05). 
 
Mice with orthotopic ME180 empty vector control and LAMP3 knockdown xenografts were 
exposed to the hypoxia regimen and assessed for primary tumour growth and metastasis to the 
pelvic lymph nodes. As expected, both LAMP3 knockdown and empty vector control tumours 
were considerably smaller in the hypoxia treatment group compared with sham-treated 
controls (see Figure 4B). In contrast to disruption of PERK-signalling (see Figure 3), 
knockdown of LAMP3 resulted in a trend towards somewhat larger primary tumours in the 
sham treated group (see Figure 4B; compare EV and shLAMP3 sham). However, consistent 
with the PERK-signalling deficient cells, LAMP3 knockdown entirely prevented hypoxia-
induced metastasis to the lymph nodes, and in fact resulted in a trend towards fewer colonised 
nodes (see Figure 4C). Thus, despite the fact that the shLAMP3 primary tumours were 
somewhat larger on average, they did not exhibit any measurable hypoxia-induced metastasis. 
A similar effect was observed when assessing metastatic score (see Figure 4D). The results 
from this experiment suggest that signalling through the UPR promotes hypoxia-mediated 
metastasis in part through induction of LAMP3.  
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FIGURE 4 Knockdown of LAMP3 inhibits hypoxia-induced lymph node metastasis. A. Quantification LAMP3 
protein expression as assessed by immunofluorescence staining in LAMP3 knockdown and empty vector control 
tumours. Bars represent the mean of twenty tumours. Error bars depict SD (Unpaired Student’s t-test, two-tailed **p 
< 0.005). B. Size of the orthotopic tumours at the end of the experiment, 25 days post orthotopic implantation. Each 
symbol represents a tumour from one animal. Horizontal lines represent the mean values for each group. Animals 
carrying tumours ≤0.01 grams and/or 2 standard deviations above or below group mean were excluded from analysis 
because of positive correlation between primary tumour size and lymph node metastasis13 (Unpaired Student’s t-test, 
one-tailed). C. On the y-axis is shown the total number of colonised lymph nodes in each animal (out of a total of 
eight). The size of the circle represents the number of animals (labelled in the centre). D. On the y-axis is shown 
metastatic scores. The metastatic score for each animal was calculated using the formula: 
(p1*1)+(p2*1)+(p3*2)+(p4*3) where p1 is the number of involved nodes for lymph node pair 1, p2 is the number of 
involved nodes for lymph node pair 2 etc. The size of the circle represents the number of animals (labelled in the 
centre, Mann-Whitney U test, one-tailed *p < 0.05). 
 
Activation of the PERK/eIF2α-arm of the UPR promotes hypoxia tolerance 
The potential mechanisms contributing to the defect in hypoxia-induced metastasis were 
investigated by characterising the microenvironments of the orthotopic xenografts using 
immunohistochemistry (IHC) for vasculature, perfusion and hypoxia. Although PERK-
signalling has been reported to regulate angiogenesis21 we found no differences in vessel 
content or perfusion in the PERK-signalling deficient tumours exposed to sham treatment or 
to hypoxia (see Figure 5A and Supplementary Figure 7). Several studies have also 
demonstrated that activation of the PERK/eIF2α/ATF4-arm of the UPR increases hypoxia 
tolerance and consequently promotes higher levels of tumour hypoxia20,26,40. The fact that the 
GADD34 tumours are smaller than controls is consistent with these observations (see Figure 
3B). In order to directly test the contribution of PERK-signalling on hypoxia tolerance we 
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conducted clonogenic assays under hypoxia in dox-treated and untreated cells in vitro. Figure 
5B shows that ME180-GADD34-C cells are indeed significantly more sensitive to anoxia 
induced cell death following doxycycline. However, the fraction of hypoxic tumour cells as 
assessed by EF5 staining in vivo was not significantly different between tumours with intact vs. 
inhibited PERK-signalling (see Figure 5C). Thus, although PERK-signalling deficient cells are 
more sensitive to hypoxia-induced cell death, differences in the proportion of viable hypoxic 
cells in the primary tumour cannot account alone for the loss of metastasis in the PERK-
signalling deficient group.  
FIGURE 5 Activation of the PERK/eIF2α-arm of the UPR promotes hypoxia tolerance and cell migration and 
invasion through LAMP3. A. The microvessel density of ME180-GADD34-C orthotopic xenografts was evaluated by 
immunofluorescence staining (CD31). Bars represent the mean of ten tumours. Error bars depict SD. B. Clonogenic 
survival ME180-GADD34-C and empty vector control (EV) cells after exposure to anoxia in the presence or absence 
of doxycycline. Mean and SEM of three independent experiments is shown (one-way ANOVA, **p < 0.005, (-)dox 
EV vs. rest). C. Fraction EF5 labelled tumour area (left) Horizontal lines represent the mean values for each group. 
Right: dual immunofluorescence labelling for hypoxia (EF5, green) and vessels (CD31, red). 
 
LAMP3 influences migration of hypoxic cells 
Characterisation of the microenvironment of sham and hypoxia treated tumours also 
demonstrated no difference in angiogenesis in the control vs. LAMP3 knockdown tumours 
(see Supplementary Figure 8). LAMP3-deficient tumours did have a slightly larger hypoxic 
fraction compared to empty vector control tumours (see Supplementary Figure 9A), although 
this finding can be accounted for based on a strong relationship between primary tumour size 
and hypoxic fraction (see Supplementary Figure 9B). Unlike the PERK-deficient cells, LAMP3 
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knockdown and empty vector controls showed a comparable sensitivity to hypoxia-induced 
cell death in vitro as assessed by clonogenic survival (see Figure 6A). These data suggest that 
LAMP3 does not promote hypoxia-induced metastasis through regulation of angiogenesis 
and/or hypoxia tolerance. We investigated a more direct role of LAMP3 in the metastatic 
phenotype by measuring cell migration under normoxic (21% O2) and hypoxic (1% O2) 
conditions in LAMP3 knockdown and empty vector control cells using in vitro transwell 
migration assays. The two lines showed similar migratory capacity during normoxia (see Figure 
6B). However, hypoxia exposure significantly enhanced migration of empty vector control 
cells, whereas migration of the LAMP3 knockdown cells was unaffected. Cell motility was also 
evaluated in these cells using a 3D spheroid migration assay. Multicellular spheroid cultures 
grown in a 3D environment are characterised by a necrotic core surrounded by viable hypoxic 
cells and thus mimic some of the properties of cells grown in vivo. We observed that migration 
of cells out of the spheroids was strongly reduced by LAMP3 knockdown (see Figure 6C), 
reflecting impaired motility of the hypoxic LAMP3-deficient cells. Taken together, these 
results are consistent with a model in which LAMP3 promotes metastasis during hypoxia by 
promoting cancer cell migration.  
FIGURE 6 LAMP3 promotes cell migration and invasion during hypoxia. A. Clonogenic survival shLAMP3 and empty 
vector control cells in response to anoxic exposure. Mean and SEM of three independent experiments is shown. B. 
Transwell migration assay. Migration of shLAMP3 and empty vector control cells was monitored during both 
normoxic and hypoxic (1% oxygen) conditions. Mean and SD of two independent experiments is shown (two-way 
ANOVA *p < 0.05) C. 3D spheroid migration assay. Left: representative images of shLAMP3 and empty vector 
control spheroids. Right: The area covered by migrating cells during a period of 18 hours. Mean and SD of two 
independent experiments is shown (Unpaired Student’s t-test ***p < 0.0001). 
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DISCUSSION 
Previous clinical studies have identified tumour hypoxia as an important predictor of 
metastasis in cervical cancer patients treated with surgery and/or radiotherapy5,7. This includes 
previously published results from an ongoing study assessing hypoxia in cervical cancer 
patients receiving radiotherapy at the Princess Margaret Cancer Centre in Toronto7. In this 
study of 106 patients, hypoxia was shown to be a significant prognostic marker for overall 
survival in a multivariate model and this effect was due primarily to differences in distant 
metastasis rather than local control. Here, we used biopsies from the same trial involving a 
similar group of cervix cancer patients. Our data show that in these patients, LAMP3 
expression is regulated by both genetic gains/amplifications of LAMP3 and by tumour 
hypoxia. Similar to other studies in cervix cancer37, approximately half of all patients showed 
copy number aberrations and this was associated with increased LAMP3 mRNA and protein 
expression. However, in the other half we found that hypoxia was strongly and significantly 
associated with LAMP3 expression. Although we did not have sufficient samples to investigate 
directly if LAMP3 expression was driving poor outcome in these patients, its direct association 
with hypoxia, which has been shown to drive poor outcome, strongly implicate LAMP3 as a 
contributor to metastasis in these patients.  
Our in vivo data support a role for the PERK/eIF2α/ATF4-arm of the UPR and LAMP3 in 
particular in hypoxia-driven metastasis. We have presented evidence for two different 
contributions of this pathway to hypoxia-induced metastasis. The first is through a direct 
influence on the tolerance of cells to hypoxia, since overexpression of GADD34 markedly 
reduced cell survival in cells exposed to hypoxia in vitro and also impaired tumour growth in 
vivo. These data are consistent with other reports demonstrating that the UPR pathway is an 
important mediator of hypoxia tolerance and tumour growth by affecting cellular processes 
that include autophagy, angiogenesis and pH regulation19-21,26,41. Tumour cells with a higher 
hypoxia tolerance, by definition, have a higher probability to escape the primary tumour and 
survive in an avascular metastatic site regardless of how or when they acquire other metastatic 
phenotypes. However, tolerance mechanisms cannot alone account for the PERK contribution 
to hypoxia-induced metastasis in our model. We did not observe significant differences in 
overall levels of hypoxia in the PERK-signalling proficient and deficient tumours at the end of 
the hypoxia treatment schedule. Instead, our data suggest that PERK/eIF2α-regulation of 
LAMP3 is a key driver of both the migratory phenotype and development of lymph node 
metastases in response to hypoxia. Silencing LAMP3 caused no reduction in hypoxia tolerance 
in vitro, hypoxic fraction in vivo, or primary tumour size, but did effectively inhibit hypoxia-
induced metastasis in vivo and hypoxia-induced migration in two different in vitro models. 
Interestingly, knockdown of VEGFC-signalling also achieves a reduction in hypoxia-induced 
metastasis in this model39. Thus, it is clear that multiple pathways are likely contributing and 
required to observe increased metastasis in response to hypoxia.  
LAMP3 and its functional role in cancer have not been investigated in much detail. LAMP3 
and other LAMP family members are lysosomal membrane glycoproteins characterised by a 
long luminal domain containing multiple O- and N-linked glycosylation sites as well as several 
disulfide bonds, a transmembrane domain and a short cytoplasmic tail42. Cell surface 
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expression of LAMPs is often observed in cancer cells and has been shown to correlate with 
the metastatic ability of colon carcinoma cell lines43. We identified LAMP3 as a hypoxia 
responsive gene regulated by PERK/eIF2α-signalling and showed that it is also found on the 
cell surface33. We also showed that LAMP3 is overexpressed in breast cancer33 and moreover 
that it is an independent prognostic factor for locoregional control in a subgroup of patients 
treated with radiotherapy44. However, the biological function of LAMP3 in migration and 
metastasis in tumour cells is not understood. LAMP1 was shown to be required for proper 
formation of membrane ruffles and filopodia in migrating tumour cells45 and it is possible that 
LAMP3 exerts a similar function in response to hypoxia. A role for LAMP3 in cell-cell 
adhesion has also been proposed since it is a highly glycosylated protein that is often localised 
to the cell surface of tumour cells42,46 and other LAMP family members have already been 
implicated in cell adhesion47. By mediating binding to endothelial cells for example, LAMP3 
might facilitate tumour cell extravasation.  
These data support accumulating evidence implicating ER-stress responses as important 
contributors to aggressive hypoxic tumour biology19,26,41. This potential importance of ER-
stress responses in cancer has led to some attempts to identify and incorporate agents aimed at 
disrupting ER homeostasis either alone or in combination with conventional agents26,48-50. Our 
findings suggest that such agents are likely to be most effective when given in curative settings 
in combination with conventional therapy or with other agents that target well oxygenated 
cells. This approach would produce synergy not only by targeting distinct populations of cells 
in the tumour, but also by targeting intrinsic mechanisms that enable the hypoxic cells to 
escape and colonise distant nodes or other organs.  
 
SUPPLEMENTARY MATERIAL 
 
SUPPLEMENTARY MATERIALS AND METHODS  
Western blot analysis  
Blots were probed with anti-GADD34 (sc-794, Santa Cruz), anti-eIF4E (610270, BD Transduction Laboratories), anti-
CHOP (MA1-250, Thermo Scientific), anti-LAMP3 (AF4087, R&D Systems), anti-phospho-eIF2α (Ser51) (#3597, 
Cell Signaling) and anti-eIF2α (AHO1182, Invitrogen) detecting total eIF2α. Bound antibodies were visualised using 
HRP-linked secondary antibodies (anti-goat (Invitrogen), anti-mouse and anti-rabbit (GE healthcare)) and ECL 
luminescence (Pierce).  
  
Clonogenic assay  
Single cells were plated for clonogenic survival at a range of 100-400 cells per 10-cm dish in triplicate and were allowed 
to adhere for 6 hours before being exposed to anoxia for the indicated time periods. Colony formation was continued 
for 11-14 days at 21% O2. Colonies were stained with methylene blue (Sigma). Fifty cells or more were considered 
colonies.  
  
Immunohistochemical staining  
The expression of LAMP3 in orthotopic xenografts and cervix cancer patient biopsies was investigated as follows: 
Frozen sections (5 µm) were fixed for 20 minutes with 2% paraformaldehyde, rinsed 3 × 5 minutes each with PBS and 
then incubated with anti-LAMP3 antibody (AF4087, R&D Systems) at a 50-fold dilution overnight at room 
temperature in a humidity chamber. Slides were rinsed 3 × 5 minutes each with PBS and incubated with donkey anti-
goat-Cy3 at a 100-fold dilution for 1 hour at room temperature in a humidity chamber. Slides were then rinsed 3 × 5 
minutes each with PBS and counterstained with DAPI at a concentration of 1 µg/ml for 5 minutes. Samples were then 
rinsed 3 × 5 minutes each with PBS. Images were captured on the TISSUEscope 4,000 slide scanner (Biomedical 
Photometrics) at 0.5 µm resolution. Tumour-infiltrating, LAMP3-positive, mature dendritic cells which show an 
intense, dot-like staining pattern were excluded from the analysis by applying an upper LAMP3 signal threshold.  
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Spheroid formation and migration  
Multicellular tumour spheroids were acquired as follows: V-shaped 96-wells plates (Greiner Bio-one) were coated with 
0.5% (w/v) poly-HEMA (Sigma) in 95% ethanol. The ethanol was allowed to evaporate for three days. Per well 10,000 
cells were added, after which the plate was centrifuged for 10 minutes at 1,000 × g. Cells were allowed to form 
spheroids for 24 hours. Next, spheroids were transferred to a flat-bottomed 96-wells plate (Greiner Bio-one) and 
allowed to migrate. Images were obtained using a inverted microscope (Zeiss) in combination with IP-lab imaging 
software (Scanalytics Inc., Fairfax, VA, USA).  
  
Transwell migration assays  
Transwell migration assays were performed using non-coated inserts with 8 µm pores in a 24-wells format (Greiner 
Bio-one). Before the start of the assay, cells were deprived of serum overnight. Per insert 40,000 cells were seeded in 
the upper compartment. Serum containing medium was added to the lower compartment as a chemoattractant. Cells 
were allowed to migrate for 24 hours. For hypoxic assays this migration was performed under hypoxic conditions. 
Afterwards, membranes were fixed in 70% ethanol and stained with 0.5% (w/v) crystal violet (Sigma). Cells that had 
not migrated to the lower side of the membrane were removed with a cotton swab. Staining was solubilised with 1% 
(w/v) sodium dodecyl sulphate (SDS, Sigma) and absorbance was measured at 595 nm.  
  
FISH analysis  
RP11-1012H23 clone was selected from the Human UCSC Genome Browser assembly (Feb.2009 CRch37/hg19). The 
clone starts at 182,724,231 and ends at 182,902,423 bps on chromosome 3 thus covering the region of the LAMP3 
gene (starts at 182,840,004 ends at 182,880,667). The BAC clone was directly labelled with SpO fluorochrome using a 
commercially available nick translation kit according to the manufacturer’s instructions (Abbott Laboratories). TMA 
slides were deparaffinised in xylenes and incubated in cytric buffer (pH 6.0) for 55 minutes at 80 ˚C, followed by 
pepsin (Sigma) digestion (75,000 U in 0.01 N HCl) for 22-25 minutes at 37 ˚C. Probes and target tissues were co-
denatured for 7 minutes at 75 ˚C and hybridised for two days at 37 ˚C. After washings, the slides were counterstained 
with 4',6-Diamidino-2-phenylindole, dihydrochloride (DAPI). The FISH analysis was performed on a Zeiss Imager.M1 
microscope (Carl Zeiss Canada Ltd., Canada) equipped with a camera (JAI Inc., San Jose, CA, USA) and the 
MetaSystems Isis FISH Imaging System (MetaSystems GmbH, Altlussheim, Germany). 
 
SUPPLEMENTARY TABLES AND FIGURES 
 
SUPPLEMENTARY TABLE 1 Patient characteristics 
 Frequency % 
Age 47.5 (26.4 – 83.9) 
Tumour size (cm) 5 (2.3 – 8.6) 
unknown 2 2.1 
FIGO stage   
IB 26 27.96 
IIA 2 2.15 
IIB 41 44.09 
IIIB 23 24.73 
IV 1 1.08 
Grade   
MD 56 60.22 
PD 29 31.18 
WD 3 3.23 
unknown 5 5.38 
Node status (Overall)   
negative 47 50.54 
positive 31 33.33 
equivocal 15 16.13 
Median O2, mmHg 3.1 (-1 – 102.4) 
unknown 6 6.5 
HP5, % 62.2 (0 – 98.3) 
unknown 6 6.5 
Initial haemoglobin, g/l 126 (77 – 148) 
unknown 3 3.2 
Note: data are expressed as number of patients, except 
for age, tumour size, median O2, HP5 and initial 
haemoglobin concentration (median, range). 
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SUPPLEMENTARY TABLE 2 Relationship LAMP3  expression and 
continuous clinical parameters 
 LAMP3/CEP7 < 1.5 LAMP3/CEP7 ≥ 1.5 
 Spearman r p Spearman r p 
Age 0.15 0.39 -0.29 0.2 
Tumour size -0.075 0.67 -0.014 0.95 
Haemoglobin -0.092 0.6 0.13 0.62 
IFP 0.15 0.39 -0.27 0.24 
HP5 0.39 0.024 -0.16 0.48 
 
 
SUPPLEMENTARY TABLE 3 Relationship LAMP3  expression and categorical clinical parameters 
 LAMP3/CEP7 < 1.5 LAMP3/CEP7 ≥ 1.5 
 min median max Wald p min median max Wald p 
FIGO stage           
stage IB 0.2199 0.6458 1.083   0.5674 0.7075 1.127   
stage II 0.3873 0.9562 1.617   0.2431 1.37 2.21   
stage III+ 0.6341 0.8736 1.795 0.177 0.0344 0.5988 0.9826 1.996 0.202 0.244 
Grade           
PD 0.6053 0.8769 1.275   0.2431 0.9267 1.357   
WD/MD 0.2199 0.6567 1.795 -0.0834 0.56 0.5674 1.338 2.21 0.345 0.195 
Overall node           
negative 0.2199 0.7004 1.617   0.2431 1.127 2.21   
positive 0.3696 0.8769 1.795 -0.0722 0.59 0.6219 1.221 1.766 -0.0424 0.869 
 
 
SUPPLEMENTARY FIGURE 1 Scatter plot of LAMP3/CEP7 ratios and LAMP3 protein (A) or mRNA (B) expression 
in human cervix tumours. A straight line was fitted through the data (Spearman correlation test). C. LAMP3/CEP7 
ratios in normal human cervix tissue, either squamous (cases 1-4) or glandular (cases 5-8).  
 
SUPPLEMENTARY FIGURE 2 In vitro validation ME180 host cell lines. eGFP fluorescence in ME180 cells expressing a 
doxycycline-inducible eGFP reporter gene. Shown are fluorescence microscopy images following 0, 6 and 24 hours of 
doxycycline incubation (1 µg/ml).  
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SUPPLEMENTARY FIGURE 3 In vivo validation ME180 host cell lines. The in vivo growth and metastatic potential of 
two ME180 host cell lines was tested: clone 10.6 and clone 10.8. Both cell lines stably express the Tetracycline 
repressor and contain a single copy of the Flp Recombination Target (FRT) site. These two host line-features allow for 
rapid generation of ME180 sublines with isogenic, doxycycline-inducible expression of a transgene. The cervix 
tumours established from the host clones were grown orthotopically for a total 21 days and were daily exposed to the 
hypoxia treatment from day 9. A. Size orthotopic xenografts after 21 days of growth. Each symbol represents a 
tumour from one animal. As for the parental ME180 cells, the tumours derived from both host lines were considerably 
smaller following the hypoxia treatment. Total number of metastatic lymph nodes (B) and metastatic score (C) per 
animal; both ME180 clone 10.6 and 10.8 tumours had maintained the potential to spontaneously metastasise to the 
regional lymph node chain in an oxygen-dependent manner. Clone 10.8 was used to construct a ME180 subline with 
doxycycline-inducible expression of the eGFP reporter gene. The orthotopic tumours were grown for 21 days and 
were daily exposed to the hypoxia treatment from day 9. D. Size orthotopic xenografts after 21 days of growth. Each 
symbol represents a tumour from one animal. E. and F. eGFP expression and the doxycycline treatment did not affect 
the growth of the cervix tumours or nodal metastasis. Horizontal lines represent the mean values for each group.  
 
 
 
 
 
SUPPLEMENTARY FIGURE 4 Validation ME180-GADD34-C cells. A. Induction kinetics of doxycycline regulated 
expression of the hamster GADD34 C-terminus region in ME180-GADD34-C cells. Levels of protein expression 
were measured by immunoblotting in cells grown in the presence or absence of doxycycline for the indicated periods 
of time. eIF4E was used as a loading control. B. ME180-GADD34-C and EV control (EV) cells were pre-incubated 
with doxycycline for 72 hours (+dox) or left untreated (-dox), and subsequently exposed to 0, 6 or 16 hours of anoxia. 
CHOP mRNA expression was measured by RT-qPCR. Mean and SEM of three independent experiments is shown 
(two-way ANOVA, p < 0.05, **p < 0.005, (-)dox EV vs. rest).  
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SUPPLEMENTARY FIGURE 5 LAMP3 expression measured in stable LAMP3 knockdown cells. A. LAMP3-deficient 
and empty vector control cells were exposed to anoxia for 24 hours and LAMP3 expression was quantified by RT-
qPCR. Mean and SEM of two independent experiments is shown (two-way ANOVA, **p < 0.01). B. LAMP3 protein 
levels in stable LAMP3 knockdown cells (shLAMP3) and empty vector control cells (EV control) exposed to 24 hours 
of anoxia. Asterisks indicate non-specific protein bands.  
 
SUPPLEMENTARY FIGURE 6 LAMP3 protein expression was assessed by immunofluorescence staining in LAMP3 
knockdown and empty vector control tumours.  
 
 
SUPPLEMENTARY FIGURE 7 Human VEGF mRNA expression in ME180-GADD34-C orthotopic xenografts. 
Relative VEGF mRNA levels were measured by RT-qPCR using human-specific primers. Bars represent the mean 
levels of ten GADD34-C cervix tumours per group. Error bars depict SD. 
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SUPPLEMENTARY FIGURE 8 Microvessel density and hVEGF expression in shLAMP3 orthotopic xenografts. A. The 
microvessel density of the xenografts was evaluated by immunofluorescence staining (CD31). Bars represent the mean 
levels of ten tumours per group. Error bars depict SD. B. VEGF mRNA levels were measured by RT-qPCR using 
human-specific primers. Bars represent the mean levels of ten cervix tumours per group. Error bars depict SD.  
 
SUPPLEMENTARY FIGURE 9 Hypoxic fraction shLAMP3 orthotopic xenografts. A. Fraction of EF5 labelled tumour 
area. Horizontal lines represent the mean values for each group. B. Correlation between hypoxic fraction and tumour 
size. A straight line was fitted through the data. 
 
ACKNOWLEDGEMENTS 
The authors would like to thank ANTHONY FYLES, MICHAEL MILOSEVIC and BLAISE CLARKE 
for providing uterine cervix cancer TMA sections and TREVOR DO, TRUDEY NICKLEE and 
MELANIE MACASAET for advice and technical assistance on the immunohistochemical 
stainings in these and other tissue samples. We would also like to thank OLGA LUDKOVSKI for 
the FISH analysis and JENNA SYKES for help with the statistical analysis. This work was 
financially supported by the Ontario Ministry of Health and Long Term Care (OMOHLTC), 
the Terry Fox New Frontiers Research Program (PPG09-020005 to BW and MK), the Ontario 
Institute for Cancer Research and Terry Fox Research Institute (Selective therapies program to 
BW), the Canadian Institute for Health Research (CIHR grant 201592 to BW and MK and 
CIHR grant 102757 to RH), the Dutch Cancer Society (KWF grant UM 2008-4068 to BW), 
the transnationale Universiteit Limburg (TUL 30943099T to BW), the EU 7th framework 
program (METOXIA project 222741 to BW and MK) and the Terry Fox New Investigator 
awarded to MK. The views expressed do not necessarily reflect those of the OMOHLTC. 
HYPOXIC ACTIVATION OF THE UPR PROMOTES METASTASIS 
 91 
REFERENCES 
1. BRIZEL, D. M., SIBLEY, G. S., PROSNITZ, L. R. et al. Tumor hypoxia adversely affects the prognosis of carcinoma 
of the head and neck. Int J Radiat Oncol Biol Phys 1997; 38: 285-289. 
2. HOCKEL, M., KNOOP, C., SCHLENGER, K. et al. Intratumoral pO2 predicts survival in advanced cancer of the 
uterine cervix. Radiother Oncol 1993; 26: 45-50. 
3. NORDSMARK, M., OVERGAARD, J. A confirmatory prognostic study on oxygenation status and loco-regional 
control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol 2000; 
57: 39-43. 
4. BRIZEL, D. M., SCULLY, S. P., HARRELSON, J. M. et al. Tumor oxygenation predicts for the likelihood of distant 
metastases in human soft tissue sarcoma. Cancer Res 1996; 56: 941-943. 
5. HOCKEL, M., SCHLENGER, K., ARAL, B. et al. Association between tumor hypoxia and malignant progression in 
advanced cancer of the uterine cervix. Cancer Res 1996; 56: 4509-4515. 
6. PITSON, G., FYLES, A., MILOSEVIC, M. et al. Tumor size and oxygenation are independent predictors of nodal 
diseases in patients with cervix cancer. Int J Radiat Oncol Biol Phys 2001; 51: 699-703. 
7. FYLES, A., MILOSEVIC, M., HEDLEY, D. et al. Tumor hypoxia has independent predictor impact only in patients 
with node-negative cervix cancer. J Clin Oncol 2002; 20: 680-687. 
8. MILOSEVIC, M., WARDE, P., MENARD, C. et al. Tumor hypoxia predicts biochemical failure following 
radiotherapy for clinically localized prostate cancer. Clin Cancer Res 2012; 18: 2108-2114. 
9. ROFSTAD, E. K., DANIELSEN, T. Hypoxia-induced metastasis of human melanoma cells: involvement of vascular 
endothelial growth factor-mediated angiogenesis. Br J Cancer 1999; 80: 1697-1707. 
10. STACKPOLE, C. W., GROSZEK, L., KALBAG, S. S. Benign-to-malignant B16 melanoma progression induced in 
two stages in vitro by exposure to hypoxia. J Natl Cancer Inst 1994; 86: 361-367. 
11. YOUNG, S. D., HILL, R. P. Effects of reoxygenation on cells from hypoxic regions of solid tumors: anticancer 
drug sensitivity and metastatic potential. J Natl Cancer Inst 1990; 82: 371-380. 
12. YOUNG, S. D., MARSHALL, R. S., HILL, R. P. Hypoxia induces DNA overreplication and enhances metastatic 
potential of murine tumor cells. Proc Natl Acad Sci U S A 1988; 85: 9533-9537. 
13. CAIRNS, R. A., HILL, R. P. Acute hypoxia enhances spontaneous lymph node metastasis in an orthotopic murine 
model of human cervical carcinoma. Cancer Res 2004; 64: 2054-2061. 
14. CAIRNS, R. A., KALLIOMAKI, T., HILL, R. P. Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT 
murine tumors. Cancer Res 2001; 61: 8903-8908. 
15. ROFSTAD, E. K., GAUSTAD, J. V., EGELAND, T. A. et al. Tumors exposed to acute cyclic hypoxic stress show 
enhanced angiogenesis, perfusion and metastatic dissemination. Int J Cancer 2010; 127: 1535-1546. 
16. HARRIS, A. L. Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38-47. 
17. BLAIS, J. D., FILIPENKO, V., BI, M. et al. Activating transcription factor 4 is translationally regulated by hypoxic 
stress. Mol Cell Biol 2004; 24: 7469-7482. 
18. KOUMENIS, C., NACZKI, C., KORITZINSKY, M. et al. Regulation of protein synthesis by hypoxia via activation of 
the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2alpha. Mol 
Cell Biol 2002; 22: 7405-7416. 
19. ROMERO-RAMIREZ, L., CAO, H., NELSON, D. et al. XBP1 is essential for survival under hypoxic conditions and 
is required for tumor growth. Cancer Res 2004; 64: 5943-5947. 
20. BI, M., NACZKI, C., KORITZINSKY, M. et al. ER stress-regulated translation increases tolerance to extreme 
hypoxia and promotes tumor growth. EMBO J 2005; 24: 3470-3481. 
21. BLAIS, J. D., ADDISON, C. L., EDGE, R. et al. Perk-dependent translational regulation promotes tumor cell 
adaptation and angiogenesis in response to hypoxic stress. Mol Cell Biol 2006; 26: 9517-9532. 
22. KORITZINSKY, M., ROUSCHOP, K. M., VAN DEN BEUCKEN, T. et al. Phosphorylation of eIF2alpha is required for 
mRNA translation inhibition and survival during moderate hypoxia. Radiother Oncol 2007; 83: 353-361. 
23. AMERI, K., LEWIS, C. E., RAIDA, M. et al. Anoxic induction of ATF-4 through HIF-1-independent pathways of 
protein stabilization in human cancer cells. Blood 2004; 103: 1876-1882. 
24. HARDING, H. P., NOVOA, I., ZHANG, Y. et al. Regulated translation initiation controls stress-induced gene 
expression in mammalian cells. Mol Cell 2000; 6: 1099-1108. 
25. HARDING, H. P., ZHANG, Y., ZENG, H. et al. An integrated stress response regulates amino acid metabolism and 
resistance to oxidative stress. Mol Cell 2003; 11: 619-633. 
26. ROUSCHOP, K. M., VAN DEN BEUCKEN, T., DUBOIS, L. et al. The unfolded protein response protects human 
tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. J Clin Invest 
2010; 120: 127-141. 
27. MA, Y., HENDERSHOT, L. M. Delineation of a negative feedback regulatory loop that controls protein translation 
during endoplasmic reticulum stress. J Biol Chem 2003; 278: 34864-34873. 
28. CHAN, D. A., GIACCIA, A. J. Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev 2007; 26: 333-339. 
29. LUNT, S. J., CHAUDARY, N., HILL, R. P. The tumor microenvironment and metastatic disease. Clin Exp 
Metastasis 2009; 26: 19-34. 
CHAPTER FIVE 
 92 
30. ERLER, J. T., BENNEWITH, K. L., COX, T. R. et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone 
marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009; 15: 35-44. 
31. YANG, M. H., WU, M. Z., CHIOU, S. H. et al. Direct regulation of TWIST by HIF-1alpha promotes metastasis. 
Nat Cell Biol 2008; 10: 295-305. 
32. OSINSKY, S. P., GANUSEVICH, II, BUBNOVSKAYA, L. N. et al. Hypoxia level and matrix metalloproteinases-2 and 
-9 activity in Lewis lung carcinoma: correlation with metastasis. Exp Oncol 2005; 27: 202-205. 
33. MUJCIC, H., RZYMSKI, T., ROUSCHOP, K. M. et al. Hypoxic activation of the unfolded protein response (UPR) 
induces expression of the metastasis-associated gene LAMP3. Radiother Oncol 2009; 92: 450-459. 
34. KANAO, H., ENOMOTO, T., KIMURA, T. et al. Overexpression of LAMP3/TSC403/DC-LAMP promotes 
metastasis in uterine cervical cancer. Cancer Res 2005; 65: 8640-8645. 
35. NOVOA, I., ZENG, H., HARDING, H. P. et al. Feedback inhibition of the unfolded protein response by GADD34-
mediated dephosphorylation of eIF2alpha. J Cell Biol 2001; 153: 1011-1022. 
36. FYLES, A., MILOSEVIC, M., PINTILIE, M. et al. Long-term performance of interstial fluid pressure and hypoxia as 
prognostic factors in cervix cancer. Radiother Oncol 2006; 80: 132-137. 
37. WANGSA, D., HESELMEYER-HADDAD, K., RIED, P. et al. Fluorescence in situ hybridization markers for 
prediction of cervic al lymph node metastases. Am J Pathol 2009; 175: 2637-2645. 
38. CAIRNS, R. A., HILL, R. P. A fluorescent orthotopic model of metastatic cervical carcinoma. Clin Exp Metastasis 
2004; 21: 275-281. 
39. CHAUDARY, N., MILOSEVIC, M., HILL, R. P. Suppression of vascular endothelial growth factor receptor 3 
(VEGFR3) and vascular endothelial growth factor C (VEGFC) inhibits hypoxia-induced lymph node metastases 
in cervix cancer. Gynecol Oncol 2011; 123: 393-400. 
40. ROUSCHOP, K. M., DUBOIS, L. J., KEULERS, T. G. et al. PERK/eIF2alpha signaling protects therapy resistant 
hypoxic cells through induction of glutathione synthesis and protection against ROS. Proc Natl Acad Sci U S A 
2013. 
41. VAN DEN BEUCKEN, T., RAMAEKERS, C. H., ROUSCHOP, K. et al. Deficient carbonic anhydrase 9 expression in 
UPR-impaired cells is associated with reduced survival in an acidic microenvironment. Radiother Oncol 2009; 
92: 437-442. 
42. DE SAINT-VIS, B., VINCENT, J., VANDENABEELE, S. et al. A novel lysosome-associated membrane glycoprotein, 
DC-LAMP, induced upon DC maturation, is transiently expressed in MHC class II compartment. Immunity 
1998; 9: 325-336. 
43. SAITOH, O., WANG, W. C., LOTAN, R. et al. Differential glycosylation and cell surface expression of lysosomal 
membrane glycoproteins in sublines of a human colon cancer exhibiting distinct metastatic potentials. J Biol 
Chem 1992; 267: 5700-5711. 
44. NAGELKERKE, A., MUJCIC, H., BUSSINK, J. et al. Hypoxic regulation and prognostic value of LAMP3 expression 
in breast cancer. Cancer 2011; 117: 3670-3681. 
45. GARRIGUES, J., ANDERSON, J., HELLSTROM, K. E. et al. Anti-tumor antibody BR96 blocks cell migration and 
binds to a lysosomal membrane glycoprotein on cell surface microspikes and ruffled membranes. J Cell Biol 
1994; 125: 129-142. 
46. OZAKI, K., NAGATA, M., SUZUKI, M. et al. Isolation and characterization of a novel human lung-specific gene 
homologous to lysosomal membrane glycoproteins 1 and 2: significantly increased expression in cancers of 
various tissues. Cancer Res 1998; 58: 3499-3503. 
47. SAWADA, R., LOWE, J. B., FUKUDA, M. E-selectin-dependent adhesion efficiency of colonic carcinoma cells is 
increased by genetic manipulation of their cell surface lysosomal membrane glycoprotein-1 expression levels. J 
Biol Chem 1993; 268: 12675-12681. 
48. FELDMAN, D. Irestatin, a potent inhibitor of IRE1α and the unfolded protein response, is a hypoxia-selective 
cytotoxin and impairs tumor growth. J Clin Oncol ASCO Annual Meeting Proceedings Part I 2007; 25: 3514. 
49. DAVENPORT, E. L. MOORE, H. E., DUNLOP, A. S. et al. Heat shock protein inhibition is associated with 
activation of the unfolded protein response pathway in myeloma plasma cells. Blood 2007; 110: 2641-2649. 
50. OBENG, E. A., CARLSON, L. M., GUTMAN, D. M. et al. Proteasome inhibitors induce a terminal unfolded protein 
response in multiple myeloma cell. Blood 2006; 107: 4907-4916. 
HYPOXIC ACTIVATION OF THE UPR PROMOTES METASTASIS 
 93 
 
 
  
 
 
 
 
 
CHAPTER SIX 
 
 
HYPOXIC REGULATION OF THE PERK/ATF4/LAMP3-ARM OF THE 
UNFOLDED PROTEIN RESPONSE IN HEAD AND NECK SQUAMOUS CELL 
CARCINOMA 
 
ANIKA NAGELKERKE 
FRED C.G.J. SWEEP 
HANNEKE STEGEMAN 
REIDAR GRÉNMAN 
JOHANNES H.A.M. KAANDERS 
JOHAN BUSSINK 
PAUL N. SPAN 
 
Submitted. 
 
 
 
CHAPTER SIX 
 96 
ABSTRACT 
Background 
LAMP3 was previously described as a factor induced by hypoxia via the PERK/ATF4-arm of 
the unfolded protein response (UPR) in several cancer cell lines. We found that LAMP3 was 
associated with metastasis formation, treatment resistance and survival in breast cancer. Here, 
we examined the hypoxic regulation of the PERK/ATF4/LAMP3-arm of the UPR in head 
and neck squamous cell carcinoma (HNSCC). 
Methods 
LAMP3 expression levels were examined in patient biopsies of 29 head and neck squamous 
cell carcinomas by immunohistochemistry and correlated to clinicopathological parameters. 
HNSCC xenografts were stained for LAMP3 and the exogenous hypoxia marker 
pimonidazole. A panel of twelve HNSCC cell lines was cultured under hypoxic conditions after 
which both mRNA and protein expression for PERK, ATF4 and LAMP3 was evaluated. 
Results 
In HNSCC patients, high LAMP3 expression correlated with N-stage (p = 0.019) and the 
occurrence of distant metastases during follow-up (p = 0.039). Patients with high LAMP3 
levels had a worse metastasis-free survival, which was highly statistically significant (p = 0.008). 
Intriguingly, LAMP3 expression was localised exclusively in normoxic areas of tumours and 
xenografts. mRNA and protein expression of PERK, p-eIF2α, ATF4 and LAMP3 were not 
universally induced in a panel of HNSCC cell lines after exposure to 0.1% O2. Instead, in some 
HNSCC cell lines expression remained unaltered or was even inhibited under hypoxic 
conditions. mRNA expression of CA9 was induced by hypoxia in cell lines in which the UPR 
was inhibited. However, induction of ER-stress via tunicamycin resulted in vast expression of 
PERK, ATF4 and LAMP3. 
Conclusions 
The current data reveal that LAMP3 is relevant for prognosis in HNSCC. However, the 
PERK/ATF4/LAMP3-arm of the UPR responds differently to hypoxic conditions in HNSCC 
compared to other tumour types. Therefore, HNSCCs may represent a subset of tumours that 
deal with hypoxia in an atypical manner.  
 
KEYWORDS 
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INTRODUCTION 
The presence of hypoxic regions within solid tumours is of unequivocal importance for patient 
prognosis in a variety of cancer types. Hypoxia arises as a consequence of an imbalance 
between the supply and consumption of oxygen within a tumour. Inadequate vascularisation is 
one of the underlying mechanisms impairing oxygenation. As a consequence, tumour cells are 
either too remote from blood vessels to receive sufficient amounts of oxygen (diffusion-limited 
hypoxia) or vessels are structurally and functionally not correctly formed restricting the oxygen 
supply (perfusion-limited hypoxia)1-3. The consequences of hypoxia in tumours are severe. 
Patients with hypoxic tumours have a worse prognosis compared to patients with well-
oxygenated tumours4-11. Hypoxia can cause resistance to various treatment modalities12, of 
which radiotherapy is a well-known example13. In addition, hypoxia can influence gene 
expression, can cause genetic instability and promote invasiveness and metastasis14. Hypoxic 
cells are also less susceptible to apoptotic cell death15. Apparently, hypoxic regions represent a 
niche in which tumour cells can survive and enhance their aggressiveness.  
Cell survival under hypoxic conditions can be mediated by the unfolded protein response 
(UPR)16-19. Under conditions of stress, such as hypoxia, misfolded proteins will accumulate in 
the endoplasmic reticulum (ER). The UPR is aimed at restoring homeostasis by alleviating this 
ER-stress. In other words, the UPR provides cells with ways to survive cellular stress. Three 
fundamental ER-resident transmembrane proteins convey UPR-signalling: PERK (PKR-like 
ER kinase), IRE1 (inositol-requiring enzyme 1) and ATF6 (activating transcription factor 
6)16,17,19. Of these three arms, the PERK-arm has been examined most extensively. PERK is a 
kinase that can phosphorylate eIF2α (eukaryotic initiation factor 2α), thereby preventing 
general mRNA translation20. Nevertheless, translation of a small number of mRNAs will be 
preferentially induced under stress conditions. ATF4 (activation transcription factor 4) is one 
of the factors induced by ER-stress in a PERK-dependent manner21. ATF4 itself is an 
indispensible transcription factor, overexpressed in cancer22, inducing the expression of several 
genes essential for cell survival23. 
Recently, a novel target gene of the UPR was identified: lysosome-associated membrane 
protein 3 (LAMP3)21,24. This protein is induced by hypoxia as part of the PERK/ATF4-arm. 
Indeed, LAMP3 was found upregulated by hypoxia in a panel of different tumour cell lines24. 
In addition, LAMP3 has prognostic value in breast cancer patients and cervical cancer 
patients25,26. Increasing evidence from our laboratory emphasises the importance of LAMP3 in 
tumour biology with functions in hypoxia-induced metastasis and therapy resistance (27,28 and 
CHAPTER SEVEN). This prompted us to explore whether LAMP3 expression is also relevant 
for prognosis in a cohort of head and neck squamous cell carcinoma patients, since hypoxia is 
a strong adverse factor in this tumour type. 
 
MATERIALS AND METHODS 
Patients 
In this study, 29 patients with HNSCC located in the oral cavity, oropharynx, hypopharynx or 
larynx were included. All patients were treated at the Radboud University Nijmegen Medical 
Centre, Nijmegen, the Netherlands and all gave written informed consent. Pre-treatment 
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tumour biopsies were obtained and immediately stored in liquid nitrogen until further 
processing. Prior to taking biopsies, the hypoxic cell marker pimonidazole was administered to 
patients as previously described29,30. 
 
Growth of HNSCC xenografts 
HNSCC xenografts of ten other patient biopsies and four UT-SCC cell lines were established 
as previously described31,32. 
 
Immunohistochemistry, image acquisition and analysis 
Immunohistochemical staining of xenografts was performed as described earlier26. Patient 
material was stained similarly, with the exception that vessels were stained using the mouse 
anti-human endothelium antibody PAL-E (Euro Diagnostica, Arnhem, the Netherlands) 
diluted 1:10. Alexa-Fluor-647-conjugated chicken anti-mouse IgG (A21463, 2 mg/ml, 
Invitrogen) diluted 1:100 was used as the secondary antibody. All images were acquired using a 
Zeiss Axioskop fluorescence microscope (Zeiss, Göttingen, Germany) in combination with IP-
lab imaging software (Scanalytics Inc., Fairfax, VA, USA). LAMP3 expression was established 
by using an adapted semiquantitative H-score. Average staining intensity was determined by 
IP-lab and multiplied by an estimate of the percentage of positive cells. 
 
Cell culture, hypoxic incubations and tunicamycin treatment 
Twelve UT-SCC cell lines were maintained in Dulbecco’s modified Eagles medium 
supplemented with 10% (v/v) foetal bovine serum, 20 mM Hepes, 1× non-essential amino 
acids, 2 mM L-glutamine and 10 U/ml penicillin, 10 µg/ml streptomycin (all from PAA 
Laboratories, Cölbe, Germany) at 37 ˚C with 5% CO2. Hypoxic conditions were induced with 
a H35 Hypoxystation (Don Whitley Scientific Ltd., Shipley, UK). For treatment with 
tunicamycin, cells were incubated with 1 µg/ml Tunicamycin from Streptomyces sp., T7765 
(Sigma Aldrich, St. Louis, MO, USA) for 24 hours. 
 
RNA isolation, cDNA synthesis and RT-qPCR 
RNA was isolated using the Total RNA purification kit (Norgen Biotek Corp., Thorold, 
Canada) according to the manufacturer’s instructions. Next, 1 µg of RNA was reverse 
transcribed using the iScript cDNA synthesis kit (Bio-Rad Laboratories Inc., Richmond, CA, 
USA). RT-qPCR was performed with SYBR green (Applied Biosystems, Foster City, CA, 
USA) on a CFX96 real-time PCR detection system (Bio-Rad) and the following primers: PERK 
FW: 5’- CTGATTTTGAGCCAATTC-3’ and RV: 5’- CCGGTACTCGCGTCGCTG-3’, ATF4 FW: 5’-
CCTTCACCTTCTTACAACCT-3’ and RV: 5’-GTAGTCTGGCTTCCTATCTC-3’, LAMP3 FW: 5’-
TGAAAACAACCGATGTCCAA-3’ and RV: 5’-TCAGACGAGCACTCATCCAC-3’, CA9 FW: 5’-
GAGGCCTGGCCGTGTTG-3' and RV: 5’-CTGAGCCTTCCTCAGCGATT-3', 18S FW: 5’-
GTAACCCGTTGAACCCCATT-3’ and RV: 5’-CCATCCAATCGGTAGTAGCG-3’. A pre-developed 
assay (Applied Biosystems) was used for the reference gene HPRT1 (hypoxanthine 
phosphoribosyl transferase 1)33. 18S was used as the reference gene for analysis of gene 
expression during hypoxic conditions34.  
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Western blot analysis 
Western blot analysis was performed as previously described26. Primary antibodies used were: 
rabbit anti-PERK (#5683), rabbit anti-phospho-eIF2α (#3597), rabbit anti-ATF4 (#11815) (all 
from Cell Signaling Technology, Beverly, MA, USA), rabbit anti-LAMP3 (LS-B7698, Lifespan 
Biosciences Inc., Seattle, WA, USA) and mouse anti-α-tubulin (Calbiochem, San Diego, CA, 
USA). All antibodies were diluted 1:1,000. Western blots were quantified using ImageJ 
(National Institutes of Health, Bethesda, MD, USA). 
 
Statistical analysis 
Statistical analyses were performed using GraphPad Prism 4.0 software (GraphPad Software 
Inc., La Jolla, CA, USA). Associations between LAMP3 expression and clinicopathological 
parameters were assessed using Mann-Whitney U or Kruskal-Wallis tests. Patient survival was 
evaluated using the Kaplan-Meier method with log-rank test. RT-qPCR data were analysed 
using Student’s t-tests and correlations were assessed using Spearman’s rank correlation test. p 
< 0.05 was indicative of statistical significance. Asterisks indicate statistical significance relative 
to the corresponding control, where * is p < 0.05, ** is p < 0.01 and *** is p < 0.001. 
 
TABLE 1 Patient and tumour characteristics and LAMP3 expression levels 
Age [Mean (range)] 59 (36 - 84) LAMP3 expression   
 n % Median  min - max p  
Total 29 100 135  65 - 487  
Gender     0.474a 
Male 26 90 137  65 - 487  
Female 3 10 108  84 - 207  
T-classification     0.736b 
T1/2 10 34 148  84 - 240  
T3 13 45 131  65 - 487  
T4 6 21 136  119 - 164  
N-classification     0.019a 
N0 7 24 103  65 - 146  
N+ 22 76 152  84 - 487  
Tumour site     0.225b 
Larynx 11 38 131  65 - 487  
Hypopharynx 9 31 187  91 - 240  
Oropharynx 7 24 110 84 - 225  
Oral cavity 2 7 153  146 - 160  
Distant metastasis occurrence     0.039a 
no 21 72 127  65 - 487  
yes 8 28 178  135 - 240  
aMann-Whitney U test  
bKruskal-Wallis test 
 
RESULTS 
High LAMP3 expression is associated with N-stage, metastasis formation and survival 
Twenty-nine patients were included in this study. In Table 1, the clinical characteristics are 
presented. The median duration of follow-up for all patients was 28.2 months and for 
surviving patients 83.9 months. Patient biopsies were stained for LAMP3, the hypoxic cell 
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marker pimonidazole and vessels. Expression of LAMP3 was scored semi-quantitatively and 
correlated with clinicopathological parameters (see Table 1). A significant association was 
found between LAMP3 expression and N-stage, where patients with positive lymph nodes had 
higher levels of LAMP3 (p = 0.019, see Figure 1A). In addition, patients who developed distant 
metastases within the first 24 months of follow-up had higher LAMP3 expression compared to 
patients without distant metastases (p = 0.039, see Figure 1B). Next, patients were 
dichotomised based on the median LAMP3 expression score. Patients with high LAMP3 levels 
in their primary tumour displayed a reduced overall, disease-free and metastasis-free survival, 
but differences with the low LAMP3 group were only statistically significant for metastasis-free 
survival (p = 0.008, see Figure 1C, D and E). 
FIGURE 1 Association of LAMP3 expression levels with clinicopathological parameters. Association between LAMP3 
and (A) N-stage or (B) development of metastases. Horizontal lines represent median values. Open symbols are 
outliers above the range of the chosen y-axis. Kaplan-Meier estimates of overall (C), disease-free (D) and metastasis-
free (E) survival. 
 
LAMP3 expression in tumour biopsies and xenografts is localised exclusively in 
normoxic areas 
As previous data showed that LAMP3 is associated with hypoxia in breast cancer26, we next 
examined LAMP3 expression in relation to the exogenous hypoxia marker pimonidazole. 
Unexpectedly, co-staining of LAMP3 with pimonidazole in the patient biopsies revealed that 
LAMP3 expression was localised exclusively in normoxic areas. A representative example of a 
staining is given in Figure 2.  
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FIGURE 2 Merged pseudo-coloured fluorescent images of LAMP3 (red), pimonidazole (green) and vessels (blue) in a 
biopsy from a squamous cell carcinoma of the larynx (A). A larger magnification of the white rectangle is shown in (B). 
Original magnification is 100×. Bars equal 100 µm. 
 
To further substantiate these findings, LAMP3 expression relative to pimonidazole and vessels 
was evaluated in a panel of different HNSCC xenografts. Ten SCCNij and four UT-SCC 
xenografts were stained. Six of the ten SCCNij xenografts and one out of the four UT-SCC 
xenografts showed expression of LAMP3. Two representative images are shown in Figure 3. 
Similar to the patient biopsy material, in these xenografts LAMP3 expression was again limited 
to the non-hypoxic areas close to the vasculature (see Figure 3A and B).  
 
FIGURE 3 Merged pseudo-coloured fluorescent images of LAMP3 (red), pimonidazole (green) and vessels (blue) in a 
SCCNij202 xenograft (A) and an UT-SCC45 xenograft (B). Original magnification is 100×. Bars equal 100 µm. 
 
PERK, ATF4 and LAMP3 expression is not universally induced after hypoxic exposure 
of UT-SCC cells 
To further examine how hypoxia affects the PERK/ATF4/LAMP3-arm of the UPR in 
HNSCC, a panel of UT-SCC cells was cultured under hypoxic conditions. First, basal 
expression of PERK, p-eIF2α, ATF4 and LAMP3 was evaluated in the UT-SCC cells (see 
Figure 4A-C and D). Levels were found to vary considerably between different cell lines. In 
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addition, mRNA and protein expression did not show similar levels of expression (see Figure 
4E). Direct comparison of LAMP3 mRNA expression with that previously found in breast 
cancer cells26 revealed that mRNA expression in UT-SCC cells was not substantially lower or 
higher.  
FIGURE 4 Basal mRNA expression levels of (A) PERK, (B) ATF4 and (C) LAMP3 in a panel of twelve UT-SCC cell 
lines. Data are presented as mean + SD. Results are from two representative experiments with three replicates each. D. 
Basal protein expression of PERK, p-eIF2α, ATF4 and LAMP3 in the UT-SCC cell panel. α-tubulin represents the 
loading control. Numbers below the bands indicate densitometric analysis corrected for the corresponding α-tubulin. 
E. Correlation between mRNA and protein expression of PERK (left), ATF4 (middle) and LAMP3 (right) in twelve 
UT-SCC cell lines. 
 
Exposure of UT-SCC cells to 0.1% O2 for up to 72 hours led to diverse effects on the mRNA 
expression of PERK, ATF4 and LAMP3 (see Figure 5A, B and C). mRNA expression of both 
PERK and ATF4 was not universally induced after hypoxic exposure (see Figure 5A and B). A 
significant induction of expression by hypoxia was found in five and two cell lines, 
respectively. The other cell lines showed a significant inhibition of expression (five and two cell 
lines, respectively) or effects were not significant (two and eight cell lines, respectively). Figure 
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5C shows that LAMP3 mRNA expression is significantly downregulated in seven of the twelve 
UT-SCC cell lines tested. In contrast, two cell lines showed a significant induction after 
hypoxic exposure and in three cell lines effects were not significant. 
Next, three UT-SCC cell lines were selected for analysis of protein expression after hypoxia. 
UT-SCC5 (PERK, ATF4 and LAMP3 mRNA induction after hypoxia), UT-SCC24A 
(induction of PERK mRNA, no effect on ATF4 mRNA and inhibition of LAMP3 mRNA 
after hypoxia) and UT-SCC45 (PERK, ATF4 and LAMP3 mRNA inhibition after hypoxia) 
were chosen to obtain a diverse panel with regard to the effect of hypoxia on the UPR. Results 
on the protein level were not always identical to the effects found on the mRNA level (see 
Figure 5D). Intriguingly, expression of PERK, ATF4 and LAMP3 was reduced in both UT-
SCC5 and UT-SCC24A cells. UT-SCC45 cells showed an induction at 24 hours of hypoxic 
exposure for PERK and LAMP3, whereas ATF4 expression was inhibited at all time points. 
Data on expression of phospho-eIF2α are in conflict with PERK, ATF4 and LAMP3 as a 
substantial induction in all three cell lines after hypoxic incubation was found (see Figure 5D).  
 
 
FIGURE 5 Effect of hypoxic exposure (0.1% O2) on (A) PERK, (B) ATF4 and (C) LAMP3 mRNA expression in 
twelve UT-SCC cell lines. Data are presented as mean + SD. Results are from two representative experiments with 
three replicates each. D. Protein expression of PERK, p-eIF2α, ATF4 and LAMP3 after hypoxic exposure (0.1% O2) 
of three UT-SCC cell lines. α-tubulin represents the loading control. Numbers below the bands indicate densitometric 
analysis corrected for the corresponding α-tubulin. 
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CA9  expression is induced in UT-SCC5, -24A and -45 cells upon hypoxic exposure 
Next, we wanted to verify that hypoxic culture actually induces a transcriptional response in 
UT-SCC cells. Therefore, the mRNA expression of the endogenous hypoxia marker carbonic 
anhydrase 9 (CA9) was evaluated in UT-SCC5, -24A and -45 cells. CA9 is a known 
downstream target of hypoxia-inducible factor 1 (HIF1) the master regulator of the hypoxic 
response. All cell lines displayed a massive induction of CA9 expression, ranging from a 50-
fold induction in UT-SCC45 at 24 hours to a 25,000-fold induction in UT-SCC5 after 72 hours 
(see Figure 6A). This indicates that these cells have a functional HIF-pathway and can respond 
to hypoxic conditions. 
 
ER-stress induces PERK , ATF4  and LAMP3  mRNA expression in UT-SCC5, -24A 
and -45 cells 
Next, the effect of ER-stress on mRNA expression of PERK, ATF4 and LAMP3 was 
examined in three UT-SCC cell lines. Therefore, cells were exposed to tunicamycin, an 
inhibitor of N-linked glycosylation, which induces ER-stress and consequentially the UPR. A 
24-hour tunicamycin treatment was sufficient to induce a vast increase in PERK, ATF4 and 
LAMP3 mRNA expression in all three cell lines (see Figure 6 B, C and D). This indicates that 
the PERK/ATF4/LAMP3-arm is not defective in these cell lines. 
FIGURE 6 A. Effect of hypoxic exposure (0.1% O2) on CA9 mRNA expression in three UT-SCC cell lines. Effect of 
treatment with 1 µg/ml tunicamycin for 24 hours in three UT-SCC cell lines on mRNA expression of (B) PERK, (C) 
ATF4, and (D) LAMP3. Data are presented as mean + SD. Results are from two representative experiments with 
three replicates each. 
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DISCUSSION 
In this study, LAMP3 expression was assessed in a cohort of head and neck squamous cell 
carcinomas. Patients with positive lymph nodes and patients developing metastases showed 
higher LAMP3 expression levels in their primary tumour. In addition, patients with high 
LAMP3 expression had a significantly worse metastasis-free survival than patients with low 
LAMP3 expression in their tumours. These data indicate that also in head and neck squamous 
cell carcinomas LAMP3 is of importance for tumour progression. Further examination of the 
association of LAMP3 with hypoxia revealed that in contrast to other tumour types24,26, 
LAMP3 was not linked with hypoxia in HNSCC. Instead, expression was located exclusively in 
normoxic areas of both primary tumours and xenografts. Culturing HNSCC cells under 
hypoxic conditions revealed that in most cell lines hypoxia did not induce expression of PERK, 
ATF4 or LAMP3. Instead, in most cell lines, expression levels of these factors remained 
unaltered or were even inhibited after exposure to hypoxia. This is distinctly different from 
tumour cells of other origins, in which the UPR was vastly induced by hypoxia24,26. The 
observation that phosphorylated eIF2α accumulates during hypoxia, whereas its downstream 
targets ATF4 and LAMP3 do not, underlines the unusual manner in which the UPR appears to 
be regulated in these cells. However, phosphorylation of eIF2α does not rely exclusively on 
PERK. eIF2α can be phosphorylated by other factors, but this is in response to stresses other 
than hypoxia35,36. Whether eIF2α is phosphorylated by a PERK-independent mechanism in 
HNSCC cells and what effect this has on ATF4 activity remains to be elucidated.  
The data presented in the current study show that expression of PERK and ATF4 is still 
present in HNSCC cells, but is not always induced by hypoxia. Several studies have shown that 
PERK and ATF4 are induced during conditions of (severe) hypoxia20-23,37 and that these 
factors are essential for tumour survival18,37,38. In xenografts of transformed mouse embryonic 
fibroblasts ATF4 colocalised with hypoxia as indicated by the marker EF5 (ref. 37). In addition, 
tumours with defective PERK-signalling had a higher number of apoptotic cells in hypoxic 
areas compared to tumours with intact PERK-signalling. Hypoxia induces LAMP3 expression 
via PERK and ATF4 in tumour cell lines of multiple origins (i.e. colon, breast, prostate, lung 
and cervical cancer cells)24. However, none of the studies above examined HNSCC. We found 
that ER-stress provoked by tunicamycin in HNSCC cells did induce a response of the UPR. 
This demonstrates that the PERK-arm of the UPR is not defective in HNSCC. Previously, 
PERK-/- tumours were found to exhibit less and smaller hypoxic areas compared to tumours 
where PERK is still intact37. Extensive hypoxic regions were still present in HNSCC 
xenografts, which is different from the effects of defective PERK-signalling. The expression of 
other hypoxia-regulated genes was conventionally induced under hypoxic conditions. Together, 
these results clearly show that HNSCC represent a group of tumours that respond atypically to 
hypoxia with regard to the PERK/ATF4/LAMP3-arm of the UPR. We hypothesise that there 
are two possibilities as to what is happening in these cells. Either 0.1% O2 for up to 72 hours is 
not sufficient to induce ER-stress in these cells or pathways other than the PERK/ATF4-arm 
are active to deal with hypoxia-induced stress. Our current in vitro data are limited to 
examination of effects after hypoxia at 0.1% O2. The UPR is maximally induced under 
conditions of anoxia39. However, 0.1% O2 is also sufficient for its activation, albeit with 
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different, slower kinetics26. Nevertheless, it would be interesting to validate these results in a 
broader range of oxygen concentrations, as this may provide more information on the oxygen 
dependency of the observed effects. However, if hypoxia does not induce stress in HNSCC 
cells, then apparently these cells are very well adapted to hypoxic conditions. Previously, 
survival of UT-SCC cells was found to be relatively insensitive to 0.5% O2 (ref. 32), indicating 
that hypoxia is well tolerated in these cell lines. The absence of a hypoxia-induced response on 
the PERK/ATF4-arm in HNSCCs may have important implications for how these tumours 
deal with conditions of hypoxia. Perhaps HNSCC cells behave differently under hypoxic 
conditions in terms of their metabolism. As the UPR is mainly activated to deal with an 
overload of misfolded proteins in the ER, absence of a response during hypoxic conditions 
suggests that these cells have a low requirement for protein folding. In addition, it would be 
interesting to see how hypoxic exposure affects the other two pathways of the UPR besides the 
PERK-arm. So far, it is unclear whether there is crosstalk between the different arms of the 
UPR, although redundancy has been suggested16,40.  
In conclusion, this study examined the prognostic value of LAMP3 in HNSCC. Patients with 
high LAMP3 levels had a worse survival, which despite the small size of the cohort, was highly 
statistically significant for metastasis-free survival. Intriguingly, LAMP3 expression was 
localised exclusively in normoxic areas of tumours and xenografts. Analysis of mRNA and 
protein expression of PERK, ATF4 and LAMP3 in HNSCC cell lines revealed that in a 
number of cell lines expression was not induced, but unaltered or even inhibited after exposure 
to 0.1% O2. These data suggest that HNSCC represent a subset of tumours that deal with 
cellular stress induced by hypoxia in an atypical manner.   
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ABSTRACT 
Background 
Lysosome-associated membrane protein 3 (LAMP3) is a member of the so-called LAMP-
family of proteins, which are involved in the process of autophagy. Autophagy is induced by 
tamoxifen in breast cancer cells and may contribute to tamoxifen resistance. Here, the 
significance of LAMP3 for tamoxifen resistance in breast cancer was examined.  
Methods 
Clonogenic survival of MCF-7 breast cancer cells with LAMP3 knockdown after tamoxifen 
treatment was analysed. LAMP3 mRNA expression was quantified and the predictive value for 
first-line tamoxifen treatment was evaluated in 304 patients with advanced breast cancer. 
Results 
Treatment of MCF-7 cells with tamoxifen induced LAMP3 mRNA expression. Expression of 
p62 and LC3B was increased after LAMP3 knockdown, suggesting that LAMP3 knockdowns 
have a suppressed ability to complete the autophagic process. LAMP3 knockdown cells were 
also more sensitive to tamoxifen treatment. In addition, knockdown of autophagy-associated 
genes also resulted in sensitisation to tamoxifen. Tamoxifen resistant MCF-7 cells had a seven-
fold higher LAMP3 mRNA expression and elevated basal autophagy levels. LAMP3 
knockdown significantly resensitised resistant cells to tamoxifen. In patients treated with first-
line tamoxifen for advanced disease (n = 304), high mRNA expression of LAMP3 was 
associated with shorter progression-free survival (p = 0.003) and shorter post-relapse overall 
survival (p = 0.040), also in multivariate analysis. 
Conclusions 
These results indicate that LAMP3 contributes to tamoxifen resistance in breast cancer cells. 
Tamoxifen resistant cells can be resensitised to tamoxifen by knockdown of LAMP3. LAMP3 
may be clinically relevant to counter tamoxifen resistance in human breast cancer patients. 
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INTRODUCTION 
Tamoxifen, a non-steroidal anti-oestrogen, has been used for more than 40 years as a 
hormonal therapeutic in oestrogen receptor (ESR) positive breast cancer1. Tamoxifen 
physically competes with oestrogens to bind to the ESR, thereby decreasing the proliferative 
stimuli of oestrogens2. Despite its effectiveness in an adjuvant setting as well as in first-line 
therapy for advanced disease, a large group of patients will eventually develop resistance to 
tamoxifen3. In theory, tumour cells lacking expression of the ESR (ESR-negatives) should be 
insensitive to tamoxifen treatment. Nevertheless, some ESR-negative tumours show a good 
response whereas not all ESR-positive tumours respond to treatment with tamoxifen4. In 
general, two forms of resistance to anti-oestrogens are recognised: intrinsic resistance and 
acquired resistance. Intrinsic resistance arises when there is no response to tamoxifen from the 
onset of treatment. It is caused first and foremost by the lack of ESR expression. The 
mechanisms behind acquired resistance are more complex and are related to the development 
of ESR insensitivity or alterations in signalling through the ESR5.  
Treatment of breast cancer cells with tamoxifen was found to induce the process of autophagy 
(Greek for ‘self-eating’ and also referred to as macroautophagy)6 and it has been suggested that 
autophagy contributes to tamoxifen resistance7,8. Autophagy is an evolutionary conserved 
process, in which cellular components can be degraded and recycled in order to preserve 
energy9. Cytoplasmic material is sequestered in double membrane vesicles, called 
autophagosomes. After fusion with lysosomes, the content is degraded by lysosomal 
hydrolases. At basal levels, autophagy is crucial for cellular homeostasis in numerous 
physiological conditions, but also pathological disorders employ autophagy. In addition, 
autophagy can be one mechanism by which cells overcome stressful conditions. Survival of 
stress conditions, such as hypoxia and endoplasmic reticulum stress, can be mediated by a 
collection of pathways called the unfolded protein response (UPR)10,11. One arm of the UPR, 
the PKR-like endoplasmic reticulum kinase (PERK)/activating transcription factor 4 (ATF4)-
arm, was previously shown to induce autophagy12-14. ATF4 is essential for hypoxia-induced 
autophagy, upregulating MAP1LC3B (referred to as LC3B)13,14. Recently, lysosome-associated 
membrane protein 3 (LAMP3) was identified as a downstream target of the PERK/ATF4-arm 
of the UPR15, induced by hypoxia and involved in hypoxia-mediated metastasis16,17. LAMP3 is 
a member of the so-called LAMP-family, which plays an essential role in autophagy18,19. 
LAMP-proteins are thought to be responsible for the fusion of the autophagosome with the 
lysosome18.  
Recently, we showed that LAMP3 has prognostic value for locoregional control in breast 
cancer17. In addition, we also found that LAMP3 mRNA expression was higher in ESR-
negative breast tumours, which basically have intrinsic resistance to tamoxifen. In this study, 
we examined whether LAMP3 could promote tamoxifen resistance. 
 
MATERIALS AND METHODS 
Chemicals 
4-Hydroxytamoxifen and Bafilomycin A1 were purchased from Sigma Aldrich (St. Louis, MO, 
USA). 
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Cell culture 
Both MCF-7 and MDA-MB-231 cells were obtained from LCG Promochem (London, UK). 
Cells were cultured in Dulbecco’s modified Eagles medium supplemented with 10% (v/v) 
foetal bovine serum, 2 mM L-glutamine, 20 mM Hepes, 1× non-essential amino acids and 10 
U/ml penicillin, 10 µg/ml streptomycin (all from PAA Laboratories, Cölbe, Germany) at 37 ˚C 
with 5% CO2.  
 
Western blot analysis 
Western blotting was performed as previously described17. Primary antibodies used were: 
rabbit anti-LC3B (#3868), rabbit anti-p62 (#8025) rabbit anti-ATG5 (#8540), rabbit anti-
BECN1 (#3495), all from Cell Signaling Technology (Danvers, MA, USA) and mouse anti-α-
tubulin (Calbiochem, San Diego, CA, USA) all diluted 1:1,000. Densitometric analysis of 
Western blots was performed using ImageJ (National Institutes of Health, Bethesda, MD, 
USA). Western blot analysis of autophagy markers was interpreted according to previously 
published guidelines20,21. Western blots were cropped for purposes of clarity. 
 
RT-qPCR of cell lines 
RNA was isolated using the Total RNA purification kit from Norgen (Norgen Biotek Corp., 
Thorold, Canada) with an on-column DNase treatment. One µg of RNA was reverse 
transcribed with the iScript cDNA synthesis kit (Bio-Rad Laboratories Inc., Richmond, CA, 
USA), according to the manufacturer’s instructions. mRNA expression of reverse transcribed 
LAMP3 was analysed using quantitative real time polymerase chain reaction (RT-qPCR) on a 
CFX96 real-time PCR detection system (Bio-Rad) with SYBR green (Applied Biosystems, 
Foster City, CA, USA) and the following primers: LAMP3: FW 5’-
TGAAAACAACCGATGTCCAA-3’ and RV 5’-TCAGACGAGCACTCATCCAC-3’; MAP1LC3B: FW 5’-
AACGGGCTGTGTGAGAAAAC-3’ and RV 5’-AGTGAGGACTTTGGGTGTGG-3’; ATG5: FW 5’-
GCAAGCCAGACAGGAAAAAG-3’ and RV 5’-GACCTTCAGTGGTCCGGTAA-3’; BECN1: FW 5’-
AGGTTGAGAAAGGCGAGACA-3’ and RV 5’-AATTGTGAGGACACCCAAGC-3’; ESR1 (oestrogen 
receptor α): FW 5’-CCACCAACCAGTGCACCATT-3’ and RV 5’-GGTCTTTTCGTATCCCACCTTTC-3’; 
PGR (progesterone receptor): FW 5’-CGCGCTCTACCCTGCACTc-3’ and RV 5’-
TGAATCCGGCCTCAGGTAGTT-3’. Expression of the reference gene HPRT1 (hypoxanthine 
phosphoribosyl transferase 1) was analysed using a pre-developed assay from Applied 
Biosystems (Hs.412707). 
 
Stable LAMP3  transfections 
Constructs of short hairpin RNAs (shRNA) targeting LAMP3 or a non-coding sequence were 
kindly provided by PROF. B.G. WOUTERS (Ontario Cancer Institute, Toronto, Canada). 
Lentiviral pseudo-typed particles were formed in HEK293FT cells with the ViraPower 
lentiviral expression system according to the manufacturer’s instructions (Invitrogen, Carlsbad, 
CA, USA). MCF-7 and MDA-MB-231 cells were infected at a low passage number. 
Transfected cells were selected by puromycin (4 µg/ml) treatment for approximately 10 days.  
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Transient transfections 
siRNA-mediated knockdowns were performed using Saint-Red (Synvolux Therapeutics, 
Groningen, the Netherlands) according to the manufacturer’s instructions. siRNAs were from 
Sigma: MAP1LC3B: SASI_Hs01_00212376 and SASI_Hs02_00356118, ATG5: 
SASI_Hs02_00338435 and SASI_Hs01_00173158, BECN1: SASI_Hs01_00090914 and 
SASI_HS02_00336256, LAMP3: SASI_Hs01_00214236 and SASI_Hs02_00345584. 
 
Colony forming assays after tamoxifen treatment 
Clonogenic cell survival was analysed by plating 500 cells in T25 bottles. Cells were allowed to 
adhere overnight before treatment with indicated concentrations of 4-hydroxytamoxifen for 24 
hours. Concentrations were lower for MCF-7 cells compared to MDA-MB-231 cells to 
maximally visualise the dose-response curves. Once colonies in the control flasks comprised at 
least 50 cells (up to 10 days), cells were fixed for 10 minutes in 70% ethanol at 4 ˚C. Colonies 
were stained with 0.5% (w/v) crystal violet (Sigma). Colonies of 50 cells or more were scored 
manually. 
 
Patients  
Total RNA extracted from frozen ESR-positive primary breast tumour tissue specimens as 
described previously22 from female patients entering the clinic between 1981 and 1996 with 
operable breast cancer was used. Cytosolic tumour protein expression levels of ESR were 
determined as described previously23 and tumours with  ≥10 fmol/mg protein were classified 
as ESR-positive. All patients included developed a measurable recurrence during follow-up and 
were treated with first-line tamoxifen (40 mg daily). To meet REMARK recommendations24 
we provide the inclusion criteria for final analysis in this study: (1) at least 100 mg freshly 
frozen tumour material available, (2) more than 30% epithelial tumour cell nuclei in 
haematoxylin and eosin-stained sections, (3) specimen of good RNA quality and sufficient 
quantity according to pre-defined criteria and last but not least (4) adherence to pre-defined 
clinical inclusion criteria. Full details of these quality and quantity controls as well as the clinical 
inclusion criteria have been described previously22. After applying these criteria 304 patients 
remained. Relevant clinicopathological characteristics of the patients and their primary tumours 
are given in Table 1. The median follow-up time of patients alive was 43 months, range 4-149 
months. Two hundred and fifteen patients (71%) did not receive prior adjuvant systemic 
therapy, while 57 patients (19%) were previously treated with adjuvant chemotherapy [35 
patients (12%) with non-anthracycline-based (CMF) and 22 patients (7%) with anthracycline-
based (FAC/FEC) regimens]. Thirty patients (10%) presented with distant metastases at initial 
diagnosis (M1 patients), two patients were not without disease after primary surgery. 
Progression-free survival (PFS) was defined as the time elapsed between initiation of tamoxifen 
therapy and first detection of disease progression as defined by standard International Union 
against Cancer criteria25. Our studies on prognostic and predictive markers have been 
approved by the medical ethics committee of the Erasmus MC Rotterdam, the Netherlands 
(MEC 02.953). Furthermore, this retrospective study was performed in accordance with the 
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Code of Conduct of the Federation of Medical Scientific Societies in the Netherlands 
(http://www.fmwv.nl). 
 
RT-qPCR of clinical samples 
RT-qPCR was used to measure ESR1, PGR, ERBB2 and LAMP3 expression from cDNA 
preparations generated as described previously22,26 using the Taqman Hs0018088 m1 gene 
expression assay from Applied Biosystems to measure LAMP3. For the clinical cohort, 
expression levels were normalised against the average expression levels of three reference 
genes (HMBS, HPRT1 and B2M) as described previously22. 
 
Statistics 
Statistical analysis of in vitro data was performed using Student’s t-tests. Statistical significance 
was set at two-sided p-values < 0.05. Asterisks indicate statistical significance, where * is p < 
0.05, ** is p < 0.01 and *** is p < 0.001. Differences in levels between grouping variables 
among patient and tumour characteristics were assessed with the Mann-Whitney U test or 
Kruskal-Wallis test, including a Wilcoxon-type test for trend, when appropriate. The strengths 
of the associations between continuous variables were tested with Spearman rank correlation 
(rs). Expression levels of LAMP3, ERBB2, ESR1 and PGR mRNA were transformed to 
reduce distribution skewness to allow the use of a Cox proportional hazard model to calculate 
the hazard ratio (HR) and 95% (confidence interval) CI in the analysis of PFS. Three equal 
thirds were used to categorise the variable into low, intermediate, and high. Survival curves 
were generated using the method of Kaplan and Meier (1958) and the log-rank test was used to 
test for differences. 
 
RESULTS 
4-Hydroxytamoxifen treatment of MCF-7 cells reduces their survival and induces 
LAMP3 expression and autophagy  
First, the effect of 4-hydroxytamoxifen, the active metabolite of tamoxifen, on survival of two 
commonly used breast cancer cell lines was examined. ESR-positive MCF-7 and ESR-negative 
MDA-MB-231 breast cancer cells were treated with increasing concentrations of 4-
hydroxytamoxifen, after which clonogenic survival was evaluated. MCF-7 cells showed a 
significant reduction in cell survival at 1 µM and higher, whereas MDA-MB-231 cells did not 
show any decrease in survival with up to 10 µM of 4-hydroxytamoxifen (see Figure 1A). Next, 
the effect of tamoxifen on the mRNA expression of LAMP3 was evaluated. Figure 1B shows 
that treatment of MCF-7 cells with increasing concentrations of 4-hydroxytamoxifen led to a 
dose-dependent induction of LAMP3 mRNA expression. However, in MDA-MB-231 cells 
this response was absent, despite the clear upregulation of LAMP3 in this cell line by other 
drugs and stresses found previously15,17. It appears that in these two cell lines, LAMP3 
induction is only present in cells that are sensitive to tamoxifen. Subsequently, the effect of 4-
hydroxytamoxifen on autophagy was studied in MCF-7 cells using Western blot analysis for 
p62 and LC3B, two autophagosomal markers21. Treatment with 5 µM of 4-hydroxytamoxifen 
for up to 72 hours reduced the expression of p62 (see Figure 1C). At 48 hours of exposure, 
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MCF-7 cells showed a strong induction of LC3BII, but this was reduced to basal levels by 72 
hours. As p62 expression inversely correlates with autophagy levels, these data collectively 
indicate that 4-hydroxytamoxifen can induce autophagy in MCF-7 cells. This was verified 
further by exposing MCF-7 cells to both 4-hydroxytamoxifen and the autophagy inhibitor 
bafilomycin A1. Bafilomycin A1 blocks fusion of the autophagosome with the lysosome. 
During exposure to bafilomycin A1, tamoxifen treated cells showed an increase in both p62 
and LC3BII expression compared to cells not treated with bafilomycin A1 (see Figure 1C). 
This suggests that the autophagic flux is upregulated during tamoxifen treatment.  
FIGURE 1 Effect of tamoxifen treatment on MCF-7 and MDA-MB-231 cells. A. Clonogenic survival of MCF-7 and 
MDA-MB-231 cells after treatment with 4-hydroxytamoxifen for 24 hours. B. LAMP3 mRNA expression in MCF-7 
and MDA-MB-231 cells after treatment with 4-hydroxytamoxifen for 24 hours. Asterisks indicate statistical 
significance compared to the corresponding control. Data are presented as mean values ± standard deviation. 
Measurements were carried out in two independent experiments with three replicates each. C. Western blot analysis 
for p62, LC3B and α-tubulin of MCF-7 cells after treatment with 5 µM 4-hydroxytamoxifen for the time indicated. 
Cells were also treated with a combination of 5 µM 4-hydroxytamoxifen with 100 ng/ml bafilomycin A1 for 24 hours. 
Numbers below the bands indicate densitometric analysis relative to the corresponding α-tubulin.  
 
LAMP3  knockdown inhibits autophagy and sensitises MCF-7 cells to treatment with 
4-hydroxytamoxifen 
To evaluate the role of LAMP3 in tamoxifen-induced autophagy, MCF-7 and MDA-MB-231 
cells were subjected to shRNA-mediated LAMP3 knockdown. Both shRNAs could reduce the 
mRNA expression of LAMP3 by at least 75% (see Figure 2A). Next, the basal autophagy 
activity was evaluated in the LAMP3 knockdowns by Western blotting for p62 and LC3B. 
Both p62 and LC3BII expression levels were elevated in the LAMP3 knockdown cells (see 
Figure 2B). This increased expression of p62 and LC3BII indicates that autophagy is 
compromised in the LAMP3 knockdown cells. Considering the location of LAMP3 in the 
lysosomal membrane, the autophagic pathway is potentially blocked during fusion of the 
autophagosome with the lysosome. Treatment of MCF-7 LAMP3 knockdown cells with 5 µM 
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of 4-hydroxytamoxifen led to a slight increase in both LC3BII and p62 levels (see Figure 2B). 
This suggests that tamoxifen induces autophagy to a lesser extent in LAMP3 knockdown cells 
and that these cells are indeed autophagy compromised. To examine the role of LAMP3 in 
sensitivity to tamoxifen treatment, MCF-7 cells with a stable knockdown of LAMP3 were 
exposed to 4-hydroxytamoxifen. Figure 2C shows the clonogenic survival of these cell lines. It 
was found that LAMP3 knockdown in the ESR-positive MCF-7 cells enhances sensitivity to 
cell death induced by 4-hydroxytamoxifen. On the other hand, the ESR-negative MDA-MB-
231 cells did not respond to 4-hydroxytamoxifen treatment, and LAMP3 knockdown could 
not sensitise these cells to 4-hydroxytamoxifen (see Figure 2D). 
FIGURE 2 Effect of LAMP3 knockdown on tamoxifen sensitivity. A. LAMP3 mRNA expression of MCF-7 and 
MDA-MB-231 cells after shRNA-mediated knockdown of LAMP3. B. Western blot analysis for autophagy markers in 
MDA-MB-231 and MCF-7 cells after shRNA-mediated knockdown of LAMP3. MCF-7 cells with knockdown of 
LAMP3 were also treated with 5 µM 4-hydroxytamoxifen for 24 hours. Numbers below the bands indicate 
densitometric analysis relative to the corresponding α-tubulin. Clonogenic survival of (C) MCF-7 and (D) MDA-MB-
231 cells after shRNA-mediated knockdown of LAMP3 and treatment with 4-hydroxytamoxifen for 24 hours. 
Asterisks indicate statistical significance compared to the corresponding control. Data are presented as mean values ± 
standard deviation. Measurements were carried out in two independent experiments with three replicates each. 
 
Knockdown of autophagy-associated genes sensitises MCF-7 cells to treatment with 4-
hydroxytamoxifen  
Next, the role of autophagy in 4-hydroxytamoxifen sensitivity was assessed in MCF-7 cells. 
With siRNA-mediated knockdown, mRNA expression of the autophagy-associated genes 
MAP1LC3B, ATG5 and BECN1 was successfully abolished (see Figure 3A). Figure 3B shows 
that on the protein level knockdown was also observed, although to a lesser extent. 
Knockdown of ATG genes was previously shown to result in an inhibition of autophagy21. 
Here, in general the siRNA-mediated knockdowns could sensitise MCF-7 cells to treatment 
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with 4-hydroxytamoxifen, although some siRNAs were more effective that others (see Figure 
3C-E). 
FIGURE 3 Effect of knockdown of autophagy genes on tamoxifen sensitivity. A. mRNA expression of MAP1LC3B, 
ATG5 and BECN1 in MCF-7 cells after siRNA-mediated knockdown of these genes. B. Western blot analysis of 
LC3B, ATG5 and BECN1 in MCF-7 cells after siRNA-mediated knockdown of these genes. Numbers below the 
bands indicate densitometric analysis relative to the corresponding α-tubulin. Clonogenic survival of MCF-7 cells after 
siRNA-mediated knockdown of (C) MAP1LC3B, (D) ATG5, (E) BECN1 and treatment with 4-hydroxytamoxifen for 
24 hours. Asterisks indicate statistical significance compared to the corresponding control. Data are shown as mean 
values ± standard deviation. Measurements were carried out in two independent experiments with three replicates 
each. 
 
Tamoxifen resistant cells have higher LAMP3 mRNA expression, show induced levels 
of autophagy and can be resensitised to tamoxifen treatment by LAMP3  knockdown  
To study the effect of tamoxifen resistance on LAMP3 expression, MCF-7 cells were cultured 
to 4-hydroxytamoxifen resistance. Initially, wild type cells were exposed to 0.5 µM 4-
hydroxytamoxifen. Once cells had adapted to this dose, the concentration was increased 
stepwise with 0.5 µM. This process was repeated during several months until cells could 
tolerate 10 µM. Proliferation of this tamoxifen resistant cell population was slower than wild 
type cells. Analysis of mRNA expression for both the ESR and PGR revealed that these 
tamoxifen resistant cells still expressed the ESR, albeit to a lesser extent, whereas the PGR was 
lost completely (see Figure 4A). Compared to wild type MCF-7 cells, the tamoxifen resistant 
cells showed a significant increase in levels of LAMP3 mRNA expression (see Figure 4B). In 
addition, tamoxifen resistant MCF-7 cells showed altered levels of basal autophagy, as 
suggested by the decreased LC3BII and p62 expression levels (see Figure 4C). To see whether 
the decrease in LC3BII represented a reduction in autophagosomes or an increased turnover 
of autophagosomes, fusion of the autophagosome with the lysosome was blocked by 
bafilomycin A1 treatment. In both wild type and tamoxifen resistant cells, LC3BII and p62 
accumulated (see Figure 4C). This suggests that autophagosomes are not reduced in tamoxifen 
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resistant cells, as LC3BII is present in similar quantities in wild type and resistant cells after 
bafilomycin  A1 treatment. Therefore, tamoxifen resistant cells appear to have an increased 
turnover of autophagosomes compared to wild type cells. Next, siRNA-mediated knockdown 
for LAMP3 was applied on tamoxifen resistant cells (see Figure 4D). The siRNAs used 
successfully abrogated LAMP3 mRNA expression by at least 60%. Subsequently, the 
sensitivity of these tamoxifen resistant LAMP3 knockdown cells was evaluated. Figure 4E 
shows that knockdown of LAMP3 in combination with treatment with 10 µM of 4-
hydroxytamoxifen could resensitise tamoxifen resistant MCF-7 cells to tamoxifen. 
FIGURE 4 Effect of knockdown of LAMP3 on tamoxifen sensitivity in MCF-7 tamoxifen resistant cells. mRNA 
expression of (A) ESR and PGR and (B) LAMP3 in MCF-7 cells cultured resistant to 10 µM 4-hydroxytamoxifen. C. 
Western blot analysis of p62 and LC3B in MCF-7 cells cultured to 10 µM 4-hydroxytamoxifen resistance with and 
without treatment with 100 ng/ml bafilomycin A1 for 24 hours. Numbers below the bands indicate densitometric 
analysis relative to the corresponding α-tubulin. D. mRNA expression of LAMP3 after siRNA-mediated knockdown 
in MCF-7 tamoxifen resistant cells. E. Clonogenic survival of MCF-7 tamoxifen resistant cells after siRNA-mediated 
knockdown of LAMP3 and treatment with 10 µM 4-hydroxytamoxifen for 24 hours. Asterisks indicate statistical 
significance compared to the corresponding control. Shown are mean values + standard deviation. Measurements were 
carried out in two independent experiments with three replicates each.  
 
LAMP3  mRNA expression in patients with advanced breast cancer  
As LAMP3 was associated with tamoxifen resistance in cultured breast cancer cells, the 
association of LAMP3 mRNA with response to first-line tamoxifen treatment was investigated 
in 304 patients with advanced breast cancer. As shown in Table 1, LAMP3 mRNA levels were 
higher in patients with non-soft tissue or bone metastases compared to patients with soft tissue 
metastases (p = 0.034). LAMP3 mRNA expression was also higher in ERBB2-high tumours (p 
= 0.036) and correlated negatively with expression of ESR1 (rs = -0.30, p < 0.001) and PGR (rs 
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= -0.16, p = 0.004). Interestingly, in these patients high mRNA expression of LAMP3 was 
associated with a shorter PFS time (p = 0.003) and a shorter post-relapse overall survival time 
(p = 0.040) after start of tamoxifen treatment for advanced disease (see Figure 5A and B, 
respectively). The patients with the highest tertile of LAMP3 expression had a worse PFS after 
start of first-line tamoxifen in both Cox univariate (hazard ratio (HR) = 1.57, 95% confidence 
interval (CI) = 1.18 – 2.09, p < 0.001) and multivariate (HR = 1.37, CI = 1.01 - 1.86, p = 
0.032) analyses (see Table 2). Median PFS was 9.9 months (CI = 7.3 - 14.0) for the tertile with 
low LAMP3 expression, 12.0 months (CI = 9.0 - 14.4) for the intermediate group, and 6.6 
months (CI = 5.5 - 8.2) for the high expression group.  
 
TABLE 1 Associations of LAMP3  mRNA expression levels with clinicopathological factors 
 n % Median Interquartile range p* 
Total 304 100 0.0048 0.012  
Age in categories (y) (rs = -0.10) 0.092a 
≤55 119 39 0.0050 0.016  
56-70 110 36 0.0045 0.013  
>70 75 25 0.0048 0.008  
Menopausal status     0.34b 
pre 79 26 0.0048 0.016  
post 225 74 0.0048 0.011  
Tumour size     0.84c 
pT1 83 27 0.0048 0.019  
pT2 + unknown 181 60 0.0048 0.010  
pT3/4 40 13 0.0049 0.011  
Disease-free interval     0.038d 
≤12 months 76 25 0.0038 0.007  
12-36 months 133 44 0.0046 0.011  
>36 months 95 31 0.0072 0.016  
Dominant site of relapse     0.034d 
Soft tissue (LRR) 35 12 0.0103 0.020  
Bone 157 52 0.0042 0.010  
Viscera (other) 112 37 0.0057 0.013  
ERBB2  mRNA     0.036b 
Low 257 85 0.0044 0.010  
High 40 13 0.0095 0.017  
Unknown 7 2    
ESR  mRNA (rs = -0.30) <0.001a 
PGR  mRNA (rs = -0.16) 0.004a 
*Two-sided p-value 
aSpearman rank correlation 
bMann-Whitney U test 
cKruskal-Wallis test, a non-parametric test for trend was not applicable 
dKruskal-Wallis test, followed by a non-parametric test for trend 
 
DISCUSSION 
In this study, we found that knockdown of LAMP3 in the ESR-positive MCF-7 breast cancer 
cell line can sensitise cells to treatment with tamoxifen and can even revert resistance to 
tamoxifen. In addition, LAMP3 plays a functional role in autophagy. This could explain its 
association with tamoxifen sensitivity, as knockdown of the more crucial autophagy genes 
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LC3B, ATG5 and BECN1 also led to a sensitisation to treatment with tamoxifen. mRNA 
expression assessed in a cohort of advanced breast tumours showed that LAMP3 levels are 
associated with disease progression during tamoxifen treatment. 
FIGURE 5 Kaplan-Meier survival curves. Patients were divided in three equally sized groups based on LAMP3 mRNA 
expression levels in the primary tumour (low, intermediate and high LAMP3 mRNA expression). A. Kaplan-Meier 
progression-free survival curves. High mRNA expression of LAMP3 is associated with shorter median progression-
free survival time (p = 0.003). B. Kaplan-Meier post-relapse overall survival curves. High mRNA expression of 
LAMP3 is associated with shorter post-relapse median overall survival time (p = 0.040). The number of patients at risk 
is indicated at the bottom of the graphs at different time points during follow-up. Low LAMP3 mRNA expression is 
represented by the blue, intermediate by the red and high by the green graph. 
 
The usefulness of tamoxifen in breast cancer is incontrovertible. However, not all ESR-
positive tumours will initially respond to tamoxifen and responding tumours will eventually 
develop resistance. It is therefore of vital importance to identify factors and mechanisms 
involved in tamoxifen resistance. Several studies have previously identified so-called BCAR 
(breast cancer anti-oestrogen resistance) genes27,28. In addition, the process of autophagy may 
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also be an important contributor. Overexpression of BECN1, a factor involved in the 
nucleation step of the autophagic cascade, rendered MCF-7 cells more resistant to treatment 
with 4-hydroxytamoxifen29. In addition, BECN1 was found to downregulate oestrogenic-
signalling and growth response. Others observed that inhibition of autophagy, by siRNAs or 
chemicals, could sensitise breast cancer cells to tamoxifen7,8,30. Breast cancer cells that were 
cultured to tamoxifen resistance could be resensitised by autophagy inhibition8. 
 
TABLE 2 Cox uni- and multivariate analysis for PFS of categorised LAMP3  in oestrogen receptor-positive 
tumours from 304 patients whose recurrence was treated with first-line tamoxifen monotherapy 
Factor of base model n % Univariate analysis Multivariate analysis* 
 304 100 HR 95% CI p  HR 95% CI p  
Age (y)     0.036   0.29 
≤55 119 39 1.00   1.00   
56-70 110 36 0.83 0.63 - 1.08  0.87 0.65 - 1.17  
>70 75 25 0.67 0.50 - 0.91  0.77 0.55 - 1.07  
Menopausal status     0.26    
pre 79 26 1.00      
post 225 74 0.86 0.66 - 1.12     
Disease-free interval     < 0.001   < 0.001 
≤12 months 76 25 1.00   1.00   
12-36 months 133 44 0.64 0.48 - 0.86  0.67 0.50 - 0.90  
>36 months 95 31 0.54 0.39 - 0.74  0.54 0.39 - 0.74  
Dominant site of 
relapse 
    0.63   0.33 
LRR 35 11 1.00   1.00   
Bone 157 52 1.20 0.82 - 1.77  1.19 0.80 - 1.79  
Other 112 37 1.18 0.79 - 1.76  1.35 0.89 - 2.06  
ESR  mRNA level 
(continuous) 
304 100 0.75 0.65 - 0.87 < 0.001 0.77 0.66 - 0.91 0.002 
PGR  mRNA level 
(continuous) 
304 100 0.90 0.84 - 0.97 0.003 0.91 0.85 - 0.99 0.025 
      Addition to base model 
LAMP3  mRNA (as 
categorised variable) 
    < 0.001   0.032 
Low 102 34 1.00   1.00   
Intermediate 101 33 0.94 0.71 - 1.25  0.92 0.69 - 1.23  
High 101 33 1.57 1.18 - 2.09  1.37 1.01 - 1.86  
The expression levels of LAMP3 were evaluated as categorised variables. Factors were added separately to the base 
model in the multivariate analysis. 
*The multivariate analysis is stratified for menopausal status. ESR and PGR levels were analysed as log transformed 
continuous variable. 
 
Whether autophagy is a pro-survival or pro-death pathway has been controversial for some 
time31-33. Initially, autophagy is aimed at recycling energy in order to survive. However, it 
appears that when conditions become too harsh, even autophagy is not able to save cells and 
eventually death will occur. In tamoxifen treatment, autophagy is apparently aimed at cell 
survival, as its inhibition can sensitise cells to tamoxifen-induced death. In this study, 
autophagy in LAMP3 knockdown cells was found to be compromised. Apart from LAMP3, its 
family members LAMP1 and -2 are also implicated in the lysosomal degradation pathway34. 
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LAMP2-deficient cells are autophagy inhibited as autophagic vacuoles accumulate18. LAMP2-
deficiency causes the lysosomal glycogen storage disorder Danon’s disease. In knockout-mice 
LAMP1-deficiency has a relatively mild phenotype, possibly due to the compensation of 
LAMP1-deficiency by increased levels of LAMP2 (ref. 35). In addition, knockdown of LAMP1 
or LAMP2 was found to be sufficient to sensitise cells to anti-cancer drugs36. 
In our previous study17, ESR-negative tumours were found to have a higher LAMP3 mRNA 
expression and in the present study we describe a negative correlation between LAMP3 and 
ESR mRNA in ESR-positive patients. Tamoxifen resistant MCF-7 cells were also found to 
have a higher LAMP3 mRNA expression. Apparently, LAMP3 expression is higher in tumour 
cells with a non-functional or non-existing ESR. In the current study, LAMP3 knockdown 
could sensitise both MCF-7 wild type and tamoxifen resistant cells to tamoxifen treatment, 
however cells with intrinsic tamoxifen resistance (MDA-MB-231) remained resistant to 
tamoxifen. This suggests that the presence of ESR is required for sensitisation.  
LAMP3 expression is induced via the PERK/ATF4-arm of the UPR15. The UPR has been 
implicated in resistance to numerous cancer therapies37-40. Increased expression of ATF4 for 
instance has been associated with desensitisation to several therapies41,42. Recently, 
overexpression of x-box-binding protein 1 (XBP1), a downstream factor in the UPR, led to a 
reduced sensitivity of ESR-positive breast cancer cells to anti-oestrogen treatment43. Also, 
knockdown of glucose-related protein 78 (GRP78), a major player in the UPR, could restore 
anti-oestrogen sensitivity in resistant cells, whereas GRP78 overexpression caused resistance in 
sensitive cells44. Together with the results from our current study, the UPR emerges as an 
important factor in resistance to anti-oestrogen therapy.  
In conclusion, LAMP3 is an important mediator of resistance to tamoxifen in breast cancer. 
Pharmacological inhibition of autophagy, the UPR and/or LAMP3 may represent an attractive 
opportunity to increase tamoxifen efficacy in both tamoxifen-sensitive and -resistant ESR-
positive tumours. 
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ABSTRACT 
Background 
Lysosome-associated membrane protein 3 (LAMP3) is induced by the PKR-like ER kinase 
(PERK)/activating transcription factor 4 (ATF4)-arm of the unfolded protein response (UPR) 
during hypoxia. LAMP3 has prognostic value in breast cancer patients treated with 
radiotherapy. Here, we specifically investigated the role of the PERK/ATF4/LAMP3-arm in 
the radiation response of breast cancer cells.  
Methods 
Radiosensitivity of breast cancer cells was examined after siRNA-mediated knockdown of 
PERK, ATF4 and LAMP3. Activation of DNA damage repair proteins was evaluated by 
Western blotting and immunocytochemistry.  
Results 
Knockdown of the PERK/ATF4/LAMP3-arm and chemical inhibition of PERK could 
radiosensitise MDA-MB-231 cells significantly. Western blot analysis of several DNA damage 
repair proteins showed that LAMP3 knockdowns had an attenuated DNA damage response 
after radiation compared to controls. γH2AX foci analysis revealed that LAMP3 knockdowns 
had a reduced number of positive cells after irradiation, indicating that their DNA damage 
repair signalling response is decreased. In addition, the effect of autophagy inhibition was 
examined and revealed a radiosensitising effect and the presence of residual γH2AX foci.  
Conclusions 
The PERK/ATF4/LAMP3-arm causes radioresistance of breast cancer cells by increasing 
DNA damage repair signalling. Inhibition of PERK and/or autophagy may sensitise tumours 
to radiotherapy. 
 
KEYWORDS 
breast cancer, radiation, resistance, UPR, LAMP3 
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INTRODUCTION 
Radiotherapy is one of the mainstays of local treatment for a number of different tumour types, 
including breast cancer. Radiosensitivity differs strongly between tumour types and within one 
tumour type. Even within a single tumour sensitivity may vary. Three major mechanisms of 
radioresistance have been described: intrinsic radioresistance, hypoxia and cell proliferation1. 
Both hypoxia and cell proliferation can be counteracted by modifying therapies such as 
accelerated radiotherapy with hypoxia modification2. Intrinsic radioresistance of tumours is 
more difficult to alter as multiple signalling pathways are likely to be involved3 and inter-
tumour differences will make it hard to define a universal treatment regime.  
Ionising radiation can cause the accumulation of misfolded proteins, thereby activating the 
UPR4. The UPR represents several pathways aimed at surviving stress conditions. Therefore, 
interference with the UPR in tumour cells could be used as a novel cancer therapy. One UPR-
pathway, the PERK-arm, may be particularly interesting in this respect5,6. A previous study 
showed that PERK-deficient tumours are smaller than tumours with intact PERK-signalling 
and cells deficient in PERK have a decreased survival when exposed to hypoxic stress7. In 
addition, PERK-deficient tumour cells are less proficient in translating mRNAs involved in 
angiogenesis and cell survival8,9. Loss of PERK causes cancer cells to be highly susceptible to 
oxidative DNA damage10. 
One mechanism the UPR induces to survive stress is autophagy. Irradiated cells show 
increased activation of autophagy11,12. Therefore, UPR-induced autophagy may represent an 
attractive pathway to radiosensitise cells. Autophagy (also known as macroautophagy) is aimed 
at recycling cellular components. Its blockage can sensitise cancer cells to a number of 
different treatments13, including radiotherapy11.  
LAMP3 is induced by the PERK/ATF4-arm14 (see Supplementary Figure 1) and plays a role in 
autophagy (CHAPTER SEVEN). We recently found that high LAMP3 mRNA levels lead to a 
worse locoregional control in a cohort of breast cancer patients15. This prognostic relevance 
remained only in patients treated with radiotherapy. Therefore, LAMP3 could be involved in 
radioresistance. Here, we explored whether the PERK/ATF4/LAMP3-arm causes 
radioresistance and whether this pathway can be therapeutically exploited. 
 
MATERIALS AND METHODS 
Cell culture 
Cell lines were purchased from LGC Promochem (London, UK) and cultured as described 
earlier6. 
 
Chemicals 
GSK2606414 was from Toronto Research Chemicals Inc. (Toronto, Canada). Chloroquine 
diphosphate salt and Bafilomycin A1 were from Sigma Aldrich (St. Louis, MO, USA).  
 
siRNA- and shRNA-mediated knockdown 
siRNA- and shRNA-mediated knockdown was performed as previously described6. siRNAs 
(Sigma) for GADD34 were SASI_Hs02_00345455 and SASI_Hs01_00237406. 
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RT-qPCR 
RT-qPCR analysis was performed as described earlier6. GADD34 primers were: FW 5’-
CCCAGAAACCCCTACTCATGATC-3’ and RV 5’-GCCCAGACAGCCAGGAAAT-3’. 
 
Western blot analysis 
Western blotting was performed as previously described15. Primary antibodies were rabbit anti: 
PERK (#5683), phospho-eIF2α (#3597), ATF4 (#11815), phospho-H2AX (#2577), 
phospho-CHK1 (#2349), phospho-CHK2 (#2661) and phospho-ATR (#2853), and the DSB 
repair kit (#9653), all from Cell Signaling Technology (Danvers, MA, USA). Rabbit anti-
GADD34 (10449-1-AP) was from ProteinTech Europe (Manchester, UK) and rabbit anti-
LAMP3 (LS-B7698) from Lifespan Biosciences Inc. (Seattle, WA, USA). Mouse anti-α-tubulin 
was from Calbiochem (San Diego, CA, USA). All antibodies were diluted 1:1,000. Western blot 
quantification was performed using ImageJ (National Institutes of Health, Bethesda, MD, 
USA) and values were corrected for α-tubulin. 
 
Colony forming assay 
Assays were performed as previously described6 with minor modifications. The following 
number of cells was plated: 0, 1 and 2 Gy: 500, 4 Gy: 2,000, 6 Gy: 4,000, 8 Gy: 8,000. Cells 
were allowed to adhere overnight before single-dose irradiation using an X-Rad Biological 
Irradiator (Precision X-Ray, North Branford, CT, USA) at a dose rate of 3.1 Gy/min. Once 
colonies in the 0 Gy comprised at least 50 cells, they were fixed, stained and scored.  
 
Immunocytochemistry 
Cell monolayers on coverslips were fixed 10 minutes in ice-cold methanol. Stainings were 
performed as previously described15 with minor modifications. The primary antibody was 
rabbit anti-phospho-H2AX (#2577, Cell Signaling Technology) 1:250 and Cy3-conjugated 
donkey anti-rabbit (Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA) 1:600 
was the secondary antibody. Cells were scored manually for γH2AX positivity, where nuclei 
containing four foci or more were scored positive. 
 
Data analysis and statistics 
Survival curves were plotted semi-logarithmically with mean surviving fractions as a function 
of radiation dose. Curves were fitted using the linear-quadratic model [S = exp (αD-βD2)] with 
GraphPad Prism 4.0 software (GraphPad Software, Inc., La Jolla, CA, USA). Predicted values 
for α and β were used to calculate surviving fraction at 4 Gy (SF4). Unless stated otherwise, all 
data are presented as mean ± SD. All experiments were performed in duplicate and, unless 
stated otherwise, with three replicates each. Statistical analysis was carried out using two-sided 
Student’s t-tests. Statistical significance was accepted at p < 0.05. Asterisks indicate statistical 
significance compared to the corresponding (negative) controls: *** is p < 0.001, ** is p < 0.01 
and * is p < 0.05. 
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RESULTS 
Irradiation induces PERK, p-eIF2α , ATF4 and LAMP3 in MDA-MB-231 and MCF-7 
cells 
First, the effect of radiation on the PERK/ATF4/LAMP3-arm was examined. Both MDA-
MB-231 and MCF-7 breast cancer cells were irradiated with 4 Gy. mRNA and protein was 
harvested after short time points (0, 1 and 3 hours after irradiation) as well as after longer time 
points (24 and 48 hours after irradiation). Figure 1A-C shows PERK, ATF4 and LAMP3 
mRNA expression. Initially, in MDA-MB-231 cells PERK and ATF4 showed a slight, but 
significant decrease one hour after irradiation. At later time points, expression of all three 
genes was significantly induced in both cell lines. On the protein level, expression of PERK, p-
eIF2α, ATF4 and LAMP3 was also examined (see Figure 1D). In MDA-MB-231 cells all 
proteins were induced after irradiation and similar to mRNA, most profoundly at later time 
points. In MCF-7 cells, protein induction was also observed, but with different kinetics.  
 
 
FIGURE 1 mRNA expression of PERK (A), ATF4 (B) and LAMP3 (C) at different time points after irradiation with 4 
Gy in MDA-MB-231 and MCF-7 breast cancer cells. D. Western blot analysis of PERK, p-eIF2α, ATF4 and LAMP3 
at different time points after irradiation with 4 Gy in MDA-MB-231 and MCF-7 breast cancer cells.  
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Knockdown of PERK , ATF4  and LAMP3  sensitises MDA-MB-231 and MCF-7 cells 
to irradiation 
Next, the effect of siRNA-mediated knockdown of PERK, ATF4 and LAMP3 on survival 
after radiation was examined. First, efficiency of siRNAs was evaluated on mRNA and protein 
levels (see Supplementary Figure 2). All siRNAs were found to abrogate expression of their 
targets, but efficiencies varied between the siRNAs. Figures 2A-C show results of clonogenic 
assays after irradiation. Data points were fitted to the linear-quadratic model and the surviving 
fractions after 4 Gy were calculated (see Supplementary Figure 3A-C). In MDA-MB-231 cells, 
all knockdowns radiosensitised cells significantly. However, in MCF-7 cells effects were less 
unequivocal. Where knockdown of ATF4 could radiosensitise cells, PERK knockdown 
showed very little effect and LAMP3 knockdown was only effective with one siRNA. It should 
be noted that this cell line is intrinsically already more radiosensitive than MDA-MB-231 cells. 
 
Knockdown of GADD34  renders MDA-MB-231 and MCF-7 cells more resistant to 
irradiation 
The effect of knockdown of GADD34 on radiosensitivity was also evaluated. First, 
knockdown efficiency was examined. Both siRNAs could reduce the expression of GADD34 
by at least 40% (see Supplementary Figure 4A). However, on the protein level, knockdown was 
only apparent in MDA-MB-231 cells. As GADD34 serves as a negative feedback regulator on 
the PERK-arm, LAMP3 expression after GADD34 knockdown was also studied. 
Supplementary Figure 4B shows that in MDA-MB-231 cells, GADD34 knockdown led to an 
induction of LAMP3 mRNA expression. However, this effect was not present in MCF-7 cells 
within the time frame investigated. Assessment of survival after irradiation revealed that 
GADD34 knockdown cells were more radioresistant than control cells (see Figure 2D and 
Supplementary Figure 3D).  
 
Treatment of MDA-MB-231 and MCF-7 cells with a chemical PERK inhibitor 
sensitises cells to irradiation 
To examine whether these findings could have potential therapeutic value, the effect of 
pharmacological inhibition of PERK by a PERK inhibitor (GSK2606414) on radiosensitivity 
was investigated. Supplementary Figure 5 shows that treatment with this inhibitor could 
successfully abrogate LAMP3 mRNA expression by 50% in MDA-MB-231 cells. However, the 
effect in MCF-7 cells was not significant. Also, no inhibition of LAMP3 on the protein level 
was found. It is important to note that the cells used were unstressed, which may abrogate the 
need for PERK-signalling. Assessment of cell survival after treatment with GSK2606414 
followed by irradiation indicates that MDA-MB-231 cells can be sensitised by this treatment 
(see Figure 2E and Supplementary Figure 3E). However, in MCF-7 cells PERK inhibitor 
treatment did not result in radiosensitisation.   
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FIGURE 2 Clonogenic survival of MDA-MB-231 and MCF-7 cells after PERK (A), ATF4 (B) or LAMP3 (C) 
knockdown and treatment with irradiation. D. Clonogenic survival of MDA-MB-231 and MCF-7 cells after GADD34 
knockdown and treatment with irradiation. E. Clonogenic survival of MDA-MB-231 and MCF-7 cells after pre-
treatment with 10 µM PERK inhibitor for 24 hours and subsequent irradiation. 
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LAMP3  knockdown in MDA-MB-231 cells decreases the DNA damage repair 
response 
The observation that knockdown of the PERK/ATF4/LAMP3-arm radiosensitised cells 
prompted us to examine whether the DNA damage response of LAMP3 knockdown cells was 
different compared to control cells. For this purpose, breast cancer cells carrying a shRNA-
mediated knockdown of LAMP3 were generated. First, knockdown efficiency was evaluated. 
Supplementary Figure 6A shows that both shRNAs successfully diminished LAMP3 mRNA 
expression in MDA-MB-231 as well as in MCF-7 cells. Effects on the protein level were less 
apparent, though the overall protein expression levels of LAMP3 were relatively low, as 
observed previously14. Next, cell survival after irradiation was evaluated in these LAMP3 
knockdown cells (see Supplementary Figure 6B and Supplementary Figure 3F). Similar to 
siRNA-mediated knockdown, stable knockdown also led to radiosensitisation. However, in 
MDA-MB-231 cells the shRNA with the lower knockdown efficiency on the mRNA level 
(knockdown 1) was ineffective in this respect. Subsequently, γH2AX foci formation, one of the 
earliest events in the DNA damage repair pathway, was analysed in both MDA-MB-231 
control and LAMP3 knockdown cells after irradiation (see Figure 3A). γH2AX positive cells 
were scored. Figure 3B shows that the number of cells positive for γH2AX was significantly 
reduced in LAMP3 knockdown cells. Again, effects were more substantial in LAMP3 
knockdown 2. These cells are severely deficient in formation of radiation-induced γH2AX foci. 
To further validate this effect, Western blot analysis was performed for γH2AX expression on 
irradiated LAMP3 knockdown cells. In accordance with the results from the foci analysis, 
γH2AX protein expression was induced after irradiation in control cells, but to a lesser extent 
in LAMP3 knockdown cells (see Figure 3C). To further examine the effects of LAMP3 
knockdown on radiation-induced DNA damage repair, a number of other proteins involved in 
double-strand break repair were analysed on Western blot (see Figure 3C). Overall, analysis of 
these markers indicates that similar to γH2AX, other DNA damage repair proteins show a 
diminished response after irradiation in LAMP3 knockdown cells compared to control cells 
(see Figure 3D). Again, this effect was predominantly present in LAMP3 knockdown 2. These 
cells also presented with the largest knockdown of LAMP3 mRNA expression, a prevalent 
radiosensitising effect and the highest reduction in cells positive for γH2AX foci.  
 
Autophagy inhibition sensitises cells to irradiation 
As LAMP3 is involved in the autophagy pathway, the effect of blocking autophagy on 
radiosensitivity was examined. Two autophagy inhibitors, chloroquine and bafilomycin A1, 
which inhibit fusion of autophagosomes with lysosomes were used for this purpose. 
Unirradiated MCF-7 cells were more sensitive to treatment with chloroquine than MDA-MB-
231 cells. Therefore, MCF-7 cells were treated with a lower dose. Figure 4A and 
Supplementary Figure 3G show that both chloroquine and bafilomycin A1 radiosensitised 
MDA-MB-231 cells. However, MCF-7 cells were only radiosensitised by bafilomycin A1. 
Subsequently, γH2AX foci formation after chloroquine treatment and radiation was examined 
in MDA-MB-231 cells. Cells treated with chloroquine showed a similar response to irradiation 
as untreated cells, but γH2AX foci persisted longer (see Figure 4B and C). 
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FIGURE 3 A. Pseudo-coloured images of γH2AX foci formation in MDA-MB-231 control and LAMP3 knockdown 
cells at different time points after irradiation with 2 Gy. For foci analysis, 2 Gy was found to be optimal, as 4 Gy 
overloaded control cells with foci. Original magnification is 200×. Bars equal 100 µm. B. Quantification of A. Nuclei 
positive for γH2AX foci were scored in five random fields per time point. C. Western blot analysis of factors of the 
DNA damage response in MDA-MB-231 control and LAMP3 knockdown cells at different time points after 
irradiation with 4 Gy. D. Densitometric quantification of C. To give an overall overview of DNA damage repair 
proteins, a cumulative graph was used. Protein levels were normalised against α-tubulin expression.  
 
DISCUSSION 
In this study, we show that the PERK/ATF4/LAMP3-arm of the UPR can confer resistance 
to radiotherapy in breast cancer cells. This appears to be mediated by interference of LAMP3 
with the DNA damage response, possibly via autophagy.  
Typically, radiation induces double-strand breaks (DSBs) in the DNA. One of the earliest 
events to repair DSBs is phosphorylation of serine 139 of histone H2AX: within minutes after 
exposure to radiation γH2AX is formed. As repair takes place, H2AX will be gradually 
dephosphorylated. Previously, radiosensitive cell lines displayed decreased loss of γH2AX with 
more residual foci than radioresistant cells16. In the current study, LAMP3 knockdown cells 
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were found to have limited γH2AX after irradiation and further examination revealed that in 
fact the entire DNA damage repair pathway is severely impaired. Loss of DNA repair capacity 
is associated with an increase in sensitivity to radiation17. Normally, DSBs induced by radiation 
are recognised and repaired, thereby protecting cells from death. Left unidentified or 
unrepaired, DSBs could ultimately lead to lethality. 
 
FIGURE 4 A. Clonogenic survival of MDA-MB-231 and MCF-7 cells after pre-treatment with 50 or 25 µM 
hydroxychloroquine (HCQ), respectively, or 5 ng/ml bafilomycin A1 (Baf A1) for 24 hours and subsequent irradiation. 
B. Pseudo-coloured images of γH2AX foci formation in MDA-MB-231 cells treated with hydroxychloroquine at 
different time points after irradiation with 2 Gy. Original magnification is 200×. Bars equal 100 µm. C. Quantification 
of B. Nuclei positive for γH2AX foci were scored in five random fields per time point. 
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Overall, our results from clonogenic survival assays show that the effects of knockdowns and 
pharmacological agents on radiosensitivity were smaller in MCF-7 cells compared to MDA-
MB-231 cells. Untreated, MDA-MB-231 cells are more radioresistant than MCF-7 cells. MDA-
MB-231 cells carry a mutation in the p53 gene, whereas MCF-7 cells have wild type p53 (ref. 18). 
Loss of p53 has been previously implicated in radioresistance19 and may explain the difference 
in intrinsic radiosensitivity of these cell lines.  
In our previous study, we found that breast cancer patients treated with radiotherapy had a 
reduced locoregional control if LAMP3 mRNA levels were high15, whereas this effect was 
absent in patients not receiving radiotherapy. LAMP3 expression is induced under hypoxic 
conditions and hypoxia is a main mechanism causing radioresistance. Therefore, this 
prognostic effect could be simply due to LAMP3 positive tumours being more hypoxic, where 
LAMP3 is merely a hypoxia-marker. In the current study, LAMP3 knockdown in well-
oxygenised cell cultures resulted in radiosensitisation. Thus, LAMP3 causes radioresistance 
independent of cellular oxygenation status. 
LAMP3 is not the first PERK-associated factor to be implicated in the radiation response. 
NRF2 (nuclear factor-erythroid 2-related factor 2) is activated in a PERK-dependent manner 
to induce anti-oxidant genes20. NRF2 can protect colon epithelial cells from radiation-induced 
DNA damage by enhancing DNA damage repair signalling21. KIM et al. recently showed that 
PERK knockdown in MCF-7 cells causes resistance to radiation22. Our current data, as well as 
results reported earlier10,21 indicate an opposite effect of PERK on radiosensitivity. As the UPR 
represent a survival mechanism during conditions of stress (such as radiation), abrogating 
PERK-signalling is likely to cause a decrease in cell survival. 
The precise mechanism behind radioresistance mediated by LAMP3 is not fully elucidated. 
However, previous work indicates that LAMP3 is involved in autophagy (CHAPTER SEVEN). 
Also, ATF4 is essential for hypoxia-induced autophagy23,24. Autophagy has been described in 
multiple studies as a potential mechanism involved in radiosensitisation of cells. DNA damage 
can even trigger autophagy, indicating that autophagy is necessary for repair25. In addition, 
autophagy can regulate the removal of DNA repair factors from the cell26. However, 
interference with the autophagic pathway has proved to be not universally applicable. The 
autophagy inhibitor chloroquine was found to radiosensitise MDA-MB-231 cells, but not 
HBL-100 or HCT-116 cells11,23. In addition, knockdown of essential autophagy genes in 
combination with irradiation led to different effects in different cell lines with different 
knockdowns27. Other studies indicate that not inhibition but promotion of autophagy may 
serve as a mechanism to radiosensitise cells (reviewed in 28). Underlying causes of these 
differences are unknown, but effects are likely to be tumour type and context-dependent. 
In conclusion, this study shows that knockdown of the PERK/ATF4/LAMP3-arm of the 
UPR can radiosensitise breast cancer cells. LAMP3 knockdown cells exhibit a significant 
decrease in DNA damage signalling and repair. In addition, pharmacological inhibition of 
PERK, resulting in a reduced mRNA expression of LAMP3, could be used as a radiosensitiser. 
These data indicate that therapeutic intervention of the PERK/ATF4/LAMP3-pathway may 
represent an attractive approach to sensitise tumour cells to radiation. 
 
CHAPTER EIGHT 
 138 
SUPPLEMENTARY MATERIAL 
Supplementary data associated with this article can be found, in the online version, at 
http://dx.doi.org/10.1016/j.radonc.2013.06.037.  
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ABSTRACT 
Background 
Constitutive γH2AX expression might indicate disruption of the DNA damage repair pathway, 
genomic instability, or shortened telomeric ends. Here, we quantified expression of 
endogenous γH2AX and its downstream factor 53BP1 in a large number of breast cancer cell 
lines (n = 54) and a node-negative breast cancer cohort that had not received adjuvant systemic 
treatment (n = 122). 
Methods 
Formalin fixed paraffin embedded breast cancer cell lines and tumours were 
immunohistochemically analysed for γH2AX and 53BP1 expression and related to cell line, 
patient and tumour characteristics and to disease progression. 
Results 
In breast cancer cell lines, γH2AX positivity was associated with the triple negative/basal like 
subgroup (p = 0.005) and with BRCA1 (p = 0.011) or p53 (p = 0.053) mutations. Specifically in 
triple negative breast cancer patients a high number of γH2AX foci indicated a significantly 
worse prognosis (p = 0.006 for triple negative vs. p = 0.417 for oestrogen receptor (ESR), 
progesterone receptor (PGR) or ERBB2 positive patients). A similar association with disease 
progression was found for 53BP1. In a multivariate analysis with tumour size, grade and triple 
negativity, only the interaction between triple negativity and γH2AX remained significant 
(p = 0.002, hazard ratio = 6.77, 95% CI = 2.07 - 22.2). 
Conclusions 
Constitutive γH2AX and 53BP1 staining reveals a subset of patients with triple negative breast 
tumours that have a significantly poorer prognosis. 
 
KEYWORDS 
γH2AX, breast neoplasms, 53BP1, DNA damage 
γH2AX EXPRESSION IN BREAST CANCER 
 143 
INTRODUCTION 
The DNA damage repair pathway is activated upon damage to DNA caused by a plethora of 
causes such as ionising radiation, hypoxia, reactive oxygen species and certain chemicals, as 
well as replicational or transcriptional errors1. Several types of damage can occur, including 
double-strand breaks (DSBs) in which both DNA strands have been cleaved. If left unrepaired, 
DSBs are lethal for the cell2,3. One of the first events in reaction to activation of the DNA 
damage repair pathway is phosphorylation of histone H2AX on serine 139 on each side of the 
break, yielding γH2AX foci4-7. γH2AX recruits other factors such as 53BP1, BRCA1, MDC1 
and the MRE11-RAD50-NBS1 (MRN) complex to sites of damage8-12. Unrepaired DSBs, 
indicated by retention of irradiation induced γH2AX foci, have predictive value in tumours as a 
biomarker for sensitivity to radiotherapy13. 
Constitutive, endogenous γH2AX foci are rare in normal primary human cells and tissues14. 
However, tumour cells show different degrees of constitutive phosphorylated H2AX in the 
absence of exogenously induced DSBs14. Cell lines with more endogenous foci exhibit more 
chromosomal instability than those with fewer endogenous foci15. Colocalisation of 
endogenous foci with other DNA repair factors (e.g. 53BP1, MRN-complex) seems to indicate 
that actual DNA repair is taking place at these sites16,17. Endogenous expression of γH2AX has 
not only been observed in tumour cell lines, but also in cancer tissues and even in their 
precursor lesions, suggesting a role for activated DNA damage repair in tumourigenesis18,19. 
Data from recent studies indicate that the endogenous expression of DNA damage response 
factors may also be associated with damaged, shortened telomeres20-22 or hypoxia23. 
Recently, an association between γH2AX expression and BRCA1 mutation status and triple 
negativity has been found in a cohort of breast cancers24. Whether endogenous expression of 
γH2AX is consequential in breast cancer has, to the best of our knowledge, not been 
described. In the current study the constitutive expression of γH2AX and its downstream 
factor 53BP1 were examined in breast cancer cell lines and breast cancer tissues and correlated 
with clinicopathological parameters and outcome. 
 
MATERIALS AND METHODS 
Tumour arrays 
A breast cancer cell microarray of 54 breast cancer cell lines in triplicate was constructed as 
described previously25. A tumour microarray was constructed from formalin fixed paraffin 
embedded breast tumours26. Tumour cores were marked on haematoxylin and eosin-stained 
slides by a pathologist. Two millimetre diameter punches were made with a Tissue-Tek Quick 
Ray puncher (Sakura Inc.) and embedded in fresh paraffin. 
 
Patients 
Breast cancer patients were selected from a cohort surgically treated between January 1991 and 
December 1996 that had no axillary lymph node invasion, received no adjuvant systemic 
treatment and had at least five years follow up or an earlier recurrence during follow-up26. By 
enriching for triple negative tumours, in order to obtain approximately equal sized groups of 
breast cancer subtypes, the selection criteria led to a patient cohort (n = 122) with 25% ESR 
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positive, 13% PGR positive, 30% ERBB2-positive and 44% triple negative patients. As 
approved by the institutional review board and according to national law, coded tumour tissues 
were used. 
 
Immunohistochemical staining of formalin fixed paraffin embedded tissue sections 
Sections were stained as described previously27 with minor modifications. For γH2AX sections 
were rinsed in tris buffered saline (TBS, pH 7.4) and normal donkey serum was diluted in 1% 
BSA in TBS with 0.2% Triton X-100 (Sigma Aldrich, St. Louis, MO, USA). The primary 
antibodies used were rabbit anti-phospho-H2AX (#2577, Cell Signaling Technology, Danvers, 
MA, USA) diluted 1:500 in TBS with 1% BSA and rabbit anti-53BP1 (210-419-R050, Alexis 
Biochemicals Corp., San Diego, CA, USA) diluted 1:5,000. The secondary antibody was biotin-
conjugated donkey anti-rabbit IgG (711-066-152, Jackson) diluted 1:400 in TBS (γH2AX) or 
phosphate buffered saline (PBS, 53BP1). 
 
Image acquisition, scoring procedure and statistical analysis 
All images were captured with a Leica DM 6,000 microscope using IP-lab imaging software 
(Scanalytics Inc., Fairfax, VA, USA). Stained sections were viewed at a magnification of 200× 
and manually scored by at least two independent researchers (A.N and S.K. or P.S.) according 
to γH2AX or 53BP1 staining intensity, where 0 indicates no staining present, 1 is light staining, 
2 is moderate staining and 3 intense staining. Figure 2 and Figure 4 of the results section show 
examples of the different staining intensities found. 
 
Statistical analyses 
Statistical analyses were performed using SPSS 16.0 software (SPSS Benelux BV., Gorinchem, 
the Netherlands). Differences in staining intensities between patient subgroups were analysed 
with χ2 tests and/or Spearman rank correlation tests. Disease progression was defined as time 
between primary surgery and any recurrence (local or regional) or distant metastasis. Death by 
any cause was treated as censoring event in Kaplan-Meier survival curves with log-rank testing 
of differences in disease progression between patient subgroups. Multivariate analyses were 
performed with Cox Proportional Hazard modelling with backward selection of variables 
based on the Likelihood Ratio. A p < 0.05 was considered statistically significant. 
 
RESULTS 
γH2AX and 53BP1 antibody validation 
The γH2AX and 53BP1 antibodies used in this study were validated on irradiated xenografted 
head and neck squamous cell carcinoma tissues. Formalin fixed paraffin embedded SCCNij3 
tumours were available from previous studies28,29. γH2AX and 53BP1 staining on normal tissue 
of the breast, kidney, liver and lung showed no noteworthy expression. After a dose of 10 Gy 
the SCCNij3 tumours showed increased γH2AX and 53BP1 foci formation (see Figure 1), 
indicating that the antibody and staining procedures were valid. 
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FIGURE 1 Antibody validation for γH2AX (A and B) and 53BP1 (C and D) in irradiated SCCNij3 xenografts. Pre-
irradiation a limited number of foci are present (A and C). Twenty-four hours after irradiation with 10 Gy foci are 
apparent (B and D). Original magnification: 400×, scale bar is 100 µm. 
 
Endogenous γH2AX expression in a large panel of breast cancer cell lines 
A microarray containing cores of 54 different breast cancer cell lines, embedded in triplicate, 
was stained for γH2AX and subsequently scored. Examples of different staining intensities are 
shown in Figure 2.  
FIGURE 2 Different staining intensities of γH2AX in breast cancer cell lines, ranging from 0 to 3 (A - D). Depicted 
cell lines are: MDA-MB-175VII (A), EVSA-T (B), BT-20 (C), and MDA-MB-435s (D). Original magnification: 400×, 
scale bar is 100 µm. 
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Scores were correlated with known characteristics of the cell lines25. γH2AX positivity was 
associated with the triple negative/basal like subgroup (p = 0.005), oestrogen receptor 
negativity (p = 0.001) and with BRCA1 (p = 0.011) or p53 (p = 0.053) mutations (see Figure 3). 
 
FIGURE 3 Differences in cell lines with different γH2AX staining intensities and characteristics as fraction of cell lines 
positive for: A. triple negativity (p = 0.005), B. oestrogen receptor (p = 0.001), C. BRCA mutations (p = 0.011), and D. 
p53 mutations (p = 0.053). 
 
Expression of γH2AX and 53BP1 in breast tumours 
Next, the expression of γH2AX and 53BP1 was analysed in a heterogeneous group of 122 
non-adjuvantly treated patients with breast cancers. The range of staining intensities for both 
markers is shown in Figure 4. The γH2AX staining was found to be negative in 35% of the 
cases and highly positive in 8% of the cases.  No significant correlation was found between 
γH2AX expression and hormone receptor status. In addition, 53BP1 was stained on 
consecutive sections of the breast cancer tissue microarray. Similar to γH2AX, different 
patterns of staining intensity of 53BP1 were observed (see Figure 4). Scores for γH2AX and 
53BP1 showed a strong correlation (p < 0.001), although 53BP1 showed a higher number of 
positive tumours: 14% of the cases were negative and 32% of the cases were scored as strongly 
positive. In the receptor positive group young age (p = 0.011) and pre-menopausal status 
(p = 0.023) were associated with stronger γH2AX staining (see Table 1). In the triple negative 
patients, stronger γH2AX staining was found in patients eventually treated with lumpectomy 
vs. mastectomy (p = 0.021) and with (post-surgical) adjuvant radiotherapy (p = 0.003). 
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Expression of γH2AX and 53BP1 has prognostic relevance in triple negative breast 
cancers 
Next, the relation between γH2AX and disease progression was evaluated. Due to the small 
sample size, staining scores of 0 and 1 as well as 2 and 3 were taken together for this purpose. 
For the group as a whole, no significant associations with prognosis were found. However, 
within the group of triple negative tumours a highly significant association with disease 
progression was found (p = 0.006, see Figure 5A and B), which was absent in the hormone 
receptor positive group. Similar results were found for 53BP1 (p = 0.029, see Figure 5C and 
D). Within the triple negative breast cancers, a multivariate analysis with surgery and 
radiotherapy, both with which γH2AX was associated (see Table 1), revealed that γH2AX 
remained a significant factor (p = 0.010; hazard ratio (HR) = 4.06, 95% CI = 1.40 - 11.77). 
Thus, the prognostic relevance of γH2AX in triple negative breast cancers was independent of 
its association with these factors. 
Next, we performed a multivariate Cox Regression analysis including prognostically relevant 
parameters, i.e. tumour size, histological grade and tumour type (triple negative, steroid 
hormone and/or ERBB2 positive). All patients were node negative and did not receive 
adjuvant systemic treatment, thus these parameters were not entered in the model. In addition, 
an interaction variable for triple negativity and γH2AX was entered in the model, which would 
indicate whether the prognostic value of γH2AX was different in these tumours. Only this 
interaction between triple negativity and γH2AX remained significantly associated with disease 
progression (p = 0.002, HR = 6.77, 95% CI = 2.07 - 22.2) after correction for tumour size, 
grade and triple negativity. 
 
DISCUSSION 
Here, we found that constitutive γH2AX expression is higher in triple negative and in BRCA1 
and p53 mutated breast cancer cell lines. In addition, endogenous γH2AX and 53BP1 
expression in breast cancer tissue was evaluated and correlated with clinicopathological 
parameters and outcome in a human breast cancer patient cohort. It has been reported that 
triple negative breast cancers display more endogenous γH2AX expression24 and that this 
subset of cancers has a higher incidence of carrying aberrations in components of the DNA 
damage repair pathway24,30. In the current study a correlation between γH2AX expression and 
triple negativity was found in a group of breast cancer cell lines, but this association could not 
be confirmed in breast cancer patients. Further, basal like and/or triple negative tumours are 
known to have a larger number of BRCA1 mutation carriers, which previously have been 
associated with a higher occurrence of γH2AX positivity24. The BRCA-status of the patients 
included in the current study, however, is unknown. Nevertheless, we did find that in breast 
cancer patients high endogenous γH2AX or 53BP1 expression revealed a subset of triple 
negative tumours with poor prognosis. Our results seem to indicate that triple negative and/or 
basal like breast tumours represent a fundamentally different subgroup of tumours where 
apparently endogenous γH2AX expression has relevance for disease progression, although this 
should be validated in independent, unselected larger breast cancer patient cohorts. 
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FIGURE 4 Differences in γH2AX and 53BP1 expression in breast tumours. Typical examples of tumours with scores 
from 0 to 3 are shown. Original magnification: 400×, scale bar is 100 µm. 
 
FIGURE 5 Association of γH2AX and 53BP1 with disease progression. A. No association of low γH2AX (black line) 
or high γH2AX (dotted line) staining intensity in receptor (ESR, PGR, and/or ERBB2) positive tumours was found 
(n = 54) but in triple negative tumours (n = 42) high γH2AX leads to a significantly shorter disease-free interval 
(p = 0.006, B). C. No association of low 53BP1 (black line) or high 53BP1 (dotted line) was found in receptor 
positives (n = 61), but in triple negatives (n = 49) high 53BP1 leads to a decrease in disease-free interval (p = 0.029, D). 
Patient numbers between γH2AX and 53BP1 may differ due to loss of patient samples during the staining procedure. 
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TABLE 1 Patient characteristics of low vs .  high γH2AX expression in triple negative 
and any receptor positive breast cancer patients 
 Triple Negative Any Receptor Positive 
γH2AX Low High p Low High p 
Total n  30 12  39 15  
Mean age 57 51 0.341 59 49 0.011 
pT   0.648   0.359 
1 13 7  18 11  
2 14 5  19 4  
3 2 0  2 0  
4 1 0  0 0  
pN   -   - 
0 30 12  39 15  
1 0 0  0 0  
M   -   - 
0 30 12  39 15  
1 0 0  0 0  
Menopausal state   0.611   0.023 
pre 10 5  6 7  
post 20 7  33 8  
Grade   0.783   0.717 
I 0 0  1 1  
II 4 2  10 4  
III 18 8  18 8  
unknown 8 2  10 2  
Tumour type   0.136   0.867 
ductal 23 11  31 13  
lobular 2 0  4 1  
other 5 1  4 1  
Surgery   0.021   0.263 
mastectomy 17 1  19 5  
lumpectomy 13 11  20 10  
Adjuvant Radiotherapy   0.003   0.155 
no 18 1  17 3  
yes 12 11  22 12  
ESR   -   0.202 
negative 30 12  18 9  
positive 0 0  21 6  
PGR   -   0.449 
negative 30 12  28 12  
positive 0 0  11 3  
ERBB2   -   0.119 
negative 30 12  17 4  
positive 0 0  22 11  
 
Several studies have attempted to elucidate the exact identity of the endogenous γH2AX foci 
observed in many different cancerous lesions and whether they are associated with actual DNA 
damage. Recruitment of other downstream DNA damage repair factors to these foci has led to 
the idea that actual DNA repair is attempted at these sites16,17. One recent explanation for the 
occurrence of endogenous γH2AX in cancers is the association with telomeres, protective 
structures which form the chromosome ends in eukaryotes. Duplication of DNA results in 
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shortened telomeres after every cell cycle. Shortening of telomeres and activation of 
telomerase, an enzyme necessary for telomere lengthening, occurs frequently in (pre-
)cancerous lesions31-35. Normally, telomere shortening is a signal for replication arrest and 
replicative senescence. In the absence of a telomeric structure, chromosome ends are highly 
unstable and are prone either to degradation, merging with other chromosomes (genomic 
instability) or DNA double-strand breaks20,21. NAKAMURA et al. showed that a considerable 
number of endogenous γH2AX foci do not represent actual double-strand breaks but are in 
fact uncapped telomeres22. Thus, telomere dysfunction can lead to DNA damage and 
phosphorylation of H2AX at these sites36,37. In addition, telomere associated chromosomal 
rearrangements may lead to a tumour phenotype with the associated immortality and unlimited 
replicative potential38. However, at the moment it is unclear what endogenous γH2AX and 
53BP1 expression represents in our patients. The mechanism behind the occurrence of these 
foci and the relation with disease progression and/or treatment sensitivity remain to be 
elucidated. 
In conclusion, in the current breast cancer cohort an association was found between 
expression of the DNA damage repair factors γH2AX and 53BP1 and disease progression in 
triple negative patients. Independent validation of this finding is necessary in larger unselected 
breast cancer patient cohorts and further studies in breast cancers from germline BRCA1 
mutation carriers and by correlating γH2AX expression directly to telomere length should be 
performed to determine the nature of these foci. 
 
ACKNOWLEDGEMENTS 
The authors would like to thank MRS. IRENE OTTE-HOLLER (Department of Pathology, 
Radboud University Nijmegen Medical Centre) for her help with optimisation of staining 
protocols. 
 
REFERENCES 
1. ILIAKIS, G. Backup pathways of NHEJ in cells of higher eukaryotes: cell cycle dependence. Radiother Oncol 
2009; 92: 310-315. 
2. RODEMANN, H. P. Molecular radiation biology: perspectives for radiation oncology. Radiother Oncol 2009; 92: 
293-298. 
3. MEYN, R. E., MUNSHI, A., HAYMACH, J. V. et al. Receptor signaling as a regulatory mechanism of DNA repair. 
Radiother Oncol 2009; 92: 316-322. 
4. BURMA, S., CHEN, B. P., MURPHY, M. et al. ATM phosphorylates histone H2AX in response to DNA double-
strand breaks. J Biol Chem 2001; 276: 42462-42467. 
5. ROGAKOU, E. P., BOON, C., REDON, C. et al. Megabase chromatin domains involved in DNA double-strand 
breaks in vivo. J Cell Biol 1999; 146: 905-916. 
6. ROGAKOU, E. P., PILCH, D. R., ORR, A. H. et al. DNA double-stranded breaks induce histone H2AX 
phosphorylation on serine 139. J Biol Chem 1998; 273: 5858-5868. 
7. PORCEDDA, P., TURINETTO, V., ORLANDO, L. et al. Two-tier analysis of histone H2AX phosphorylation allows 
the identification of Ataxia Telangiectasia heterozygotes. Radiother Oncol 2009; 92: 133-137. 
8. BASSING, C. H., CHUA, K. F., SEKIGUCHI, J. et al. Increased ionizing radiation sensitivity and genomic instability 
in the absence of histone H2AX. Proc Natl Acad Sci U S A 2002; 99: 8173-8178. 
9. CELESTE, A., FERNANDEZ-CAPETILLO, O., KRUHLAK, M. J. et al. Histone H2AX phosphorylation is dispensable 
for the initial recognition of DNA breaks. Nat Cell Biol 2003; 5: 675-679. 
10. CELESTE, A., PETERSEN, S., ROMANIENKO, P. J. et al. Genomic instability in mice lacking histone H2AX. 
Science 2002; 296: 922-927. 
11. FERNANDEZ-CAPETILLO, O., CHEN, H. T., CELESTE, A. et al. DNA damage-induced G2-M checkpoint 
activation by histone H2AX and 53BP1. Nat Cell Biol 2002; 4: 993-997. 
γH2AX EXPRESSION IN BREAST CANCER 
 151 
12. MOTOYAMA, N., NAKA, K. DNA damage tumor suppressor genes and genomic instability. Curr Opin Genet 
Dev 2004; 14: 11-16. 
13. OLIVE, P. L. Retention of gammaH2AX foci as an indication of lethal DNA damage. Radiother Oncol 2011; 
101: 18-23. 
14. SEDELNIKOVA, O. A., BONNER, W. M. GammaH2AX in cancer cells: a potential biomarker for cancer 
diagnostics, prediction and recurrence. Cell Cycle 2006; 5: 2909-2913. 
15. YU, T., MACPHAIL, S. H., BANATH, J. P. et al. Endogenous expression of phosphorylated histone H2AX in 
tumors in relation to DNA double-strand breaks and genomic instability. DNA Repair (Amst) 2006; 5: 935-946. 
16. SEDELNIKOVA, O. A., HORIKAWA, I., ZIMONJIC, D. B. et al. Senescing human cells and ageing mice accumulate 
DNA lesions with unrepairable double-strand breaks. Nat Cell Biol 2004; 6: 168-170. 
17. REDON, C., PILCH, D., ROGAKOU, E. et al. Histone H2A variants H2AX and H2AZ. Curr Opin Genet Dev 
2002; 12: 162-169. 
18. BARTKOVA, J., HOREJSI, Z., KOED, K. et al. DNA damage response as a candidate anti-cancer barrier in early 
human tumorigenesis. Nature 2005; 434: 864-870. 
19. OLIVE, P. L., BANUELOS, C. A., DURAND, R. E. et al. Endogenous and radiation-induced expression of 
gammaH2AX in biopsies from patients treated for carcinoma of the uterine cervix. Radiother Oncol 2010; 94: 
82-89. 
20. CAMPISI, J., KIM, S. H., LIM, C. S. et al. Cellular senescence, cancer and aging: the telomere connection. Exp 
Gerontol 2001; 36: 1619-1637. 
21. DE LANGE, T. Telomere-related genome instability in cancer. Cold Spring Harb Symp Quant Biol 2005; 70: 197-
204. 
22. NAKAMURA, A. J., REDON, C. E., BONNER, W. M. et al. Telomere-dependent and telomere-independent origins 
of endogenous DNA damage in tumor cells. Aging (Albany NY) 2009; 1: 212-218. 
23. HARDING, S. M., COACKLEY, C., BRISTOW, R. G. ATM-dependent phosphorylation of 53BP1 in response to 
genomic stress in oxic and hypoxic cells. Radiother Oncol 2011; 99: 307-312. 
24. BARTKOVA, J., TOMMISKA, J., OPLUSTILOVA, L. et al. Aberrations of the MRE11-RAD50-NBS1 DNA damage 
sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene. Mol Oncol 
2008; 2: 296-316. 
25. HOLLESTELLE, A., NAGEL, J. H., SMID, M. et al. Distinct gene mutation profiles among luminal-type and basal-
type breast cancer cell lines. Breast Cancer Res Treat 2009; 121: 53-64. 
26. WENNEMERS, M., BUSSINK, J., GREBENCHTCHIKOV, N. et al. TRIB3 protein denotes a good prognosis in breast 
cancer patients and is associated with hypoxia sensitivity. Radiother Oncol 2011; 101: 198-202. 
27. NAGELKERKE, A., MUJCIC, H., BUSSINK, J. et al. Hypoxic regulation and prognostic value of LAMP3 expression 
in breast cancer. Cancer 2011; 117: 3670-3681. 
28. TROOST, E. G., BUSSINK, J., KAANDERS, J. H. et al. Comparison of different methods of CAIX quantification in 
relation to hypoxia in three human head and neck tumor lines. Radiother Oncol 2005; 76: 194-199. 
29. TROOST, E. G., LAVERMAN, P., KAANDERS, J. H. et al. Imaging hypoxia after oxygenation-modification: 
comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors. 
Radiother Oncol 2006; 80: 157-164. 
30. TOMMISKA, J., BARTKOVA, J., HEINONEN, M. et al. The DNA damage signalling kinase ATM is aberrantly 
reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer. Oncogene 2008; 
27: 2501-2506. 
31. SHAY, J. W., BACCHETTI, S. A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33: 787-791. 
32. MEEKER, A. K., ARGANI, P. Telomere shortening occurs early during breast tumorigenesis: a cause of 
chromosome destabilization underlying malignant transformation? J Mammary Gland Biol Neoplasia 2004; 9: 
285-296. 
33. MEEKER, A. K., HICKS, J. L., IACOBUZIO-DONAHUE, C. A. et al. Telomere length abnormalities occur early in 
the initiation of epithelial carcinogenesis. Clin Cancer Res 2004; 10: 3317-3326. 
34. MEEKER, A. K., HICKS, J. L., PLATZ, E. A. et al. Telomere shortening is an early somatic DNA alteration in 
human prostate tumorigenesis. Cancer Res 2002; 62: 6405-6409. 
35. RAYNAUD, C. M., HERNANDEZ, J., LLORCA, F. P. et al. DNA damage repair and telomere length in normal 
breast, preneoplastic lesions, and invasive cancer. Am J Clin Oncol 2010; 33: 341-345. 
36. OLIVE, P. L. Endogenous DNA breaks: gammaH2AX and the role of telomeres. Aging (Albany NY) 2009; 1: 
154-156. 
37. TAKAI, H., SMOGORZEWSKA, A., DE LANGE, T. DNA damage foci at dysfunctional telomeres. Curr Biol 2003; 
13: 1549-1556. 
38. RAYNAUD, C. M., SABATIER, L., PHILIPOT, O. et al. Telomere length, telomeric proteins and genomic instability 
during the multistep carcinogenic process. Crit Rev Oncol Hematol 2008; 66: 99-117. 
 
  
 
 
 
 
 
CHAPTER TEN 
 
 
CONSTITUTIVE γH2AX EXPRESSING TRIPLE NEGATIVE BREAST CANCERS 
EXHIBIT TELOMERE DYSFUNCTION AND HAVE NO INCREASED 
SENSITIVITY TO ANTI-CANCER DRUGS 
 
ANIKA NAGELKERKE 
SIMON J.A. VAN KUIJK 
JOHN W.M. MARTENS 
FRED C.G.J. SWEEP 
NICOLINE HOOGERBRUGGE 
JOHAN BUSSINK 
PAUL N. SPAN 
 
Submitted.
CHAPTER TEN 
 154 
ABSTRACT  
Background  
Patients with triple negative breast cancers exhibiting high endogenous γH2AX expression 
have a poor prognosis. Here, we set out to establish whether γH2AX could be a biomarker for 
an alternative treatment option for these patients and to delineate the underlying characteristics 
of tumours with high levels of γH2AX. 
Methods 
We explored the association of γH2AX with mutation status in 27 different oncogenes and 
publically available data on sensitivity to 139 different anti-cancer drugs in up to 41 breast 
cancer cell lines. Further, we correlated γH2AX expression in breast cancer tumour tissues 
with BRCA mutation status and signs of telomere dysfunction, both of which are possible 
causes for endogenous γH2AX expression. 
Results 
Triple negative breast cancer cell lines with a basal/mesenchymal phenotype express the most 
γH2AX. γH2AX positive cells exhibit more somatic p53 and BRCA1 mutations and - when 
p53 mutated - have shorter telomeres, indicative of telomere dysfunction. These cells are not 
more sensitive to any of the tested anti-cancer drugs. Also in breast cancer patients γH2AX is 
related to germline BRCA1 mutations and shorter telomeres. Telomere dysfunction could also 
explain the poorer prognosis of triple negative breast cancer patients with γH2AX positive 
tumours. 
Conclusions 
Endogenous γH2AX is associated with short telomeres, which might offer a specific target for 
therapy for this subgroup of patients with a limited number of treatment options and generally 
a poor outcome. 
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INTRODUCTION 
Phosphorylation of the histone subunit H2AX (γH2AX) is an early event in the DNA damage 
repair pathway and often used as marker for radiation-induced double-strand DNA breaks 
(DSBs)1. Earlier, we found that in the absence of exogenously induced DNA damage high 
expression of γH2AX can be found in a subset of breast cancer tissues2. In breast cancer 
patients with triple negative tumours, i.e. those tumours that do not express the oestrogen- or 
progesterone receptor, nor the epidermal growth factor receptor 2 (ERBB2), γH2AX was 
strongly prognostic2. The nature of this constitutive γH2AX is, however, unknown. Pan-
nuclear γH2AX staining could represent a pre-apoptotic signal associated with ATM- and 
JNK-dependent apoptosis during replication3. Further, γH2AX might also be associated with 
critically short/dysfunctional telomeres4. Telomeres cap the chromosomes and protect the 
ends from damage and rearrangements. Short telomeres therefore lead to DNA damage - like 
activation related to γH2AX5. Knowledge of the cause of endogenous γH2AX and how this 
would relate to prognosis in triple negative breast cancer, would offer the opportunity to find 
new targets for therapy in this subset of breast cancer patients that has a poor prognosis and 
limited treatment options. Conversely, identifying “driver” signalling pathways associated with 
endogenous γH2AX would offer the opportunity to target these pathways pharmacologically6. 
γH2AX staining might then be useful as a predictive factor for such a therapy. 
Poly(ADP-ribose) polymerase (PARP) inhibitors are used in BRCA1 mutated breast tumours7, 
as these tumours lack the homologous recombination pathway of DNA damage repair8. So far, 
PARP inhibitors have not been successful in the treatment of triple negative breast cancers9, 
which often exhibit a BRCA-like phenotype (BRCAness)10. There is thus a need for either a 
good biomarker for selecting the tumours that will be sensitive to PARP inhibition, or other 
drugs to target triple negative breast cancers6. 
In an effort to establish alternative treatment options for triple negative breast cancer patients 
and to delineate the underlying characteristics of tumours with high levels of γH2AX, we 
explored the association of γH2AX with mutation status in 27 different oncogenes and 
publically available data on sensitivity to 139 different anti-cancer drugs in up to 41 breast 
cancer cell lines. Further, we set out to correlate γH2AX expression in breast cancer tumour 
tissues with BRCA mutation status and signs of telomere dysfunction11. We assessed whether 
such an association might account for the difference in prognosis of triple negative breast 
cancer patients with high levels of γH2AX and aspired to identify drugs that would specifically 
target these tumours. 
 
MATERIALS AND METHODS 
Tumour arrays 
A breast cancer cell microarray of 54 breast cancer cell lines in triplicate and a tissue microarray 
containing formalin fixed paraffin embedded breast tumours from patients with sporadic 
tumours were established as described earlier2,12. In addition, a tumour microarray was 
constructed from formalin fixed paraffin embedded breast tumours from patients with 
sporadic tumours (n = 9), or tumours with BRCA1 (n = 29), or BRCA2 (n = 9) mutations. As 
approved by the institutional review board and according to national law, coded tumour tissues 
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were used. Tumour cores were marked on haematoxylin and eosin-stained slides by a 
pathologist. Two millimetre diameter punches were made with a Tissue-Tek Quick Ray 
puncher (Sakura Finetek Europe BV., Leiden, the Netherlands) and embedded in fresh 
paraffin. 
 
Tumour cell line characteristics 
Mutations in different oncogenes were established previously12. IC50 values for 139 different 
anti-cancer drugs were obtained from the Genomics of Drug Sensitivity in Cancer Project 
(www.cancerrxgene.org). Expression profile sub-classification of the triple negative cell lines 
was derived from 6. 
 
Telomere length 
Telomere length was quantified by RT-qPCR of genomic DNA isolated from frozen tumour 
tissue and breast cancer cell lines as described earlier13. 
 
Immunohistochemical staining of formalin fixed paraffin embedded tissue sections 
Sections were stained for γH2AX as described previously2. Antibodies used were rabbit anti-
phospho-H2AX (#2577, Cell Signaling Technology, Danvers, MA, USA) diluted 1:500 in TBS 
with 1% BSA and biotin-conjugated donkey anti-rabbit IgG (711-066-152, Jackson 
ImmunoResearch Laboratories Inc., West Grove, PA, USA) diluted 1:400 in TBS. 
 
Image acquisition and scoring procedure 
All images were captured with a Leica DM 6,000 microscope using IP-lab imaging software 
(Scanalytics Inc., Fairfax, VA, USA). Stained sections were viewed at a magnification of 200× 
and manually scored by at least two independent researchers (A.N and S.K. or P.S.) according 
to γH2AX intensity, where 0 indicates no staining present, 1 is light staining, 2 is moderate 
staining and 3 intense staining. 
 
Statistical analyses 
Statistical analyses were performed using SPSS 19.0.0 software (SPSS Benelux BV., 
Gorinchem, the Netherlands). Differences in staining intensities between patient subgroups 
were analysed with χ2 tests and/or Spearman rank correlation tests. Disease progression was 
defined as time between primary surgery and any recurrence (local or regional) or distant 
metastasis. Death by any cause was treated as censoring event in Kaplan-Meier survival curves 
with log-rank testing of differences in disease progression between patient subgroups. A p < 
0.05 was considered statistically significant. 
 
RESULTS 
Firstly, we quantified γH2AX in 54 different breast cancer cell lines using a tumour cell 
microarray. The amount of endogenous γH2AX was correlated with several cell line 
characteristics (see Figure 1A). As partly reported earlier2, high γH2AX expressing cell lines 
were more often ESR negative (p = 0.004), triple negative (p = 0.002), EGFR positive (p = 
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0.001) and vimentin (p = 0.001) or N-Cadherin (p = 0.009) positive. Also, γH2AX was highest 
in cell lines of the basal subtype (p = 0.002). Thus, γH2AX was related to triple negativity and 
basal/mesenchymal characteristics of the breast cancer cell lines. 
 
Within the triple negative cell lines γH2AX staining intensity was compared between the 
reported different subtypes (two basal-like (BL1 and BL2), immunomodulatory (IM), 
mesenchymal (M), mesenchymal stem-like (MSL) and luminal androgen receptor (LAR) 
subtype6) (see Figure 2). No significant difference was found (p = 0.17). 
 
Correlating γH2AX with mutations in 27 different oncogenes (see Figure 1B), we identified 
significant positive correlations with mutations in p53 (p = 0.048) and BRCA1 (p = 0.024), 
possibly indicating defects in DNA repair. In γH2AX expressing tumour cells, less cyclin D1 
amplifications (p = 0.036) and MAP2K4 mutations (p = 0.023) were found. 
Genomic instability, “BRCAness” and p53 mutations are often associated with short telomeres 
in a phenomenon called telomere dysfunction11. The short/dysfunctional telomeres induce a 
damage repair response with γH2AX expression4. Indeed, within p53 mutated cell lines 
γH2AX expression correlated negatively with telomere length (rs = -0.475, p = 0.009) (see 
Figure 3). 
 
FIGURE 1 Cell line characteristics (A) and proportion of oncogene mutations (B) in breast cancer cell lines with 
differing amounts of endogenous γH2AX expression (γH2AX white = 0, light grey = 1, dark grey = 2, black = 3). 
Significant Spearman correlations are shown. 
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Next, we correlated γH2AX expression with drug sensitivity of these cell lines, as obtained 
from the Genomics of Drug Sensitivity in Cancer Project. Data was available for 139 different 
drugs and up to 41 of the breast cancer cell lines on our tumour cell microarray (see 
Supplementary Table 1). A negative correlation, indicating that high γH2AX expressing cell 
lines are more sensitive (i.e. have a lower IC50) to a particular drug, was found for AS601245 
(JNK inhibitor V, a c-Jun N-terminal kinases (JNK) inhibitor) (rs = -0.497, p = 0.004) and PF-
02341066 (Crizotinib, an anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth 
factor receptor (HGFR) inhibitor) (rs = -0.839, p = 0.005). Thus, these drugs might be useful in 
treating patients with γH2AX positive breast tumours. 
FIGURE 2 There is no significant difference (p = 0.17) in endogenous γH2AX staining between triple negative breast 
cancer subclasses as defined according to 6. 
 
However, when this analysis was restricted to triple negative cell lines, none of the 139 tested 
anti-cancer drugs was more effective in breast cancer cell lines expressing higher levels of 
γH2AX  (see Supplementary Table 1). Of note, none of the tested PARP inhibitors (Olaparib, 
AG014699 [Rucaparib], ABT888 [Veliparib]) was selectively effective in γH2AX positive triple 
negative cell lines. In contrast, six different inhibitors were significantly less effective in triple 
negative cell lines with high γH2AX. The mean IC50 values for these six inhibitors (Afatinib, 
BMS708163, CCT007093, JNK9L, MTX and Nutlin3a) were indeed significantly higher in 
γH2AX expressing triple negative cells and not in receptor positive cells (see Figure 4). 
Remarkably, whereas JNK inhibition was most effective against γH2AX expressing cells when 
taking all cell lines into account (see above), in triple negative cell lines JNK9L (KIN001-204, a 
JNK inhibitor) was the least effective when γH2AX was high (rs = 0.879, p < 0.001). Thus, 
triple negative breast cancer cell lines with high levels of endogenous γH2AX are not 
specifically more sensitive to drug treatment. This is especially the case for drugs targeting 
JNK. 
FIGURE 3 Endogenous γH2AX staining intensity is negatively correlated with telomere length in p53 mutated breast 
cancer cell lines (rs = -0.475, p = 0.009). 
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FIGURE 4 γH2AX positive triple negative cell lines are less sensitive to six different anti-cancer drugs, mean IC50 
values in receptor positive vs. triple negative γH2AX negative or positive cell lines. 
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As γH2AX expression was related to BRCA1 mutations in the cell lines, we next assessed 
whether this was also true for human breast cancer patients. Possibly, γH2AX is related to 
BRCAness within the subgroup of triple negative breast cancers and might thereby be related 
to prognosis. A tissue microarray of breast cancers from sporadic or hereditary cause (BRCA1, 
BRCA2 or other) was devised and stained for γH2AX. As shown in Figure 5, more high 
γH2AX-expressing tumours were found in patients carrying a germline BRCA1 mutation as 
compared to patients with a sporadic cause of breast cancer or germline BRCA2 mutation 
carriers (21% vs. both 12.5%, p = 0.049). 
FIGURE 5 Proportion of tumours expressing γH2AX in sporadic or familial (BRCA1 or BRCA2) breast cancer cases. 
More BRCA1 tumours exhibited high γH2AX (21 vs. 12.5%, * p = 0.049). 
 
However, within triple negative breast cancer, patients with or without germline BRCA1 
mutations have similar disease outcomes14. Thus, it is unlikely that this association of γH2AX 
with BRCA1 mutations explains the difference in prognosis we found for triple negative 
tumours with high γH2AX expression. We also established that p53 mutated cell lines with 
γH2AX have short telomeres. Therefore, we next quantified the mean telomere length of our 
cohort of sporadic breast cancer patients and correlated this with γH2AX expression. We 
found that, similar to what was found in cell lines, patients with pre-treatment positive γH2AX 
staining had significantly shorter telomeres (see Figure 6A, p = 0.05). Remarkably, when 
comparing the outcome of patients dichotomised on the median telomere length, we found 
similar results as for γH2AX2, only in patients with triple negative tumours, shorter telomeres 
denoted a poorer disease-free survival (see Figure 6B and C, p = 0.042). 
FIGURE 6 A. Telomere length (in arbitrary units, AU) in tumour tissue from sporadic breast cancer cases is smaller in 
tumours expressing γH2AX. B. Short telomere length is not prognostic in hormone receptor positive tumours, but (C) 
is significantly associated with poor disease-free survival in triple negative breast tumours. 
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DISCUSSION 
Here, we report on the characteristics of triple negative breast cancer cells with high 
endogenous γH2AX staining. γH2AX positive breast cancer cells are mostly triple negative and 
have a basal/mesenchymal phenotype. They have significantly more p53 and BRCA1 
mutations and - when p53 mutated - shorter telomeres. We found that γH2AX positive triple 
negative breast cancer cells are not more sensitive for any of the tested anti-cancer drugs, 
whereas many of these drugs are successful in other breast cancer cell lines with high γH2AX 
expression. Finally, in patients we found that γH2AX is related to BRCA1 mutations and 
shorter telomeres. These shorter telomeres, signs of telomere dysfunction, could also explain 
the poorer prognosis of triple negative breast cancer patients with γH2AX positive tumours. 
In the concept of synthetic lethality PARP inhibitors are used in BRCA1 mutated breast 
tumours7. These DNA damage repair inhibitors were hypothesised to be effective in BRCA-
like triple negative breast tumours10. However, so far PARP inhibitors have not been 
successful in the treatment of triple negative breast cancers9. We hypothesised that, as γH2AX 
was specifically prognostic in triple negative breast cancer2, this marker of DSBs might also be 
a biomarker for PARP sensitivity. This would allow for the a priori selection of triple negative 
patients for PARP inhibitor treatment as an adjuvant to standard treatment. However, none of 
the tested PARP inhibitors (Olaparib, AG014699 [Rucaparib], ABT888 [Veliparib]) was 
selectively effective in γH2AX positive cell lines in the present study. 
Pan-nuclear γH2AX staining might also represent a pre-apoptotic signal associated with ATM- 
and JNK-dependent apoptosis during replication3. This seems in line with our present finding 
that γH2AX positive tumours are sensitive to JNK inhibition. Remarkably, this is reversed in 
triple negative γH2AX positive tumours, which were found to be insensitive to JNK inhibition. 
Recently, LEHMANN et al. reported on the sub-classification of triple negative breast cancers 
that also differed in their sensitivity towards particular anti-cancer drugs6. We found no relation 
between the seven different subclasses of triple negative tumours they reported and γH2AX 
staining, although the numbers of triple negative breast cancers was probably too small to 
detect this. Thus, we failed in identifying drugs that could specifically target γH2AX positive 
triple negative breast cancers. 
Although the γH2AX positive triple negative cell lines were not more sensitive to any of the 
tested anti-cancer drugs, we did find that these cell lines exhibited more BRCA1 and p53 
mutations and had significantly shorter telomeres. Importantly, this was also seen in the breast 
cancer patients, where short telomeres were associated with poor prognosis in triple negative 
patients only, similar to what was seen for γH2AX2. γH2AX can be associated to critically 
short/dysfunctional telomeres4, which will lead to activation of ATM and its downstream 
checkpoint kinases CHK1 and CHK2 (ref. 5). The consequence of this telomere dysfunction-
induced damage response is an increase in the frequency of end-to-end fusions and other 
chromosomal aberrations. Marked aneuploidy and complex chromosomal rearrangements that 
include non-reciprocal translocations, DNA fragmentation and chromosome fusions can often 
be found in tumours and this chromosome instability might represent a 'mutator phenotype' 
that allows an increased rate of chromosomal aberrations per cell division15 and a means of 
escape from cancer treatment by the selection of insensitive clones. Any potential treatment 
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option that would target dysfunctional telomeres might thus be specific for triple negative 
breast cancer with high γH2AX. Interestingly, the Wee1/CHK1 inhibitor 681640 is 
significantly effective in γH2AX positive breast cancer cell lines (rs = -0.480, p = 0.015), 
although less significantly so in triple negative tumours (rs = -0.500, p = 0.141). It remains to 
be established whether this type of anti-cancer drug is most beneficial in γH2AX positive triple 
negative breast cancers. 
Patients with γH2AX positive triple negative breast cancer have a poor prognosis, but their 
tumours are not more sensitive to any of the anti-cancer drugs tested here. Constitutive 
γH2AX is associated with short telomeres, which might offer a specific target for therapy for 
this subgroup of patients with only a few treatment options and a generally poor outcome. 
 
SUPPLEMENTARY MATERIAL 
 
SUPPLEMENTARY TABLE 1 Spearman correlation coefficients of γH2AX with drug IC50 values in breast 
cancer cell lines 
All breast tumour cell lines  Triple negative breast tumour cell lines 
drug name rs p n  drug name rs p n 
AS601245 -0.497 0.004 31  JNK9L 0.879 0.000 11 
PF_02341066 -0.839 0.005 9  Afatinib 0.717 0.020 10 
GW843682X -0.848 0.008 8  Nutlin_3a 0.684 0.029 10 
Sunitinib -0.848 0.008 8  CCT007093 0.713 0.031 9 
VX680 -0.848 0.008 8  methotrexate 0.794 0.033 7 
CMK -0.822 0.012 8  BMS_708163 0.677 0.045 9 
681640 -0.480 0.015 25  VX702 0.612 0.060 10 
Paclitaxel -0.782 0.022 8  AICAR 0.597 0.090 9 
BX795 -0.445 0.023 26  Bryostatin1 0.533 0.092 11 
Afatinib 0.436 0.023 27  Axitinib -0.546 0.102 10 
Obatoclax_Mesylate -0.402 0.025 31  Vinorelbine 0.518 0.103 11 
JNJ26854165 -0.432 0.031 25  Bexarotene -0.482 0.133 11 
Axitinib -0.391 0.044 27  681640 -0.500 0.141 10 
dasatinib -0.717 0.045 8  Epothilone_B 0.467 0.147 11 
Roscovitine -0.671 0.048 9  Thapsigargin -0.452 0.163 11 
OSI_906 -0.353 0.051 31  EHT_1864 0.508 0.163 9 
BIRB0796 -0.373 0.055 27  AZD6244 0.474 0.167 10 
CCT007093 0.359 0.072 26  PLX4720 0.467 0.173 10 
S_Trityl_L_cysteine -0.665 0.072 8  AS601245 -0.437 0.179 11 
AG014699 -0.365 0.073 25  RO3306 -0.447 0.195 10 
Cytarabine -0.350 0.074 27  Camptothecin 0.434 0.210 10 
BMS_509744 -0.652 0.080 8  Bosutinib -0.434 0.210 10 
BMS_536924 -0.652 0.080 8  Obatoclax_Mesylate -0.397 0.227 11 
MK2206 0.344 0.085 26  Embelin -0.397 0.227 11 
CGP_60474 -0.639 0.088 8  CCT018159 0.437 0.240 9 
Bortezomib -0.596 0.090 9  Pazopanib -0.382 0.246 11 
Salubrinal -0.629 0.095 8  FTI277 0.382 0.246 11 
GDC0941 0.330 0.099 26  Etoposide 0.377 0.253 11 
docetaxel -0.334 0.103 25  ABT888 0.281 0.260 18 
Midostaurin -0.298 0.103 31  BIRB0796 -0.388 0.268 10 
JW_7_52_1 -0.600 0.116 8  ABT263 0.388 0.268 10 
Parthenolide -0.559 0.118 9  PF4708671 0.410 0.273 9 
Gemcitabine -0.287 0.118 31  AZD6282 0.347 0.296 11 
Doxorubicin -0.285 0.120 31  IPA3 -0.347 0.296 11 
FH535 0.282 0.125 31  OSI_906 -0.342 0.304 11 
Thapsigargin -0.280 0.127 31  ATRA 0.362 0.304 10 
SB_216763 -0.319 0.129 24  MK2206 0.362 0.304 10 
JNKinhibitorVIII -0.295 0.135 27  metformin 0.355 0.314 10 
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Elesclomol -0.295 0.135 27  BMS_754807 0.332 0.319 11 
BI2536 -0.574 0.137 8  PF_562271 0.332 0.319 11 
Tipfarnib -0.263 0.153 31  HSP90_17AAG -0.349 0.323 10 
cisplatin -0.281 0.156 27  Nilotinib 0.349 0.323 10 
AZD6282 0.253 0.170 31  Bleomycin -0.317 0.343 11 
BMS_708163 0.257 0.205 26  Gemcitabine 0.312 0.351 11 
KIN001_135 0.466 0.206 9  GDC0941 0.329 0.353 10 
Lapatinib 0.466 0.206 9  JNJ26854165 -0.347 0.360 9 
Embelin -0.233 0.208 31  Elesclomol -0.316 0.374 10 
Bexarotene -0.232 0.209 31  PD_0332991 -0.296 0.406 10 
ZM_447439 -0.247 0.214 27  Mitomycin_C 0.276 0.411 11 
ZM447439 -0.247 0.214 27  Vinblastine 0.283 0.428 10 
KU55933 -0.248 0.222 26  Lenalidomide 0.283 0.428 10 
IPA3 -0.224 0.226 31  AMG706 -0.276 0.440 10 
Etoposide -0.224 0.227 31  KU55933 -0.276 0.440 10 
AKTinhVIII 0.223 0.228 31  Gefetinib 0.250 0.486 10 
Nutlin_3a 0.236 0.236 27  AKTinhVIII 0.231 0.494 11 
CI_1040 -0.231 0.245 27  Shikonin 0.221 0.514 11 
Bicalutamide -0.212 0.251 31  SB_216763 -0.249 0.517 9 
Camptothecin -0.226 0.256 27  GDC0449 0.241 0.533 9 
Bleomycin -0.210 0.257 31  GSK650394 -0.211 0.533 11 
GDC0449 -0.232 0.265 25  CEP_701 0.211 0.559 10 
EHT_1864 0.226 0.266 26  BI_D1870 0.211 0.559 10 
SL0101_1 -0.224 0.272 26  CHIR_99021 -0.181 0.595 11 
AZ628 -0.410 0.273 9  NCS_87877 -0.181 0.595 11 
AZD7762 -0.221 0.277 26  Cytarabine -0.184 0.610 10 
RO3306 -0.213 0.286 27  ABT888_2 0.184 0.610 10 
NVP_TAE684 -0.391 0.298 9  AG014699 0.196 0.613 9 
AP24534 -0.190 0.307 31  WO2009093972 -0.196 0.613 9 
Nilotinib -0.201 0.315 27  Tipfarnib 0.171 0.615 11 
GSK650394 -0.184 0.323 31  AZD7762 0.171 0.637 10 
DMOG -0.183 0.324 31  Doxorubicin 0.161 0.637 11 
metformin 0.194 0.332 27  ZM447439 0.151 0.676 10 
methotrexate 0.204 0.351 23  ZM_447439 0.151 0.676 10 
Bryostatin1 -0.172 0.354 31  GW441756 0.145 0.690 10 
AICAR -0.193 0.356 25  NU7441 -0.138 0.703 10 
WH4_023 -0.378 0.356 8  QS11 0.126 0.713 11 
PF4708671 0.192 0.359 25  cisplatin -0.125 0.731 10 
CEP_701 -0.181 0.367 27  SL0101_1 0.118 0.745 10 
WO2009093972 0.188 0.369 25  TW37 -0.125 0.749 9 
CCT018159 0.180 0.389 25  JNKinhibitorVIII 0.112 0.758 10 
Vinblastine -0.172 0.390 27  Bicalutamide 0.101 0.769 11 
Epothilone_B -0.158 0.397 31  CI_1040 -0.092 0.800 10 
PHA_665752 -0.317 0.406 9  NVP_BEZ235 -0.092 0.800 10 
Pyrimethamine -0.317 0.406 9  AP24534 -0.085 0.803 11 
NVP_BEZ235 -0.161 0.423 27  BX795 0.079 0.828 10 
Olaparib -0.167 0.426 25  Olaparib 0.077 0.856 8 
ABT888_2 -0.159 0.428 27  docetaxel 0.065 0.869 9 
BMS_754807 -0.147 0.429 31  Temsirolimus -0.059 0.871 10 
MS_275 -0.298 0.436 9  AUY922 0.050 0.883 11 
PD_173074 0.153 0.448 27  DMOG 0.045 0.895 11 
AMG706 -0.151 0.452 27  PD_0325901 0.033 0.928 10 
BI_D1870 -0.150 0.456 27  RDEA119 0.026 0.942 10 
CHIR_99021 -0.136 0.466 31  Vorinostat -0.026 0.952 8 
Sorafenib 0.280 0.466 9  BAY61_3606 0.020 0.953 11 
A443654 -0.300 0.470 8  SB590885 0.013 0.971 10 
PF_562271 -0.133 0.477 31  LFM_A13 0.010 0.977 11 
Lenalidomide -0.140 0.487 27  PD_173074 -0.007 0.986 10 
ABT888 -0.107 0.504 41  AZD8055 -0.007 0.986 10 
ATRA -0.134 0.505 27  PAC1 0.005 0.988 11 
AZD0530 -0.242 0.530 9  Midostaurin 0.005 0.988 11 
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cyclopamine -0.242 0.530 9  FH535 0.000 1.000 11 
Shikonin -0.103 0.580 31  cyclopamine . . 2 
Vinorelbine 0.095 0.611 31  CMK . . 2 
PD_0325901 -0.102 0.612 27  CGP_60474 . . 2 
PD_0332991 -0.096 0.642 26  CGP_082996 . . 2 
AUY922 -0.084 0.653 31  BMS_536924 . . 2 
RDEA119 0.090 0.654 27  BMS_509744 . . 2 
PLX4720 -0.090 0.657 27  BI2536 . . 2 
HSP90_17AAG 0.098 0.665 22  AZD0530 . . 2 
Z_LLNle_CHO -0.183 0.665 8  AZ628 . . 2 
Mitomycin_C -0.076 0.684 31  A443654 . . 2 
Bosutinib -0.081 0.687 27  Salubrinal . . 2 
TW37 -0.082 0.696 25  Bortezomib . . 2 
LFM_A13 0.072 0.700 31  A770041 . . 2 
GW441756 0.077 0.703 27  dasatinib . . 2 
CGP_082996 -0.156 0.711 8  Z_LLNle_CHO . . 2 
GNF2 -0.143 0.735 8  XMD8_85 . . 2 
PAC1 -0.062 0.741 31  WZ1_84 . . 2 
VX702 0.064 0.750 27  WH4_023 . . 2 
FTI277 0.057 0.760 31  VX680 . . 2 
MG132 -0.112 0.775 9  Sunitinib . . 2 
QS11 -0.051 0.785 31  Sorafenib . . 2 
Temsirolimus -0.045 0.824 27  S_Trityl_L_cysteine . . 2 
Erlotinib 0.082 0.846 8  Roscovitine . . 2 
Imatinib 0.075 0.849 9  Pyrimethamine . . 2 
ABT263 -0.031 0.877 27  Parthenolide . . 2 
XMD8_85 -0.056 0.886 9  PF_02341066 . . 2 
NU7441 -0.027 0.897 26  Paclitaxel . . 2 
WZ1_84 0.052 0.902 8  PHA_665752 . . 2 
Vorinostat 0.025 0.905 25  NVP_TAE684 . . 2 
BAY61_3606 0.018 0.923 31  MS_275 . . 2 
GSK269962a 0.037 0.924 9  MG132 . . 2 
Pazopanib -0.017 0.926 31  Lapatinib . . 2 
JNK9L -0.017 0.928 31  KIN001_135 . . 2 
AZD6244 0.019 0.928 26  JW_7_52_1 . . 2 
AZD8055 0.018 0.929 27  Imatinib . . 2 
Gefetinib -0.015 0.939 27  GW843682X . . 2 
A770041 0.026 0.951 8  GSK269962a . . 2 
SB590885 -0.006 0.975 26  GNF2 . . 2 
NCS_87877 0.001 0.996 31  Erlotinib . . 2 
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In this thesis various aspects of the association of LAMP3 and the UPR with cancer biology 
were examined. We have shown that LAMP3 has a versatile role in cancer: LAMP3 has been 
implicated in hypoxia-induced metastasis and in therapy resistance (see Figure 1). Therefore, 
LAMP3 may be of clinical relevance. In the following section our results are placed in a 
broader perspective.  
FIGURE 1 Schematic overview of the possible interactions between pathways and hallmarks in cancer. Hypoxia elicits 
adaptive responses that enables immortality and induces cell survival, genomic instability and metastasis. In this thesis, 
we describe LAMP3 as an important player in both hypoxia-induced metastasis as well as therapy resistance. 
 
LAMP3, its family members and their significance in cancer 
Analysis of LAMP3 mRNA levels in a cohort of breast cancer patients revealed that patients 
whose axillary lymph nodes were positive had higher LAMP3 levels relative to patients without 
positive nodes (CHAPTER TWO). Also, patients with high LAMP3 mRNA expression had a 
worse locoregional control. In CHAPTER FOUR we show that the UPR through the action of 
LAMP3 stimulates hypoxia-mediated migration of breast cancer cells in vitro. Together, these 
data indicate that LAMP3 plays a role in metastasis of breast cancer. Previously, LAMP3 
overexpression was associated with enhanced metastatic potential of cervical cancer cells1. 
Indeed, we could support these findings and further substantiate the extensive impact hypoxia 
has on metastasis (CHAPTER FIVE). In head and neck squamous cell carcinoma, LAMP3 also 
had prognostic value for metastasis-free survival, but this was not associated with hypoxia 
(CHAPTER SIX). LAMP3 belongs to the LAMP-family of lysosomal membrane proteins. It has 
significant similarities with LAMP1 and LAMP2 (ref. 2). Therefore, earlier studies on LAMP1 
and LAMP2 may provide useful information as to how LAMP3 may stimulate metastasis. In 
non-cancerous cells, LAMP expression is exclusively located in the lysosomal membrane. 
Cancer cells, however, were frequently found to have LAMP1 and LAMP2 expression on the 
plasma membrane3,4. Furthermore, metastatic cell lines showed an increased level of LAMP 
expression on the cell membrane compared to less metastatic cell lines3,4. The LAMP-family is 
characterised by the presence of extensive glycosylation of the proteins. When expressed on 
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the surface of cancer cells, these glycosylations may facilitate metastasis. LAMP-proteins are 
important carriers of the selectin ligand sialyl Lewis X, which is often amplified in cancer5. 
Upon hypoxic exposure of colon cancer cells, a significant induction of the sialyl Lewis X was 
found at the cell surface6. In turn this led to an increase in adhesion of cancer cells to selectins 
on endothelial cells. Therefore, LAMP-proteins have been suggested to modulate the 
interaction between endothelial cells and cancer cells1. A similar mechanism may cause 
hypoxia-mediated metastasis by LAMP3, but the precise molecular mechanism awaits further 
investigation.  
In addition, accumulating evidence suggests that LAMPs may also be responsible for resistance 
against certain cancer therapies. We demonstrated that LAMP3 can cause resistance of breast 
cancer cells to treatment with tamoxifen (CHAPTER SEVEN). Furthermore, in CHAPTER EIGHT 
we showed that LAMP3 is involved in resistance against radiotherapy in breast cancer cells. 
Previously, reduced levels of LAMP1 and LAMP2 were found to increase the sensitivity of 
breast and colon carcinoma cells to anti-cancer drugs7. Together, these data indicate that the 
LAMP-family comprises factors that mediate treatment resistance and may represent possible 
targets to enhance the effect of anti-cancer drugs and radiotherapy. Nevertheless, the presence 
of several homologues within this family may hinder their utilisation as a druggable target. If 
redundancy exists between the different LAMP homologues, inhibition of a single-family 
member may prove ineffective. 
 
Targeting the UPR as cancer therapy 
In general, as a major cellular response to stress, the UPR could represent an attractive target 
for cancer therapy, supplementing standard modes of treatment. The UPR signifies a 
fundamental process of cells to adapt to hypoxic conditions and its therapeutic targeting could 
be a way in which the therapy-resistant hypoxic cells can be eliminated. The importance of the 
UPR is emphasised by the severe effects cells deficient in UPR components experience. XBP1-
deficiency makes transformed cell more sensitive to hypoxic death and can also impair tumour 
growth8. Similar observations were made for PERK- and ATF4-deficiencies9,10. In addition, 
recently it was found that the UPR can cause resistance to treatment with chemotherapy11,12. 
LAMP3 is a target gene of the PERK/eIF2α/ATF4-arm of the UPR13. We have provided 
evidence that knockdown of LAMP3 or other components of this pathway can inhibit 
migration and invasion of cancer cells under hypoxic conditions (CHAPTER FOUR and FIVE). 
This implies that modifying UPR activity could reduce metastasis formation. Furthermore, in 
CHAPTER SEVEN we demonstrate that LAMP3 can cause resistance to treatment with 
tamoxifen in breast cancer cells. Inhibition of LAMP3 in tamoxifen resistant cells could even 
resensitise cells to treatment. Knockdown of the PERK/ATF4/LAMP3-arm also rendered 
breast cancer cells more sensitive to radiotherapy (CHAPTER EIGHT). In this chapter, we also 
introduced the use of a chemical PERK inhibitor to abrogate PERK-signalling. We found that 
LAMP3 expression was reduced after treatment with the inhibitor and that breast cancer cells 
were more radiosensitive after treatment. Use of compounds such as this one represents a 
promising step in bringing therapy directed against the UPR into clinical use. 
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In this thesis, we examined abolishing PERK-signalling as a potential therapy enhancer. The 
rationale behind this is that inhibition of UPR-signalling may deprive cancer cells of an 
important survival mechanism during stress, thereby initiating cell death. However, the 
opposite must also be considered. Hyperinduction of the UPR may generate a stress response 
that is too severe to sustain cell survival. Indeed, LIN et al. showed that persistent PERK-
signalling is lethal14. Therefore, induction of UPR-signalling must also be regarded as a 
potential approach to augment cancer therapies. 
Whilst this thesis specifically studied the PERK/ATF4/LAMP3-arm of the UPR, the choice of 
target should be taken into account. As the UPR consists of three separate arms, each with 
numerous downstream genes, the selection of a druggable target could be challenging. 
Therapeutic exploitation of the UPR is complicated further as redundancy in UPR-signalling 
has been suggested for at least some target genes15,16. Autophagy and the pro-apoptotic gene 
CHOP for example can be induced by the UPR through both PERK and IRE1 (ref. 17,18). As a 
consequence, it may prove necessary to target multiple UPR-arms. Of significance in this 
respect could be therapeutic intervention at the level of GRP78. GRP78 serves as a barrier for 
UPR activation by binding PERK, IRE1 and ATF6 in the absence of cellular stress. 
Intriguingly, a decreased expression of GRP78 resulted in tumour growth suppression and 
enhanced cell death19. In addition, GRP78 can protect tumour cells against chemotherapy20, 
whereas knockdown of GRP78 sensitised tumour cells to chemotherapy21. Previous work 
shows that chemical inhibition of GRP78 can be achieved. PARK et al. isolated a compound, 
which could inhibit transcription of GRP78 and reduced production of ATF4 and XBP1, 
especially during glucose deprivation22. Compounds like these may prove valuable when 
targeting hypoxic tumour regions, low in glucose. Another interesting study was conducted by 
CHEN et al. 23. A retroviral construct under control of the GRP78 promoter was used to drive 
the expression of a suicide gene. In mice, treatment with this construct could eradicate 
tumours completely23.  
 
Interfering with autophagy to enhance cancer treatment 
LAMP3 knockdown cells display an autophagy compromised phenotype (CHAPTER SEVEN). 
Indeed, LAMP-proteins are thought to carry out an important function in the process of 
autophagy. This is illustrated by the severe consequences of a LAMP2-deficiency, which gives 
rise to Danon’s disease, clinically characterised by cardiomyopathy24. Knockout of LAMP2 in 
cells revealed an accumulation of autophagic vacuoles and a disruption of the autophagic 
process24. 
Autophagy is being increasingly recognised as a potential target for therapeutic intervention. 
However, manipulation of the autophagic process can have both positive and negative 
outcomes. Experimental data suggest that autophagy can serve as a mechanism used to restore 
energy supplies in time of stress. Therefore, inhibition of autophagy in cancer cells during 
therapy can cause energy to become limiting, potentially triggering cell death. Autophagy was 
found to enable cells to survive stress by inhibiting apoptosis and hypoxic cells can survive 
through autophagy25. On the other hand, hyperactivating autophagy may also activate cell 
death pathways. This is exemplified by the observation that several cancer therapies stimulate 
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autophagy, indicating that autophagy could be the mechanism by which cells are killed26. For 
example, in CHAPTER SEVEN we show that treatment with tamoxifen can induce autophagy. 
Previously, autophagy induction was found to inhibit cell proliferation by means of a G2/M 
cell cycle arrest27.  
Interference with the autophagic process as a stand-alone therapy may be of limited effect. 
However, this thesis and multiple other studies have examined autophagy as a supplementary 
treatment. We demonstrated that knockdown of the autophagy genes MAP1LC3B, ATG5 and 
BECN1 could sensitise breast cancer cells to treatment with tamoxifen (CHAPTER SEVEN). 
Furthermore, the autophagy inhibitors chloroquine and bafilomycin A1 could also 
radiosensitise breast cancer cells (CHAPTER EIGHT). In addition to these data, a large body of 
literature describes how autophagy can augment cancer therapies. Inhibition of autophagy 
could enhance treatment with alkylating agents, the tyrosine kinase inhibitor imatinib, the 
proteasoom inhibitor bortezomib and the anti-oestrogen tamoxifen26. Also, autophagy 
facilitated resistance of ERBB2 positive breast cancer cells to treatment with the anti-ERBB2 
trastuzumab28 and disruption of the autophagic process, either by chemical autophagy 
inhibitors or by knockdown of autophagy genes, could resensitise resistant cells to chemo- or 
radiotherapy.  
In contrast to inhibiting autophagy to augment cancer therapy, several reports explored the 
effects of stimulating autophagy on therapy efficacy. Induction of autophagy by rapamycin, 
radiosensitised hepatoma cells that were cultured resistant to irradiation. Furthermore, 
inhibition of autophagy caused parental hepatoma cells to become more resistant to 
irradiation29. Another study showed that EB1089, a vitamin D analogue, could promote 
autophagy and also increased the sensitivity of MCF-7 cells to radiation30. In addition, 
overexpression of ATG5 and BECN1 in mouse embryonic fibroblasts enhanced their 
radiosensitivity31. Overall, results on autophagy modification to enhance the efficacy of cancer 
therapies diverge and underline the double-edged sword reputation of autophagy.  
We showed that knockdown of PERK, ATF4 and LAMP3 inhibited hypoxia-mediated cell 
migration (CHAPTER FOUR). This arm of the UPR is crucial for autophagy induction during 
conditions of hypoxia. ATF4 is stabilised by hypoxia and induces LC3B expression32. In 
CHAPTER SEVEN we found that LAMP3 is also involved in autophagy. Autophagy inhibition 
caused by LAMP3 knockdown may be responsible for the reduced hypoxia-mediated cell 
migration seen in CHAPTER FOUR. Multiple studies examined the possible association between 
autophagy and (hypoxia-mediated) metastasis. When autophagy was inhibited by silencing 
ATG12 expression, tumour cell invasion could be impaired33. Furthermore, treatment with the 
mTOR inhibitor RAD001, thereby inducing autophagy, even promoted metastasis in a cancer 
model in the rat34. The autophagic response was also associated with an elevated incidence of 
metastasis in murine models of HNSCC35. A concept termed anoikis could be the basis for the 
association of autophagy with metastasis. Anoikis signifies the apoptotic death cells experience 
when they become detached from their surroundings. Recent evidence indicates that 
autophagy can promote cell survival during anoikis36. Protection from anoikis by autophagy 
may lead to an enhanced capacity of cells to metastasise. Therefore, blockage of autophagy 
could be beneficial to restrain metastasis formation. 
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The use of autophagy inhibitors as a cancer therapy may be hindered by possible side effects. 
Evidently, autophagy represents a mechanism that is beneficial to cells and may even 
contribute to tumour suppression. The essential autophagy gene BECN1 is monoallelically 
deleted in breast carcinomas37. Therefore, autophagy can act as a haploinsufficient tumour 
suppressor mechanism. Other reports also indicate BECN1 loss in ovarian and prostate 
cancers38. Defects in the autophagy process, such as loss of BECN1 or an ATG5-deficiency 
can promote a DNA damage response, gene amplification and tumourigenesis39. Consequently, 
BECN1 heterozygosity is associated with an accumulation of γH2AX foci in tumours, 
indicative of chromosome instability. Another report also indicated that chromosome 
instability could be promoted by autophagy defects40. Autophagy was found to sustain 
metabolism and survival and could possibly protect genome integrity. Immortalised mouse 
epithelial cells, deficient in either BECN1 or ATG5 exhibit a larger number of DNA damage 
foci and other signs of genomic instability41,42. When autophagy is chronically suppressed, 
oncogenesis may be stimulated42. Mice with a diminished expression of ATG4c present with 
impaired autophagy and are predisposed to carcinogen-induced fibrosarcomas43. Defects in the 
autophagic process were also found to lead to an accumulation of p62, which functions as a 
cargo selector. It contains a LC3 interacting region, by which cargo is targeted to the 
autophagosome. p62 itself is degraded in the lysosome along with the cargo. An upregulation 
of p62 is commonly observed in human tumours44 and prolonged presence of p62 was found 
to alter gene expression and promote tumourigenesis45. Autophagy defects with increased p62 
expression could also cause activation of the DNA damage response and enhance tumour 
growth.  
Also, diminished DNA damage repair, illustrated by the lack of PARP1 leads to a reduction in 
autophagy, possibly through activation of mTOR46. Conversely, BRCA1 was found to 
negatively regulate autophagosome formation and knockdown of BRCA1 increases formation 
of autophagosomes in MCF-7 breast cancer cells47.  
 
The link between DNA damage and autophagy  
Epigenetics, referring to alterations in gene expression that are not associated with DNA 
sequence changes, is of increasing interest in cancer research. For example, the silencing of 
gene expression by hypermethylation of the CpG-rich islands in gene promoters has been 
shown to occur in the BRCA1 gene in sporadic breast cancer cases48,49. Also, tumour 
microenvironmental characteristics such as hypoxia can induce altered epigenetic regulation of 
gene expression50.  
The so-called HDACs (histone deacetylases) play important roles in the epigenetic regulation 
of gene expression as they can modulate histone tails51,52. Several types of cancer aberrantly 
express HDACs53. Inhibitors of HDACs cause increased differentiation, growth arrest and 
apoptosis54. Recently, HDACs were found to play a role in the regulation of non-histone 
proteins. Acetylation of proteins is associated with increased autophagic degradation55, as was 
shown for DNA damage repair factors56. HDAC inhibitors induce a hyperacetylated state, in 
which repair of DNA damage is negatively influenced by autophagy57. When DNA damage 
agents were combined with HDAC inhibitors, more γH2AX foci were induced56. In addition, 
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foci persisted longer, indicating that the rate of repair was slower. Thus, treatment with HDAC 
inhibitors can counteract the DNA damage repair pathway52. However, HDACs and their 
inhibitors are of further importance. HDAC6 is involved in autophagy by affecting 
autophagosome-lysosome fusion58 and HDAC inhibitors can induce autophagy by increasing 
LC3 expression and inhibiting mTOR59. Recent reports indicate that HDAC6 can also 
promote cancer cell migration and invasion60,61. The UPR is also influenced by HDACs: 
HDAC1 can repress the GRP78 promoter54. Consequently, treatment with HDAC inhibitors 
can induce GRP78, especially during conditions of ER-stress. When GRP78 expression was 
suppressed, cells were sensitised to HDAC inhibitors. GRP78 overexpression on the other 
hand caused resistance to apoptosis induced by HDAC inhibitors. HDACs can also regulate 
cell signalling by steroid hormone receptors53. Both oestrogen-signalling, oestrogen receptor 
transcription and stability are mediated by acetylation. Therefore, HDAC inhibitors could 
increase the effect of anti-oestrogens and may impair tamoxifen resistance. It has even been 
suggested that HDAC inhibitors can restore oestrogen receptor expression in ESR-negative 
breast cancer cell lines53,62,63. Together, autophagy-protected cells may be driven into apoptotic 
cell death through the use of HDAC- and autophagy inhibitors. 
 
Telomeric dysfunction and cancer therapy 
In CHAPTER NINE we described the phenomenon of endogenous expression of γH2AX in 
breast cancer. We found that in tumour tissue from breast cancer patients, the early DNA 
damage marker γH2AX was present despite the fact that they had not received (DNA damage 
inducing) therapy. In the group of triple negative patients, those with high levels of this 
constitutive γH2AX had a worse prognosis than those with lower levels. Previously, 
endogenous expression of γH2AX has been associated with genomic instability64 and 
hypoxia65. The colocalisation of these foci with other DNA damage repair proteins led to the 
idea that actual repair is taking place at these sites66. NAKAMURA et al. showed that endogenous 
γH2AX foci were often found on chromosome ends66. 
The ends of eukaryotic chromosomes are protected by specialised structures called telomeres. 
Telomeres include a tandem repetition of the sequence TTAGGG, which form a looped 
structure67. In the process of cell division DNA is replicated. The DNA polymerase 
responsible for this task cannot replicate the telomeric ends of linear DNA. As a consequence, 
genetic material is lost from chromosome ends during each cell division: about 50-200 base 
pairs will vanish68. If telomeres become critically short, making proliferation impossible, cells 
enter senescence, usually after about 50 doublings. Short telomeres are associated with 
genomic instability and can be recognised as DNA damage66.  
Tumour tissues were found to have significantly shorter telomeres69 but instead of entering 
senescence, cancer cells have acquired mechanisms by which their unlimited proliferation can 
be sustained. An enzyme called telomerase is capable of adding telomeric repeat sequences to 
the 3’ end of the DNA. Whereas germline and early embryonic cells express telomerase, most 
somatic cells do not. However, in cancers telomerase is frequently reactivated70-74. This 
reactivation can be traced back to early tumourigenesis, but is absent in normal tissue. 
Telomerase can stabilise short telomeres without necessarily lengthening them74. We described 
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that in breast cancer cell lines and tumours, constitutive γH2AX expression correlated with 
telomere length, where less constitutive γH2AX expression was associated with longer 
telomeres (CHAPTER TEN). In the group of triple negative patients, tumours with shorter 
telomeres revealed a worse prognosis for the patient compared to tumours with longer 
telomeres. 
Interestingly, recent reports indicate that hypoxia can also affect telomeres. Hypoxia can 
enhance telomerase activity in solid tumours75 as phosphorylation of the catalytic component 
of telomerase (TERT) is induced by hypoxia76. Hypoxia can also increase the activity of 
telomerase by inducing transcriptional activity of TERT77. Recently, HIF1α was found to be 
critical for telomerase function in mouse embryonic fibroblasts78. Increased telomerase activity 
during conditions of hypoxia may provide a survival advantage for tumour cells. 
Telomeres may also prove of use for cancer treatment. Telomere-based therapies exploit 
telomere erosion and dysfunction to trigger cell death. Expression of telomerase was found to 
be suppressed by tamoxifen79. In addition, activation of telomerase led to an increased 
resistance to cancer drugs, such as DNA-damaging agents. Therefore, telomerase inhibitors 
have been proposed as a promising strategy to erase cancer cells. These inhibitors were 
employed successfully in reducing growth and metastasis in breast cancer79.  
Several other telomere-based therapies proved successful in provoking telomere dysfunction80-
83. These treatments stimulated the induction of autophagy possibly through the inhibition of 
mTOR83. Combining telomere-based therapy with an autophagy inducer could further enhance 
the response83. Also, the combination of inhibiting DNA damage repair by PARP1 inhibitors 
augmented telomere-based therapies81. A potential drawback of the use of telomere-based 
therapies is that telomeres may have to become critically short before the treatment becomes 
cytotoxic84. This delay may give cancer cells time to endorse alternative mechanisms for 
telomere lengthening (ALT, alternative lengthening of telomeres), in which homologous 
recombination plays a crucial part. 
 
 
In conclusion, in this thesis we showed that LAMP3 - via the UPR and possibly autophagy - 
can elicit aggressive tumour behaviour. Thus, therapeutic targeting of the UPR or the 
autophagic cascade appears promising. We have described several novel attractive treatment 
strategies and combinations for cancer. The successful implementation in the clinic will depend 
on further knowledge of the molecular mechanisms through which these treatments act.  
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Cancer is characterised by a number of different features, known as the hallmarks of cancer. 
One important hallmark is the presence of genomic instability. The DNA damage repair 
pathway represents a significant barrier against genomic instability. In addition, tumours are 
characterised by a complex microenvironment. Hypoxia, one microenvironmental factor, can 
be detrimental for the survival of cancer cells. Therefore, cells have several mechanisms to 
combat conditions of low oxygen availability. The process of autophagy affects cancer cell 
survival during hypoxia and other types of stress by providing additional energy supplies. In 
addition, the unfolded protein response (UPR) facilitates cell survival during conditions of 
stress. Hypoxia, through the UPR, can induce the expression of lysosome-associated 
membrane protein 3 (LAMP3). Together hypoxia and LAMP3 may influence the 
aggressiveness of cancer cells. In this thesis, the contribution of LAMP3 to several cancer 
hallmarks was explored. 
 
In CHAPTER TWO, the induction of LAMP3 by conditions of hypoxia and its prognostic value 
in breast cancer was examined. LAMP3 mRNA expression varied substantially between 
different breast cancer cell lines. In addition, expression of LAMP3 mRNA was induced by 
hypoxia in an oxygen concentration dependent manner, where severe hypoxia induced higher 
expression levels than moderate hypoxia. These results could be further substantiated in breast 
cancer xenografts. LAMP3 expression showed a good colocalisation with the exogenous 
hypoxia marker pimonidazole. Next, the prognostic relevance of LAMP3 for breast cancer was 
examined. Therefore, LAMP3 mRNA expression was explored in tumours from a cohort of 
183 breast cancer patients. Patients with high LAMP3 mRNA expression in their tumour had 
more positive axillary lymph nodes and were more often negative for oestrogen receptor 
expression. In addition, patients with high tumoural LAMP3 mRNA levels had a worse 
locoregional control compared to patients with low LAMP3 mRNA expression. This 
association of LAMP3 levels with locoregional control was highly significant in patients 
receiving lumpectomy and radiotherapy as part of their treatment. 
 
Next, a laboratory study was performed to establish the best method to generate multicellular 
tumour spheroids from breast cancer cells (CHAPTER THREE). Multicellular tumour spheroids 
represent a model of intermediate complexity: spheroids are more complex than conventional 
two-dimensional cell cultures but simpler in terms of morphology and use than animal models. 
Several methods and techniques are available to generate and culture spheroids. Whilst 
searching for a decent and straightforward protocol, we came across several methods that did 
not result in the required spheroid morphology. One technique, the hanging drop method, 
yielded aggregates as flat as pancakes, in which the cells did not adhere to each other and a 
hypoxic core was not present. Other methods generated spheroids that were highly variable in 
size and shape. Eventually, an adapted liquid overlay technique in which cells are suspended in 
culture medium with Matrigel was perceived as the best method. This method yielded 
compact, round and robust spheroids of breast cancer cells. 
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These spheroids were used in the studies described in CHAPTER FOUR. As hypoxia as well as 
LAMP3 had been previously implicated in cancer metastasis, we explored whether breast 
cancer cell migration was influenced by either of these factors. It was found that hypoxia could 
accelerate cell migration. Moderate hypoxia was more effective in this respect than severe 
hypoxia. Knockdown of PERK, ATF4 or LAMP3 could reduce migration of breast cancer 
cells, but only during hypoxic conditions not during normoxia. In spheroids, LAMP3 
knockdown led to a decrease of cell invasion into a collagen matrix. In CHAPTER FIVE the 
importance of the PERK/ATF4/LAMP3 pathway in metastasis of cervical cancers was 
examined. Disruption of PERK-signalling in orthotopic xenografts resulted in an inhibition of 
hypoxia-induced metastasis to the lymph nodes. In addition, LAMP3 knockdown also 
prevented lymph node metastasis and could inhibit cell migration in vitro. Together, these 
chapters show that LAMP3 is relevant for migration and metastasis of tumour cells. 
 
CHAPTER SIX evaluated the prognostic value of LAMP3 in yet another type of cancer. In a 
cohort of 29 head and neck squamous cell carcinomas (HNSCCs) LAMP3 expression was 
associated with lymph node involvement and the occurrence of metastasis during follow-up. 
Also, patients with high LAMP3 expression levels had a worse prognosis, especially for 
metastasis-free survival. Staining for both LAMP3 and pimonidazole revealed that in HNSCC 
tumours and xenografts, LAMP3 was exclusively located in the normoxic areas. Subsequent 
experimentation with a panel of HNSCC cell lines indicated that the PERK/ATF4/LAMP3-
arm of the UPR is differently regulated than in other types of cancer cells. Hypoxia could not 
provide the general stimulus for PERK, ATF4 or LAMP3 expression. In several HNSCC cell 
lines expression of these UPR-associated factors was downregulated or unaltered after hypoxic 
exposure. In contrast, expression of CA9, a gene under control of hypoxia-inducible factor 1 
(HIF1), could be induced. In addition, different types of ER-stress were able to induce UPR 
expression. HNSCC therefore appear to represent a subset of tumours with different means of 
hypoxic regulation of gene expression. 
 
In the subsequent chapter the value of LAMP3 in resistance of breast cancer to tamoxifen was 
explored (CHAPTER SEVEN). In the oestrogen receptor positive cell line MCF-7, tamoxifen 
treatment induced the process of autophagy. In addition, tamoxifen stimulated LAMP3 
mRNA expression in MCF-7 cells. Knockdown of autophagy-associated genes as well as 
knockdown of LAMP3 could sensitise MCF-7 cells further to treatment with tamoxifen. In 
this chapter, LAMP3 knockdown cells were found to be autophagy compromised. 
Subsequently, LAMP3 mRNA levels were evaluated in the primary tumours of a cohort of 304 
patients with advanced breast cancer receiving tamoxifen treatment. Patients with high 
LAMP3 mRNA levels in their tumour had a significantly shorter progression-free survival. 
Overall, LAMP3 emerged as a factor of importance for tamoxifen resistance. CHAPTER EIGHT 
revealed that the PERK/ATF4/LAMP3-arm of the UPR is also of interest for resistance to 
radiotherapy. Knockdown of PERK, ATF4 or LAMP3 in breast cancer cells led to 
radiosensitisation. In addition, in this chapter a pharmacological inhibitor of PERK 
(GSK2606414) was introduced. This compound could abrogate LAMP3 mRNA expression 
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and could also radiosensitise breast cancer cells. Studying the expression of several DNA 
damage response factors revealed that LAMP3 knockdown cells lacked a conventional DNA 
damage repair-signalling pathway. This was illustrated upon examining phosphorylated H2AX 
(γH2AX), an early event in the repair of DNA damage. LAMP3 knockdown cells displayed 
diminished levels of γH2AX upon irradiation. These results support the data presented in 
CHAPTER TWO, where LAMP3 was found to be prognostic specifically in breast cancer 
patients treated with radiotherapy. Overall, it appears that LAMP3 is associated with therapy 
resistance in breast cancer. 
 
In CHAPTER NINE the phenomenon of endogenous phosphorylation of the histone H2AX was 
examined in breast cancer. In a panel of 54 breast cancer cell lines γH2AX positivity was 
associated with triple negativity. In a cohort of 122 breast cancer patients, a higher level of 
γH2AX in the tumour indicated a significantly worse prognosis specifically within the group of 
triple negative breast cancers. The subsequent study, presented in CHAPTER TEN, revealed that 
γH2AX positive breast cancer cell lines and tumours had shorter telomeres. Critically short 
telomeres were previously found to be recognised as actual DNA damage. Telomere length 
also presented itself of prognostic relevance, again specifically in the group of triple negative 
patients. 
 
In the last chapter, CHAPTER ELEVEN, the findings presented in this thesis were discussed in a 
broader perspective. We concluded that the UPR, through the action of LAMP3, represents an 
attractive objective for cancer therapy. 
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Kanker wordt getypeerd door een verzameling van kenmerken, genaamd de ‘hallmarks of 
cancer’ (kenmerken van kanker). Een belangrijk kenmerk is de aanwezigheid van genomische 
instabiliteit. Herstel van DNA schade kan genomische instabiliteit tegengaan. Daarnaast 
worden tumoren gekarakteriseerd door een complex micromilieu. Een te lage 
zuurstofspanning (hypoxie) is één van de veel voorkomende kenmerken van het micromilieu 
van tumoren. Hypoxie kan nadelig zijn voor de overleving van kankercellen. Daarom hebben 
deze cellen verschillende mechanismen tot hun beschikking om zich aan te passen aan 
hypoxische omstandigheden. Autofagie kan kankercellen helpen te overleven tijdens hypoxie 
en andere soorten stress, omdat dit proces binnen een cel tijdelijk voor extra energie kan 
zorgen. Daarnaast kan ook de unfolded protein response (UPR) kankerceloverleving 
bevorderen tijdens stressvolle omstandigheden. Via de UPR stimuleert hypoxie de expressie 
van het zogenaamde ‘lysosome-associated membrane protein 3’ (LAMP3). Samen kunnen 
hypoxie en LAMP3 kankercellen agressiever maken. In dit proefschrift wordt de bijdrage van 
LAMP3 aan een aantal kenmerken van kanker onderzocht. 
 
In HOOFDSTUK TWEE werd het effect van hypoxie op de expressie van LAMP3 in meer detail 
onderzocht in borstkankercellen. Ook werd hier de prognostische waarde van LAMP3 in 
borstkanker bekeken. De expressie van LAMP3 mRNA varieerde aanzienlijk tussen 
verschillende borstkankercellijnen. Het effect van hypoxie op de mRNA expressie van LAMP3 
was zuurstofconcentratie afhankelijk. Een laag zuurstofpercentage (0.1% O2) leidde tot een 
hogere expressie dan wanneer het zuurstofpercentage minder laag was (0.5% O2). Het verband 
tussen LAMP3 en hypoxie werd verder onderzocht in borstkanker xenografts. Hier liet de 
expressie van LAMP3 een goede colokalisatie zien met de exogene hypoxie marker 
pimonidazole. Vervolgens werd de mRNA expressie van LAMP3 gemeten in tumoren van 183 
borstkankerpatiënten. Patiënten met een hoge LAMP3 mRNA expressie in de tumor hadden 
meer positieve oksellymfeklieren en waren vaker negatief voor expressie van de 
oestrogeenreceptor. Daarnaast hadden patiënten met hoge LAMP3 expressie in de tumor een 
slechtere locoregionale controle in vergelijking met patiënten met een lage LAMP3 mRNA 
expressie. Dit gold specifiek voor patiënten die een lumpectomie ondergingen en postoperatief 
behandeld werden met radiotherapie.  
 
Vervolgens werd een laboratoriumstudie uitgevoerd om te bepalen welke methode de meest 
optimale multicellulaire tumor sferoïden oplevert (HOOFDSTUK DRIE). Sferoïden zijn 
complexer dan standaard celkweken, maar eenvoudiger qua morfologie en toepassing dan 
bijvoorbeeld diermodellen. Verschillende methoden en technieken zijn beschikbaar om 
sferoïden te maken en in kweek te houden. Tijdens het zoeken naar een geschikt en eenvoudig 
protocol, kwamen we verschillende methoden tegen die niet de gewenste sferoïde morfologie 
opleverden. Bij één techniek, de zogenaamde ‘hanging drop’ methode, bleven de gevormde 
celaggregaten plat. De cellen kleefden niet stevig aan elkaar en er werd geen hypoxische kern 
gevormd. Andere methoden resulteerden in sferoïden die een verschillende grootte en vorm 
hadden. Uiteindelijk werd een aangepaste ‘liquid overlay’ techniek, waarbij cellen in 
CHAPTER TWELVE 
 188 
kweekmedium met Matrigel zweven, als beste methode bevonden. Deze methode leverde 
compacte, ronde en robuuste sferoïden van borstkankercellen op. 
 
Deze sferoïden werden gebruikt in de studie beschreven in HOOFDSTUK VIER. Omdat zowel 
hypoxie als LAMP3 in eerdere studies al met uitzaaiing van kanker in verband gebracht waren, 
werd in dit hoofdstuk gekeken naar de rol van beide factoren in de migratie van 
borstkankercellen. Onder hypoxische omstandigheden migreerden borstkankercellen sneller. 
Hierbij had een laag zuurstofpercentage (0.1% O2) minder effect dan een hoger 
zuurstofpercentage (1% O2). Activatie van LAMP3 door de UPR verloopt via ‘PKR-like 
endoplasmic reticulum kinase’ (PERK) en ‘activating transcription factor 4’ (ATF4). 
Knockdown van PERK, ATF4 of LAMP3 verminderde migratie van borstkankercellen, maar 
alleen onder hypoxische omstandigheden, niet bij een reguliere zuurstofspanning. In sferoïden 
leidde knockdown van LAMP3 tot een verminderde invasie van cellen in een collageen matrix. 
In HOOFDSTUK VIJF werd gekeken of de PERK/ATF4/LAMP3-arm behalve bij borstkanker 
ook een rol speelt bij de uitzaaiing van cervixkanker. Uitschakeling van deze arm in 
orthotopische xenografts leidde tot een vermindering van uitzaaiing naar de lymfeklieren bij 
een lagere zuurstofspanning. Daarnaast verminderde knockdown van LAMP3 ook lymfeklier-
metastasering en celmigratie in vitro. Samen laten deze hoofdstukken zien dat LAMP3 relevant 
is voor migratie en uitzaaiing van verschillende soorten tumorcellen. 
 
In HOOFDSTUK ZES werd de prognostische waarde van LAMP3 onderzocht in een ander soort 
kanker. In een cohort van 29 hoofd-halscarcinomen hadden patiënten met hoge LAMP3 
expressie in de tumor meer aangedane lymfeklieren. Ook kregen zij meer metastasen 
gedurende de follow-up. Patiënten met een hoge LAMP3 expressie in hun tumor hadden een 
slechtere prognose, met name voor de metastase-vrije overleving. Dubbelkleuring van LAMP3 
met pimonidazole in hoofd-halstumoren en xenografts toonde aan dat LAMP3 uitsluitend 
gelokaliseerd was in normoxische gebieden. Verder onderzoek in cellijnen wees uit dat in 
hoofd-halscarcinomen de PERK/ATF4/LAMP3-arm van de UPR anders gereguleerd wordt 
dan in cellen van de tot nu toe onderzochte kankersoorten. Hypoxie was hier niet de stimulus 
voor PERK, ATF4 of LAMP3 expressie, die het in andere tumorcellijnen wel is. In meerdere 
cellijnen van hoofd-halscarcinomen bleef expressie van deze UPR factoren onveranderd na 
hypoxie of werd zelfs geremd onder hypoxische condities. Daarentegen kon expressie van 
CA9, een gen onder controle van hypoxia-inducible factor 1 (HIF1), wel worden geïnduceerd 
door hypoxie. Ook waren andere soorten stress wel in staat om de UPR te induceren. Daarom 
lijken hoofd-halscarcinomen zich op andere wijze aan te passen aan hypoxische stress dan 
andere tumorsoorten.  
 
In het volgende hoofdstuk werd het belang van LAMP3 in tamoxifenresistentie van 
borstkankercellen onderzocht (HOOFDSTUK ZEVEN). Autofagie werd gestimuleerd door 
behandeling met tamoxifen in de oestrogeenreceptor positieve cellijn MCF-7. Daarnaast kon 
tamoxifen mRNA expressie van LAMP3 verhogen. Knockdown van zowel autofagie-
geassocieerde genen als van LAMP3 maakte MCF-7 cellen gevoeliger voor behandeling met 
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tamoxifen. In dit hoofdstuk werd aangetoond dat in cellen met een knockdown van LAMP3 
autofagie geremd is. Vervolgens werd de LAMP3 mRNA expressie bepaald in primaire 
tumoren van een cohort van 304 patiënten met borstkanker in een gevorderd stadium 
behandeld met tamoxifen. Patiënten met een hoge LAMP3 mRNA expressie in de tumor 
hadden een significant kortere progressie-vrije overleving. LAMP3 lijkt dus betrokken te zijn 
bij tamoxifenresistentie. HOOFDSTUK ACHT liet zien dat de PERK/ATF4/LAMP3-arm van de 
UPR ook een rol speelt bij resistentie tegen radiotherapie. Knockdown van PERK, ATF4 of 
LAMP3 in borstkankercellen leidde tot een hogere gevoeligheid voor radiotherapie. Daarnaast 
werd in dit hoofdstuk een farmacologische remmer voor PERK (GSK2606414) gebruikt. Deze 
stof kon LAMP3 mRNA expressie verminderen en daarnaast ook borstkankercellen gevoeliger 
maken voor radiotherapie. Analyse van de expressie van meerdere DNA schade factoren liet 
zien dat cellen met een LAMP3 knockdown geen conventioneel DNA schade herstel hadden. 
Dit werd verder duidelijk toen de fosforylering van H2AX (γH2AX), een marker voor vroege 
DNA schade, werd onderzocht. Cellen met een knockdown van LAMP3 lieten minder 
γH2AX zien na bestraling. Deze resultaten komen overeen met de bevindingen uit 
HOOFDSTUK TWEE, waar werd gevonden dat LAMP3 specifiek prognostisch was in 
borstkankerpatiënten behandeld met radiotherapie. Het algemene beeld dat ontstaat is dat 
LAMP3 geassocieerd is met therapieresistentie in borstkanker. 
 
In HOOFDSTUK NEGEN werd het fenomeen van endogene fosforylering van histon H2AX in 
borstkanker onderzocht. In een panel van 54 borstkankercellijnen was positiviteit voor γH2AX 
geassocieerd met triple negativiteit (geen expressie van oestrogeenreceptor, 
progesteronreceptor en epidermale groeifactorreceptor (ERBB2) in de tumor). In een cohort 
van 122 borstkankerpatiënten werd gevonden dat meer endogeen γH2AX in de tumor een 
significant slechtere prognose voorspelde specifiek in de groep van triple negatieve 
borsttumoren. De daaropvolgende studie, beschreven in HOOFDSTUK TIEN, toonde aan dat 
γH2AX positieve borstkankercellijnen en -tumoren kortere telomeren hadden. Telomeren 
beschermen de uiteinden van het DNA, maar worden korter na iedere celdeling. Eerdere 
studies lieten zien dat gevaarlijk korte telomeren herkend kunnen worden als daadwerkelijke 
DNA schade. Telomeerlengte had ook prognostische waarde in borstkankerpatiënten, 
wederom specifiek in de groep van triple negatieven. 
 
In het laatste hoofdstuk, HOOFDSTUK ELF, werden de bevindingen van dit proefschrift 
bediscussieerd in een breder perspectief. We concluderen dat therapieën specifiek gericht tegen 
LAMP3 en de UPR nieuwe perspectieven bieden in de behandeling van kanker. 
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18S 18S ribosomal RNA 
3D  three-dimensional 
53BP1 p53 binding protein 1 
ANOVA analysis of variance 
ATF4 activating transcription factor 4 
ATF6 activating transcription factor 6 
ATG4c autophagy related gene 4c 
ATG5 autophagy related gene 5 
ATG12 autophagy related gene 12 
ATM ataxia telangiectasia mutated 
ATR ATM and Rad3-related 
Baf-A1 bafilomycin A1 
BECN1  beclin 1 
BRCA1/2 breast cancer susceptibility protein type 1/2 
CA9 carbonic anhydrase 9 
CD31 cluster of differentiation 31 
CEP3 centromere protein 3 
CEP7 centromere protein 7 
CHK1 checkpoint kinase 1 
CHK2 checkpoint kinase 2 
CHOP C/EBP homology protein 
CI confidence interval 
DC-LAMP  dendritic cell lysosome-associated membrane protein 
DFS disease-free survival 
DMSO dimethyl sulfoxide 
DNA-pk DNA-dependent protein kinase 
dox doxycycline 
DSB double-strand break 
DTT dithiothreitol 
EF5 [2-(2-nitro-1H-imidazole-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] 
eIF2α eukaryotic initiation factor 2α 
ER endoplasmic reticulum 
ERBB2  human epidermal growth factor receptor 2 
ESR oestrogen receptor 
EV  empty vector 
FFPE  formalin fixed paraffin embedded 
FISH  fluorescence in situ hybridisation 
GADD34  growth arrest and DNA damage-inducible protein 34 
GFP  green fluorescent protein 
GLUT  glucose transporter 
GRP78  glucose-related protein 78 
GSK2606414  PERK inhibitor 
HBSS  Hank’s buffered saline solution 
HCQ hydroxychloroquine 
HDAC histone deacetylase 
HGF  hepatocyte growth factor 
HIF1  hypoxia-inducible factor 1 
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HNSCC  head and neck squamous cell carcinoma 
HP5 hypoxic proportion, % pO2 readings <5 mmHg 
HPRT1  hypoxanthine phosphoribosyl transferase 1 
HR  hazard ratio 
IHC  immunohistochemistry 
IRE1  inositol-requiring enzyme 1 
Ku80 lupus Ku auto-antigen protein p80 
LAMP1  lysosome-associated membrane protein 1 
LAMP2  lysosome-associated membrane protein 2 
LAMP3  lysosome-associated membrane protein 3 
MAP1LC3B microtubule-associated protein 1 light chain 3B 
MDC1 mediator of DNA damage checkpoint 1 
Mre11 DNA repair protein Mre11 
mTOR mammalian target of rapamycin 
OS  overall survival 
p53 (tumour) protein 53 
p95/NBS1  Nijmegen breakage syndrome 1 
PAD  primary antibody diluent 
PARP poly (ADP-ribose) polymerase 
PBS  phosphate-buffered saline 
PERK  PKR-like endoplasmic reticulum kinase 
PFS  progression-free survival 
PGR  progesterone receptor 
Pimonidazole  (1-[(2-hydroxy-3-piperidinyl)propyl]-2-nitroimidazole hydrochloride) 
poly-HEMA  poly-hydroxyethylmethacrylate 
Rad50 DNA repair protein 50 
Rad52 DNA repair protein 52 
REMARK REporting recommendations for tumour MARKer prognostic studies 
RT-qPCR  quantitative real time polymerase chain reaction 
SD  standard deviation 
SDS  sodium dodecyl sulphate 
SEM  standard error of the mean 
SF4  surviving fraction 4 
shRNA  short hairpin RNA 
siRNA  short interfering RNA 
SQSTM1/p62 sequestosome 1 
TBS  tris-buffered saline 
TERT telomerase reverse transcriptase 
TMA  tissue microarray 
UPR  unfolded protein response 
VEGF  vascular endothelial growth factor 
XBP1  x-box-binding protein 1 
XLF XRCC4-like factor 
γH2AX  phosphorylated histone 2AX 
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